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ABSTRACT OF DISSERTATION 
 
 
THE IMPACT OF INSULIN DYSREGULATION ON PROTEIN METABOLISM IN 
HORSES 
 
Insulin plays a vital role in whole-body metabolism and provides a major anabolic 
stimulus for cellular signaling pathways, including those involved in the metabolism of 
glucose and protein. Consequently, insulin dysregulation (ID) is known to alter molecular 
signal transduction in insulin-sensitive tissues such as skeletal muscle, thereby disrupting 
glucose metabolism and compromising protein synthetic capacity. Our first objective was 
to induce ID in healthy horses by administering dexamethasone (DEX), a potent 
glucocorticoid, for 21 days. We evaluated the effects on insulin-stimulated muscle protein 
signaling components involved in the mammalian target of rapamycin (mTOR) pathway. 
DEX-induced ID reduced insulin-stimulated activation of downstream (rpS6, 4EBP-1) 
mTOR signaling and increased atrogin-1 abundance, a marker for protein breakdown 
(P<0.05). Additionally, 21 days of DEX elevated plasma amino acids levels in insulin-
stimulated conditions, indicative of reduced uptake or increase release into circulation 
(P<0.05). The second objective was to evaluate the short-term effects of DEX treatment in 
healthy horses. Plasma insulin, glucose and amino acid dynamics and activation of mTOR 
signaling pathways following an oral sugar test (OST) or intake of a high protein meal were 
evaluated before and after 7 days of DEX treatment, and after 7 days of no treatment. Seven 
days of DEX treatment increased basal levels of glucose, insulin and several amino acids 
(P<0.05). Additionally horses treated with DEX had an exacerbated insulin response to the 
OST and consumption of the high protein meal in comparison to control horses (P<0.05). 
The majority of blood metabolites returned to basal levels after 7 days of recovery from 
DEX treatment, indicating these effects were transient. Short-term DEX treatment 
decreased overall activation of mTOR and FoxO3 but increased total FoxO3 and IRS-1 
abundance (P<0.05). Postprandial activation of rpS6 was greater in horses treated with 
DEX for  7 days but was lower in those horses after 7 days of recovery from treatment 
(P<0.05). Postprandial activation of ULK and AMPK tended to be greater in DEX treated 
horses (P<0.1). Akt phosphorylation and mysotatin abundance were lower after the OST 
in DEX treated horses (P<0.05). The final objective was to evaluate whether similar 
 
 
changes in postprandial metabolic responses would be seen in horses with naturally 
occurring ID. Plasma insulin, glucose and amino acid responses following ingestion of a 
high protein meal were determined in mature horses with equine metabolic syndrome 
(EMS). Horses with EMS had higher basal plasma insulin concentrations but lower levels 
of aspartate, glutamate, asparagine and plasma urea nitrogen in comparison to healthy 
controls (P<0.05). Consumption of a high protein meal resulted in a 9-fold greater insulin 
response and higher postprandial levels of various amino acids (P<0.05).Together this 
research indicates that ID affects whole body protein metabolism by altering cellular 
signaling pathways in healthy and diseased horses. 
KEYWORDS: Horse, Insulin Dysregulation, Glucocorticoids, Protein metabolism, 
                         mTOR signaling  
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CHAPTER 1  
LITERATURE REVIEW 
 
“If there had been simple early clinical test for urine nitrogen or plasma amino acids, the 
disease we know as diabetes mellitus might have instead been called diabetes proteinus” 
[1].  
 
1.1. INTRODUCTION 
The plasticity by which cellular mechanisms respond to the disruption in 
homeostasis is essential for survival and allows for adaptation to changes in the external 
and internal environments. Conversely, the innate responses of these homeostatic 
mechanisms to different stimuli can also cause undesired physiological shifts and are 
responsible for a variety of metabolic diseases. Most western world equine management 
practices have removed the horse from its original environment, thereby introducing 
challenges to which its physiological systems may not yet have evolutionarily adapted. 
Additionally, the horse’s extensive athletic use and prolonged life span have made it 
more susceptible to physical strains and diseases, similar to humans.  
Hormonal signaling plays an essential role in the inter-organ crosstalk that is 
necessary to maintain whole-body homeostasis and aberrations in hormone signal 
transduction underlie many metabolic diseases. Insulin is a major regulatory hormone and 
its potent anabolic stimulus affects whole-body glucose, protein and lipid metabolism. 
More specifically, insulin stimulates the uptake of glucose, amino acids and fatty acids 
into cells and promotes synthesis and storage of these nutrients by upregulating 
intracellular anabolic processes, while inhibiting catabolic pathways [2]. 
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Skeletal muscle in particular is extremely sensitive to insulin stimulation and is 
responsible for the majority (60-70%) of whole-body insulin-mediated glucose uptake 
[3]. Skeletal muscle comprises about 50% of the horse’s body mass and is maintained by 
the balance between muscle protein synthesis and degradation. A key player in regulating 
this delicate balance is the mechanistic target of rapamycin (mTOR) [4]. In addition to 
providing energy and building blocks by stimulating tissue nutrient uptake, insulin 
activates several components of the mTOR pathway, while suppressing proteolytic 
factors, thereby promoting protein synthesis and consequently muscle accretion [5-7]. 
Besides its primary function as a motor for locomotion, skeletal muscle has been 
recognized as a major player in whole-body metabolism [8]. This is in part explained by 
the plasticity by which the balance between synthetic and proteolytic processes is rapidly 
shifted under different physiological conditions, thereby redistributing necessary 
substrates to maintain energy homeostasis [9, 10]. Consequently, muscle resistance to 
essential hormonal signals can have a detrimental impact on muscle metabolism and 
overall health and well-being [11-13].  
In horses, insulin signaling and tissue sensitivity to its stimulus can be altered by a 
variety of factors including genetics, developmental changes, breed, body weight, 
exercise, injury, and disease [14-24]. Additionally, external factors such as nutrition, 
supplements and veterinary drugs have shown to directly or indirectly impact insulin 
action [25-31]. In particular, pharmacological drugs with known insulin-antagonistic 
action, such as anti-inflammatory glucocorticoids, have been shown to acutely alter 
whole-body insulin function in several species including horses [32-37]. Whether 
naturally occurring or induced, insulin dysregulation (ID) leads to decreased tissue 
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nutrient uptake and stimulation of synthetic pathways and lowers the inhibition of 
catabolic pathways, potentially leading to hyperglycemia, dyslipidemia and protein 
degradation [2, 38, 39]. Consequently, abnormalities in normal insulin signaling can have 
detrimental health implications and are underlying factors in equine metabolic diseases 
such as insulin resistance, obesity, laminitis and equine metabolic syndrome [23, 24, 40, 
41].  
Despite this knowledge, the majority of research in the field of ID, both in horses 
and other species, has focused on the consequences on impaired glucose homeostasis and 
developing treatment strategies to improve glycemic control. It was not until the last few 
decades that the relationship between ID and altered protein metabolism started to gain 
more attention in human research. Studies in human and rodents have now clearly 
indicated that there are strong correlations between ID and altered whole-body protein 
metabolism [42-45]. Furthermore, it is well known that tissue insulin resistance (IR) 
decreases mTOR signaling, upregulates proteolytic pathways and can eventually lead to 
muscle atrophy [38, 46-48]. However, despite the importance of maintaining muscle 
mass for optimal health and performance, little information is available on the effects of 
ID on muscle protein metabolism in horses.  
The focus of this review is to summarize the literature pertaining to the 
knowledge of the relationship between insulin and protein metabolism, the regulation of 
mTOR pathway signaling in skeletal muscle and the consequences of ID on these 
pathways, with a review of any relevant equine literature. Specifically, following a short 
review of dietary protein digestion and absorption, the individual signaling components 
involved in muscle mTOR signaling pathways and their regulation by anabolic and 
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catabolic stimuli will be discussed. Because of the extensive use of the glucocorticoid-
induced ID model in this PhD work, the effects of glucocorticoids on skeletal muscle 
metabolism will discussed in more elaborate detail. Next, there will be an overview of 
whole body insulin function and its role in protein metabolism followed by a discussion 
of the consequences of ID on amino acid and protein metabolism as has been shown in 
other species. Finally, research pertaining ID in horses will be reviewed, specifically 
focusing of two experimental models used to study effects of ID in horses, which are 
glucocorticoid induced IR and equine metabolic syndrome. 
 
1.2. PROTEIN METABOLISM IN THE HORSE 
To understand the impact of insulin dysregulation on protein metabolism, the 
following section will give an overview of the mechanisms and regulation of protein 
metabolism, specifically focusing on muscle protein signaling pathways. First will be a 
short discussion of protein nutrition and digestion in the horse, followed by a review of 
the mTOR pathway and its regulatory role in muscle protein synthesis and degradation. 
Upstream and downstream signaling factors of mTOR will be discussed, as well as 
specific proteolytic pathways including the ubiquitin-proteasome pathway and 
autophagy. Regulatory factors affecting these pathways, including positive and negative 
growth factors, nutrients and inflammatory mediator NF-κB, will also be discussed. 
1.2.1. Protein digestion and absorption 
In order to use the amino acids provided in feed, dietary protein is broken down to 
smaller peptides and individual amino acids by enzymatic digestion in the equine 
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stomach and small intestine, and these are absorbed and enter the body amino acid pool. 
Dietary nitrogen digestibility in horses depends on the digestibility of the protein source 
(i.e. forage protein versus protein from concentrates or supplements) but reports indicate 
an approximate 60 to 95% total tract digestibility for forages and cereal grains, 
respectively [49, 50]. Additionally, studies have shown that apparent nitrogen 
digestibility also increases with increased CP intake [51]. However, excess protein or 
protein that is less available for digestion in the foregut (e.g. protein bound to fiber 
fractions) will overflow into the large intestine, where it is fermented by microbes. 
Although evidence exists of microbial amino acid production and the presence of amino 
acid transporters in the hindgut of the horse, it is still unclear whether hindgut absorption 
of nitrogen sources other than ammonia make any substantial contribution to whole-body 
protein metabolism [52, 53]. Because protein is primarily digested in the foregut, thereby 
minimizing microbial protein contributions, protein requirements in horses can only be 
met by the diet. Therefore, horses are sensitive to protein quality, requiring a diet with an 
adequate amino acid profile to meet requirements for essential amino acids. In horses, 
histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan 
and valine are thought to be dietary essential amino acids. Current NRC (NRC, 2007) 
recommendations to meet average protein requirements for a mature horse indicate a 
need for 1.26 CP/kg BW/day. Although several studies have been conducted to 
investigate which amino acids are most limiting in equine diets, there is currently only a 
specified requirement for lysine, which is estimated to be 27 g/day or 4.3% of the CP 
requirement, for the average 500 kg mature horse. 
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As they cannot be stored, there are two major metabolic fates of amino acids: they 
can be used for whole-body protein synthesis or will be shunted into pathways for their 
catabolism and excretion as CO2 and urea. Because amino acids and their metabolites 
serve a multitude of purposes in all body tissues, inter-organ amino acid transport is 
highly active and regulated. The main site of amino acid catabolism is the liver and to a 
lesser extent the intestinal cells, which have a partial urea cycle and can deliver their 
nitrogenous products to the liver via the hepatic portal vein. However, because blood 
ammonia levels are tightly regulated, amino acid catabolism in extra-splanchnic tissues 
requires transportation of nitrogen waste to the liver [54]. Nitrogen balance is maintained 
by nitrogen scavenging and “transporter” amino acids including alanine, glutamate, 
glutamine, aspartate and asparagine [55]. Further contributing to the inter-organ amino 
acid flux is the use of amino acid as energy substrates in gluconeogenic organs (i.e. liver 
and kidney) under certain conditions, such as starvation, sepsis or trauma. In comparison 
with other blood metabolites such as glucose, less is known about the regulation of 
extracellular amino acid concentrations, in particular in horses.  
Feeding has previously shown to increase plasma concentrations for essential 
amino acids in horses, with peak concentration observed between 90-120 min post-
feeding, however peak levels have shown to depend on meal type (i.e. concentrate vs 
forage) and meal size [56-58]. Subtle developmental differences in postprandial plasm 
amino acids responses have also been reported [14, 59, 60]. Plasma urea nitrogen (PUN) 
levels are often used to assess amino acid catabolism and have been used in horses to 
assess dietary protein utilization [61]. PUN levels in horses have been shown increase 
and decrease with excess protein intake or specific amino acid supplementation, 
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respectively, reflecting modulation of catabolic pathways depending on availability of 
essential amino acids [61, 62]. Similar to other species, plasma amino acid concentrations 
in horses are known to change in response to different physiological states. Both non-
essential and essential amino acids have been shown to fall to near basal levels after a 18-
30 h fast, followed by a rise in most essential amino acids at 48 h of fasting [56, 60]. 
Additionally, amino acid concentrations increased and decreased during a short and long 
bout of exercise, respectively [63]. In particular, those involved in inter-organ energy 
metabolism, including alanine and glutamine are reported to be increased with both 
exercise and fasting in horses. These results indicate that amino acids are effectively 
being mobilized and/or catabolized for energy metabolism when necessary. This provides 
evidence of the fluidity by which amino acid fluxes rapidly shift under changing 
physiological conditions, suggesting they play an essential role in maintaining whole-
body homeostasis. Consequently, these well-regulated fluxes are easily disturbed during 
illness, stress or disease, and altered amino acid metabolism has been reported in diseases 
with underlying insulin dysregulation [43, 64]. Considering the complexity of whole-
body amino acid metabolism, which has been reviewed elsewhere [54, 65], further 
Chapters will focus on the effects of insulin dysregulation on amino acid metabolism.  
1.2.2. The mTOR pathway 
 
Protein makes up about 15% of total body mass, with skeletal muscle being the 
largest pool of the body’s protein. Muscle mass accretion and atrophy are mediated by 
intricate crosstalk between the modulators of the protein synthetic and proteolytic 
pathways. In the center of this complex cellular signaling system, the mTOR pathway 
plays a key role in controlling muscle mass by regulating and activating protein 
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translational machinery. The following section will cover a general overview of mTOR 
pathway signaling and regulation based on information from cell culture, rodent and 
human studies. Relevant equine literature will be discussion in a later section.  
1.2.2.1. mTOR complexes 
 
mTOR is a serine/threonine protein kinase capable of sensing environmental and 
intracellular nutrient and energy status, thereby modulating responses of diverse cellular 
processes accordingly to promote growth and survival. mTOR forms the catalytic subunit 
of two biochemically and functionally distinct mTOR complexes, mTOR complex 1 
(mTORC1) and 2 (mTORC2). mTORC1 consists of mTOR, RAPTOR (the regulatory 
protein associated with mTOR), DEPTOR (the DEP domain-containing mTOR-
interacting protein), PRAS40 (the 40 kDa proline-rich Akt substrate) and mLST8 (the 
mammalian lethal with Sec13 protein 8). The RAPTOR and mLST8 subunits promote 
mTOR function while PRAS40 and DEPTOR act as inhibitory components [66]. The 
mTORC2 also contains mLST8 and DEPTOR, however instead of RAPTOR it is 
associated with RICTOR (the rapamycin-insensitive companion of mTOR), mSIN1 
(mammalian stress-activated map kinase-interacting protein 1) and Xpln (the exchange 
factor found in platelets and leukemia and neuronal tissues). Whereas RICTOR is 
responsible in aiding the proper assembly of mTORC2, mSIN1 plays a role in 
relocalization of mTORC2 to interact with other signaling molecules [67]. Both mTOR 
complexes are primarily found in the cytoplasm but can shuttle to the nucleus and 
lysosome when activated. mTORC1 modulates pathways for cell growth and metabolism, 
including protein synthesis and is therefore a key regulator in controlling skeletal muscle 
mass. mTORC2 is responsible for coordinating cellular proliferation and survival by 
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regulating molecules involved in cytoskeleton remodeling and inhibiting factors that 
promote apoptosis. Throughout the remainder of the dissertation, mTOR signaling will be 
referring to mTORC1 signaling unless otherwise noted.   
1.2.2.2. Upstream of mTOR signaling 
 
As a metabolic sensor, mTOR integrates several extracellular and intracellular 
signals including growth factors, energy status, amino acid availability, oxygen levels and 
mechanical stimuli (Figure 1.1). Considering mTOR’s anabolic role, its activation 
typically only occurs under conditions where sufficient energy, chemical building blocks 
and pro-growth hormonal signals are present. Therefore, postprandial mTOR activation 
promotes growth and energy storage in several tissues. Conversely, mTOR signaling is 
inhibited when resources and energy are limited. With exception of amino acids, these 
upstream signals inhibit the negative regulator tumor suppressor tuberous sclerosis 
complex 1 and 2 (TSC1/2), which activates small GTPase, Rheb (Ras homologue 
enriched in brain), an essential mTOR activator.   
Insulin and Insulin-like growth factor 
Signal transduction of both insulin and insulin-like growth factor-1 (IGF-1) is 
mediated through the IRS-1/PI3K/Akt pathway, which subsequently activates mTOR 
(Figure 1.1). Although the literature is somewhat equivocal on the distinct difference 
between insulin and IGF-1 signaling, it is suggested that insulin is primarily a metabolic 
mediator, while IGF-1 is a growth promotor [68-70]. However, the main signaling 
pathways activated by insulin and IGF-1 are largely overlapping as their receptors both 
catalyze identical phosphorylation patterns in the insulin receptor substrate (IRS) protein. 
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Additionally, both peptide hormones and their receptors are highly homologous and it has 
been illustrated that both ligands are able bind to the other’s receptor, albeit with lower 
affinity, and that the receptors are able to mediate each other’s function [69, 71]. 
Regardless, binding of insulin or IGF-1 to the membrane receptor will lead to tyrosine 
phosphorylation of the IRS, which will mediate insulin/IFG-1 action by triggering an 
intracellular signaling cascade that controls several processes [2].  
There are four well-known IRS, with IRS-1 being the major IRS in skeletal 
muscle [72]. IRS-1 can be activated by both IGF-1 and insulin, mediating the mitogenic 
effects of these growth factors [73, 74]. Phosphorylated IRS will allow for interaction 
with src-homology-2 domain protein (SH2), including adaptor proteins and enzymes such 
as phosphatidylinositol 3-kinase (PI3K) and its p85 regulatory subunit. PI3K is a key 
signaling molecule in insulin signaling, activating glucose, protein and lipid metabolic 
pathways, thereby mediating insulin’s anabolic effects [75]. PI3K action is mediated 
through serine/threonine kinases including Akt/protein kinase B, protein kinase C and 
other kinases. Activation of Akt occurs through phosphorylation at different sites, 
however, in response to insulin/IGF-1 stimulation, Akt is phosphorylated at Ser473 [76]. 
Akt activation will inhibit PRAS40, thereby causing its dissociation from mTOR. 
Additionally, Akt phosphorylates TSC2, a component of the TSC1/2 complex acting as a 
GTPase- activating protein (GAP) for the G protein Rheb [77]. Phosphorylation of TSC2 
by Akt will lift its inhibitory action on Rheb, thereby allowing it to bind and activate 
mTOR.  
In addition to mTOR activation, Akt will promote glucose uptake in fat and 
muscle tissue by stimulating GLUT-4 (glucose transporter 4) translocation to the cell 
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membrane [78]. Furthermore, Akt is also responsible for the phosphorylation of the 
Forkhead box O (FoxO) transcription factors, thereby sequestering them in the cytosol 
[79]. FoxO transcription factors are responsible for the upregulation of proteolytic 
pathways and will be discussed in greater detail later. However, Akt phosphorylation 
inhibits their function, thereby further promoting protein synthesis and decreasing protein 
degradation under the influence of anabolic hormones.  
IGF-1 and other growth factors can also stimulate mTOR through Akt-
independent pathways including the extracellular regulated kinase axis (MEK/ERK), 
which mediates the mitogenic effects of insulin and IGF-1 [3]. Activation of this pathway 
involves the activation of RAS (rat sarcoma protein) and subsequently mitogen activated 
protein 3 kinase (MAP3K). MAP3K will then stimulate MEK and ERK1/2 leading to 
inhibition of TSC2 and thus activation of mTOR.   
Cellular energy status 
In order to preserve cellular energy when growth conditions are not optimal, 
mTOR is highly sensitive to ATP levels, hypoxia and other indicators of cellular stress 
(Figure 1.2). AMP protein kinase (AMPK) is also highly sensitive to the intracellular 
energy status. As described earlier, when energy levels are high, for example after a meal, 
insulin stimulation will promote glucose transport and metabolism in the cell, thereby 
generating ATP. High levels of intracellular ATP will inhibit AMPK and allow mTOR 
activation. Conversely, when ATP levels are low, phosphorylation at Thr172 will activate 
AMPK, which will consequently phosphorylate TSC2 at Thr1227 and Ser1345, leading to its 
activation and formation of the TSC 1/2 complex thereby preventing the Rheb-mTOR 
interaction [80]. Secondly, AMPK can also inactivate mTOR through direct 
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phosphorylation of its subunit RAPTOR [81]. It has also been shown that mTOR is 
inhibited when glucose levels are low through mechanisms independent of AMPK [66]. 
Therefore, it is clear that cellular energy status will strongly determine whether mTOR 
function is shifted in favor of anabolism or maintains inactive.  
In a similar manner, cellular hypoxia and stress will inhibit mTOR through 
AMPK-dependent and -independent pathways. Hypoxia has been shown to induce the 
expression of the REDD1 gene (regulated in development and DNA damage response 1), 
which is known to inhibit mTOR signaling by activating TSC2 (Figure 1.2) [82]. REDD1 
expression can also be increased by glucocorticoids [83], explaining in part why 
exogenous glucocorticoid treatment is often associated with muscle atrophy, as will be 
discussed later in this review. Lastly, endurance exercise has also shown to increase 
REDD1 expression, which could explain mTOR inhibition during exercise [84]. 
However, other mechanical stimuli, induced by different types of exercise, have shown to 
increase mTOR activation by inhibiting TSC2, thereby promoting protein synthesis and 
muscle hypertrophy[85]. Therefore, it is clear that muscle accretion depends on cellular 
status and both positive and negative regulatory factors.  
Amino acids 
Besides their vital role as building blocks for protein synthesis, amino acids also 
provide an anabolic stimulus for mTOR activation through insulin-independent pathways 
(Figure 1.1). The pathways by which amino acids trigger mTOR activation are highly 
complex and have only recently been fully elucidated [66]. Briefly, amino acid-mediated 
activation occurs through activation of different Rag GTPases (Rags), allowing them to 
bind RAPTOR and recruit mTOR to the lysosomal surface where Rheb is located. 
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However, translocation of mTOR closer to Rheb does not necessarily activate mTOR 
directly. Considering Rheb activation is mediated by the TSC1/2 complex, as discussed 
earlier, this explains why both growth factors and amino acid are necessary to fully 
activate mTOR. The exact mechanisms by which mTOR is able to sense intracellular 
amino acids involves the lysosomal amino acid transporter SLC38A9, which has shown 
activate Rags and play a role in arginine-mediated mTOR activation in the lysosome [86]. 
Cytosolic amino acids are able to signal to mTOR through the negative and positive 
mTOR regulators GATOR1 and GATOR2 complexes, respectively. More specifically, 
GATOR2 interacting protein, Sestrin2, is a direct leucine sensor and binds GATOR2 in 
the absence of leucine, and dissociates from it upon leucine binding [87]. Through a 
similar mechanism, cytosolic arginine activates mTOR through binding of an arginine 
sensor CASTOR1, which binds and inhibits GATOR2 in the in the absence of arginine, 
while dissociating from it when bound to arginine [88]. Additional mechanisms by which 
amino acids stimulate mTOR have been described, working through Rag-dependent and -
independent pathways [66].  
1.2.2.3. Downstream effectors of mTOR signaling 
To promote cell growth, production of proteins, lipids and nucleotides must 
increase, while catabolic processes remain suppressed. Although mTOR stimulation of 
growth and development includes regulation of protein, lipid, glucose metabolism, the 
following section will only review mTOR function in the activation of protein synthesis. 
In order for protein synthesis to occur, ribosomes and protein translational machinery 
must be assembled properly for mRNA translation to initiate. This process is made 
possible by recruitment of the necessary substrates by RAPTOR, bringing them in close 
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proximity to be phosphorylated by mTOR. Key downstream targets for mTOR 
phosphorylation are p70S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding 
protein 1 (4E-BP1) (Figure 1.1) [89, 90].  
mTOR is able to directly phosphorylate S6K1 at Thr389, Thr229, Ser404 and Thr412. 
Activated S6K1 will subsequently phosphorylate and activate several components that 
promote mRNA translation initiation, including eIF4B, ribosomal protein S6 (rpS6) and 
SKAR. S6K1 interaction with SKAR, a component of exon-junction complexes, will 
enhance translation efficiently of spliced mRNA’s [91]. Activation of RNA binding 
protein eIF4B is essential for the recruitment of ribosomes to mRNA and is a positive 
regulator of the 5’ cap binding eIF4F complex, which mediates mRNA and ribosome 
association. Additionally, S6K1 will further promote eIF4B activity by stimulating 
degradation of its inhibitor PDCD4 [66]. S6K1 will also phosphorylate rpS6 at Ser235, 
Ser236, Ser240, Ser244, and Ser247. rpS6 is another vital component in protein synthesis and 
regulates cell growth by controlling cell size and division [92]. Ultimately, S6K1 is 
responsible for improving protein translational efficiency and regulating cellular 
proliferation.  
4E-BP1 inhibits translation by binding eIF4E, the rate-limiting translation 
initiation factor, thereby preventing assembly of the eIF4F complex. Phosphorylation of 
4E-BP1 by mTOR can occur at Thr37and Thr46, causing it to dissociate from eIF4E and 
allowing formation of the eIF4F complex. Formation of this complex is essential for 
mRNA and ribosome association and will be followed by scanning of the mRNA strand 
and consequently, elongation of the polypeptide chain and protein synthesis [93].  
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As mentioned previously, the mechanisms regulating protein synthesis respond to 
changes in intracellular environment and modulate pathways accordingly to protect 
cellular integrity. For example, S6K1 is known to inhibit mTOR under certain conditions, 
acting as a signaling molecule in a negative feedback loop. Hyperactivation of mTOR 
due to chronic nutrient excess, hyperinsulinemia or pro-inflammatory cytokines, has been 
shown to result in S6K1-mediated inhibition of IRS-1 signaling [66, 94]. In particular the 
potential for excess amino acids to induce this feedback mechanism has received 
considerable attention. Increased amino acid availability has been shown to induce 
insulin resistance in humans and mice, by phosphorylating IRS-1 at Ser1101 [95, 96]. 
Rather than activating IRS-1, serine phosphorylation will inhibit its function, leading to 
decreased insulin/IGF-1-mediated signaling and therefore reducing tissue insulin 
sensitivity. Activation of this feedback mechanism has been implicated in the 
pathophysiology of metabolic diseases such as obesity and diabetes in rodents and 
humans.  
1.2.3. Pathways associated with muscle protein breakdown and their interaction 
with mTOR 
Skeletal muscle mass is maintained by tightly balancing protein synthetic and 
proteolytic pathway activities. As mentioned previously, this equilibrium is dynamic and 
easily tips in favor of anabolism or catabolism depending on the physiological state. 
Muscle accretion can therefore only occur when the rate of protein synthesis exceeds the 
rate of protein degradation. Conversely, normal protein turnover plays a significant role 
in maintaining whole-body homeostasis. Despite the tight regulation of muscle protein 
turnover, there are several catabolic conditions that will disrupt the balance, resulting in 
muscle atrophy. Proteolytic mechanisms are responsive to a number of different triggers, 
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including negative growth factors (e.g. myostatin), certain hormones (e.g. 
glucocorticoids, cathecholamines), inflammatory cytokines, oxidative stress, metabolic 
stress and nutrient availability. The two major intracellular proteolytic systems in 
mammalian cells are the ubiquitin proteasome pathway (UPP) and the lysosomal system. 
Additionally, Ca2+-dependent calpains and caspases play a minor role in protein 
degradation. The three pathways of protein degradation have been recently reviewed 
elsewhere [97-101]. In order for mTOR to support cell growth, it suppresses several 
regulatory molecules involved in these proteolytic pathways. The following section will 
give a brief overview of the UPP and lysosomal pathway and their interaction with the 
mTOR pathway, as well as specific signaling through FoxO, myostatin and NF-κB 
pathways (Figure 1.2).  
1.2.3.1. The ubiquitin-proteasome pathway 
 
The ATP-dependent UPP is responsible for the turnover of most soluble and 
myofibrillar muscle protein [101]. The mechanism of this pathway consists of the 
concerted actions of enzymes that link chains of the polypeptide co-factor, ubiquitin 
(Ub), onto proteins, thereby marking them for degradation. Subsequently, these “tagged” 
proteins will be recognized by a multicatalyic protease complex that will degrade them to 
smaller peptides. There are three enzymatic components responsible for this tagging 
process: E1 (ubiquitin-activating enzyme), E2 (Ub-carrier proteins), and the key enzymes 
in the process, the E3 (Ub-protein ligases). Although more than 1000 E3 ligases have 
been identified, there are two ligases in particular that play an important role is skeletal 
muscle atrophy, which are atrogin-1 and MuRF-1 (muscle ring finger-1) (Figure 1.2). 
Under catabolic conditions, the activity of this pathway is increased by transcriptional 
17 
 
upregulation of ubiquitin, several proteasomal subunit genes as well as atrogin-1 and 
MuRF-1 [101]. Increased expression of atrogin-1 and MuRF-1 has been documented in 
several models of muscle wasting, including those associated with glucocorticoid-
mediated muscle atrophy [102-104]. Conversely, targeted gene inactivation is a major 
pathway to reduce the rate of muscle atrophy, as has been shown by deletion of atrogin-1 
and/or MuRF-1 genes [99]. Two signaling pathways in particular appear to play an 
important role in the activation of ubiquitin ligases, one that is mediated by the FoxO 
transcription factors and a second one that involves signaling through the nuclear factor-
kappa B (NF-κB) transcription factor. Both of these pathways will be discussed in greater 
detail in later sections. mTOR interaction with the UPP can occur through different 
mechanisms and is still not fully elucidated. However, as Akt is an important inhibitor of 
FoxO protein, activation of the Akt/mTOR pathway can also inhibit the upregulation of 
UPP E3 ligases [105]. Additionally, it’s been shown that mTOR activation is associated 
with less protein ubiquitination and a decrease in proteasomal chaperones, thereby 
inhibiting proper proteasome assembly [66].  
1.2.3.2. The autophagic/lysosomal pathway 
The lysosomal pathway is responsible for the degradation of portions of the 
cytoplasm, cell organelles or internalized extracellular or membrane proteins which are 
sequestered into autophagosomes. The latter will then fuse with lysosomes resulting in 
the digestion of its content by lysosomal proteases. In mammals, two protein kinases, 
Unc-51-like kinase 1 and 2 (ULK1/2), play an important role in the regulation of this 
pathway. These kinases form complexes with several autophagy regulatory proteins, 
ultimately allowing the formation of the autophagosomes. Autophagy is typically 
18 
 
upregulated during nutrient starvation, however, other stimulatory factors include 
physiological stress, certain pharmacological agents and diseases. mTOR regulation of 
autophagy works through several, complex mechanisms of which only a few will be 
discussed in this review. Under nutrient replete condition, mTOR phosphorylation of 
ULK 1 results in its deactivation, consequently reducing the formation of 
autophagosomes [106, 107]. Although ULK 1/2 function is oppositely regulated by 
phosphorylation at different sites, mTOR-mediated phosphorylation of ULK1 at Ser757 is 
known to inhibit ULK1 and is the site relevant to this dissertation research (Figure 1.2) 
[108]. mTOR has also been shown to directly inhibit other transcription factors 
implicated in the upregulation of genes for lysosomal biogenesis and autophagy 
machinery [66]. Secondly, it’s been shown that the FoxO3 transcription factor is involved 
in the upregulation of autophagy related genes; therefore FoxO inhibition when the 
Akt/mTOR pathway is activated will result in the inhibition of the UPP pathway [109]. In 
contrast to mTOR, AMPK phosphorylation of ULK1 at Ser317, Ser777 , among other 
reported sites, will results in its activation and consequently promotes autophagy [108].  
1.2.3.3. FoxO signaling    
FoxO proteins have diverse cellular functions and are implicated in the regulation 
of cell proliferation, survival and differentiation, as well as resistance to oxidative stress. 
Besides their regulatory role in protein degradation, they are also involved in 
carbohydrate and lipid metabolism and β-cell function [110]. It is therefore not surprising 
that FoxO transcription factors have also been implicated in the development of several 
diseases including insulin resistance, type II diabetes and cancer. 
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FoxO transcription factors are key players in muscle wasting by mediating 
upregulation of both the lysosomal and the UPP pathway. Mammalian cells contain three 
members of forkhead transcription factors, FoxO1 (FKHR), FoxO3 (FKHRL1) and 
FoxO4 (AFX). Although their functions largely overlap, FoxO1 has been suggested to 
play a role in the regulation of energy metabolism, modulating hepatic gluconeogenesis 
and lipid metabolism and β-cell function [110]. In a glucocorticoid model of muscle 
atrophy specifically, FoxO3a has been shown to upregulate atrogin-1 expression and 
dramatically decrease fiber size. Furthermore, addition of IGF-1 to dexamethasone (a 
potent glucocorticoid) treated cells suppressed atrogin-1 mRNA expression and increased 
Akt, FoxO1, 3 and 4 phosphorylation [111]. All three FoxO are active when 
dephosphorylated, allowing them to enter the nucleus and upregulate target gene 
expression (Figure 1.2). In vitro studies have shown that activation of AMPK leads to 
increased expression of FoxO transcription factors and consequently atrogin-1 and 
MuRF-1 [112]. Conversely, Akt will block the function of FoxO proteins through 
phosphorylation, thereby sequestering them in the cytoplasm. FoxO gene expression is 
tightly regulated, with increased expression seen in conditions associated with muscle 
atrophy such as fasting, glucocorticoid treatment and certain metabolic diseases [103]. It 
has been well illustrated that FoxO transcription factors are responsible for rapid 
induction of UPP ligases atrogin-1 and MuRF-1 gene during muscle atrophy [79]. 
Additionally, FoxO3 has also shown to increase the expression of LC3 and Bnip3, 
important markers and regulatory proteins for autophagy [109].  
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1.2.3.4. NF- κB signaling 
The family of nuclear factor-kappa B (NF- κB) transcription factors regulate a 
variety of cellular responses and contains 5 members which are further divided into 2 
groups. Different members of the NF-κB family are known to dimerize to facilitate DNA-
binding. The most prototypical heterodimers present in all cell types are the p50 and p65, 
which have been shown to be responsible for increasing pro-inflammatory and cell 
survival gene expression. Similar to FoxO protein, NF-κB dimers are sequestered in the 
cytoplasm until activated, however its inhibition is maintained by binding to IκBs 
(inhibitors of NF-κB) [113]. Activation of NF-κB, which involves ubiquitination and 
degradation of the inhibitory protein IkB, can occur through various stimuli, however, the 
majority are associated with the body’s immune response (e.g. infection, pro-
inflammatory cytokines, mitogens, cellular stresses, etc). Each of these stimuli will 
trigger distinct pathways, however, for the purpose of this review we will focus the role 
of NF-κB in skeletal muscle atrophy. In addition to the activation of NF-κB by 
degradation of the IκBs, post-translational modifications, including phosphorylation, 
acetylation and ubiquitination, have shown to regulate NF-κB p65 function. Specifically, 
it has been illustrated that IκB-kinase-mediated phosphorylation of NF-κB p65 at Ser536 
(the site measured for this dissertation research) is a major phosphorylation site for 
cytokine-induced activation of NF-κB in vivo [114].  
There are three proposed mechanisms by which NF-κB activation can lead to 
muscle protein degradation (Figure 1.2) [115]. First, NF-κB increases the expression of 
several molecules related to inflammation, including TNF-α, IL-1β, IFN-γ and IL-6, 
which are some of the most potent inducers of muscle wasting in chronic disease states 
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[116]. Inflammation-mediated muscle atrophy is complex but involves the inhibition of 
the expression and activity of growth hormones as well as enhancing the infiltration of 
immune cells into skeletal muscle tissue [117, 118]. Secondly, NF-κB augments the 
expression of several proteins of the UPP pathway. Specifically it has been shown that 
activated NF-κB increases the expression of MuRF-1 and E2 enzymes [119, 120]. Lastly, 
NF-κB is known to interfere with myogenic differentiation, in particular it impairs the 
process of muscle regeneration. The underlying mechanisms for this inhibitory action 
involves modulation of gene expression of several molecules involved in myogenic 
processes, including that of MyoD, an important myogenic transcription factor [121]. In 
addition to NF-κB, MyoD is also regulated by myostatin. 
1.2.3.5. Myostatin 
Myostatin, a member of the transforming growth factor-β family, is an important 
negative regulator of myogenesis and controls the proliferation of myoblasts. Its 
inhibitory function is mediated by decreasing the expression of myogenic genes including 
MyoD, Myf5 and myogenin. Specifically, regulation of MyoD activity by myostatin 
involves the increased phosphorylation of transcription factors Smad 2 and Smad 3, 
thereby maintaining the association between Smad 3 and MyoD, preventing MyoD 
activity and thus myoblast differentiation [122]. Specific deletion of myostatin in mice 
results in muscle hyperplasia and hypertrophy, and mutations within its gene are cause 
for the typical double-muscled phenotype in the Belgian Blue cattle breeds [123]. 
Additionally, the myostatin gene has also been implicated in muscle development and 
racing performance in horses [124]. In addition to its effect on differentiation genes, 
myostatin also affects the mTOR pathway by decreasing Akt phosphorylation, which in 
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turns results in the activation of FoxO and eventually the UPP pathway (Figure 1.2)[125]. 
Furthermore, the overexpression of myostatin reduced phosphorylation of downstream 
mTOR components S6K1, rpS6 and 4E-BP1 [126]. Conversely, genetic deletion of 
myostatin enhanced activity of rpS6 and S6K1, but not Akt and 4E-BP1 [127]. It has 
therefore been suggested that myostatin regulates protein synthesis and degradation in 
both an mTOR-dependent and -independent manner [4]. Interestingly, myostatin has also 
been shown to play an important role in glucocorticoid-induced muscle atrophy, which 
will be further discussed in the next section.  
1.2.4. Glucocorticoid-induced muscle atrophy 
Glucocorticoids (GC) are major regulators of immune function and modulate 
whole-body carbohydrate and protein metabolism when released as endocrine hormones 
in stress situations (e.g. sepsis, starvation, cachexia, etc.) or when administered as drugs 
to treat a variety of illnesses [128]. Increased circulating GC levels, whether due to 
pathophysiological conditions or exogenous GC treatment, have been associated with 
muscle atrophy [129]. Blocking GC function by adrenalectomy, deletion of muscle 
specific GC-receptors, or administration of a GC receptor antagonist during cases of 
sepsis, cachexia or starvation attenuated muscle atrophy, indicating that these hormones 
are at least in part responsible for muscle wasting [130, 131]. With this knowledge, GC-
induced muscle atrophy has proven to be a useful model to investigate the molecular 
mechanisms underlying skeletal muscle atrophy in other species such as rodents.  
Because of their prolonged lifespan and extensive athletic use, horses suffer from 
muscle wasting conditions similar to humans. However, with the exception of a few 
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studies that have investigated the mTOR pathway in healthy, young, mature [14] and 
aged [59] horses as well as those with equine Cushings disease [132], our current 
understanding of the activation of proteolytic mechanisms in equine muscle is still scarce. 
GC are commonly used anti-inflammatory drugs in equine veterinary medicine to treat a 
variety of clinical conditions. Therefore, using a GC-induced model of muscle wasting 
would not only give us further insight in the molecular mechanisms underlying muscle 
atrophy in horses but also allows us to investigate potential adverse effects of GC-use on 
protein metabolism. As the use of GC encompasses a large part of the research presented 
in this dissertation, the following section will briefly discuss the mechanisms of GC-
mediated skeletal muscle atrophy as has been reported in other species (Figure 1.3).   
1.2.4.1. Glucocorticoid mechanisms of action 
GC function is mediated through a GC-receptor (GR) mechanism, in which 
cytosolic GR exert their effects in genomic as well as non-genomic manners (Figure 1.3) 
[133]. GR receptors are present in virtually all cells and are ligand-inducible transcription 
factors [134]. Interaction of GC with the GR forms a activated receptor complex, which 
is able to bind to the GC response elements (GRE) on the promotor regions of target 
genes, thereby modulating expression of several proteins, including the upregulation and 
downregulation of anti- and pro-inflammatory proteins, respectively [133]. Despite its 
useful effects on mediating immune responses, GR also upregulates and/or 
downregulates gene expression of several other important regulators of metabolism, 
explaining the numerous adverse effects associated with excess circulating GC. 
Although, the important anti-inflammatory and immuno-suppressive effects of GC are 
mediated by genomic mechanisms, administration of GC also induce rapid clinical 
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effects. For example, it has been reported that improvements in lung function are notable 
within 2 h post GC administration in horses with recurrent airway obstruction [135]. 
Because genomic effects take hours to days to become evident, it has become clear that 
certain effects of GC are mediated through non-genomic mechanisms [136]. These 
involve non-specific interaction of GC with cellular membranes and/or receptors and 
interactions of the cytosolic GR with signaling components such as kinases, second 
messengers and molecules involved in electrolyte transfer. Through both genomic and 
non-genomic mechanisms, GC interfere with several metabolic pathways, explaining 
GC-associated development of insulin resistance and muscle atrophy. 
1.2.4.2. Anti-anabolic and catabolic actions of glucocorticoids 
Muscle atrophy caused by GC occurs through its interference with both protein 
synthetic and proteolytic pathways by blunting anabolic stimuli and insulin/IGF-1 
signaling, as well as upregulating markers for protein degradation. As mentioned 
previously, protein synthesis can only occur in the presence of amino acids and growth 
factor stimulation, both of which are downregulated by GC. 
Firstly, it has been illustrated that GC’s inhibit transport of amino acids into the 
muscle (Figure 1.3) [137]. Consequently, GC treatment has been associated with 
increased plasma amino acid levels in humans, dogs and rodents [138-142]. Additionally, 
it is also known that GC alter amino acid metabolism in several tissues including that of 
the gut, muscle and liver [143-146]. For example, GC’s are able to upregulate 
intracellular activity of the branched chain amino aminotransferase (BCAT) through 
upregulation of transcription factor KLF-15 in skeletal muscle (Figure 1.3) [147]. 
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Therefore, both decreased amino acid uptake as well as increased intracellular breakdown 
contributes to diminished amino acid-stimulated mTOR activation. Secondly, it is well 
documented that GC interfere with insulin function and cause IR, thereby inhibiting the 
stimulatory action of insulin on muscle protein synthesis. For additional details of the 
pathways by which GC induce IR, refer to section 1.3.4.1.  
In addition to inhibiting protein synthesis, GC also activate several proteolytic 
systems by increasing the expression of several components of the UPP and lysosomal 
pathways, including atrogenes (i.e. atrogin-1 and MuRF-1), subunits of the proteasome 
and molecules involved in autophagy (e.g. LC3 and Cathepsin L) (Figure 1.3) [48, 129, 
148]. Furthermore, GC are also known to modulate FoxO and myostatin activity, which 
play a significant role in muscle atrophy. A brief description of the molecular 
mechanisms by which GC interference with protein synthetic and proteolytic pathways 
will be discussed in the following sections.  
1.2.4.3. Glucocorticoid-mediates interference with Akt/mTOR signaling 
GC interfere with the insulin/Akt/mTOR pathway signaling through both genomic 
and non-genomic mechanisms (Figure 1.3). Firstly, it is known that GC reduce the 
expression and activation of IRS-1 protein by stimulating pathways leading to its 
degradation, as well as by altering mechanisms leading to its phosphorylation status 
[149]. IRS-1 inactivation by GC can be caused by inducing serine, rather than tyrosine, 
phosphorylation of IRS-1 [150, 151], as well as by inhibiting the IRS-1/PI3K interaction, 
thereby interrupting the insulin signal transduction. The latter involves increased 
expression of the p85α, a regulatory subunit for PI3K, as well as direct GR mediated 
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interference of IRS-1/PI3K binding. It has been shown that overexpression of the p85α 
subunit leads to decreased PI3K activity and consequently decrease Akt activation, 
leading to decreased myotube diameter [152]. Furthermore, the GR can bind to the p85α 
subunit, thereby preventing its association and activation of IRS-1, reducing PI3K 
activity [153]. Other mechanisms by which GC interfere with Akt activation also include 
upregulation of miR1, which reduced expression of heat shock protein 70 (HSP70), 
resulting in decreased phosphorylation of Akt [154]. 
As mentioned previously, both insulin and IGF-1 are able to stimulate protein 
synthesis, with IGF-1 being an essential anabolic hormone for muscle development. The 
potent stimulatory effect of IGF-1 on muscle protein synthesis has been illustrated by the 
fact that the addition of IGF-1 to GC-treated cells in vitro as well as the systemic 
administration or local overexpression of IGF-1 in skeletal muscle, is able to reverse 
and/or override GC-induced atrophy [102, 155, 156]. Interestingly, GC have shown to 
decrease IGF-1 production in the muscle which therefore further contributes to GC-
induced atrophy [157].  
In addition to interfering with upstream mTOR signal transduction, GC also 
directly inhibit mTOR function by enhancing transcription of two of its repressors, 
REDD1 and KLF-15 (Figure 1.3). Both genes have a functional GRE and are therefore 
direct targets for GR-mediated upregulation in the skeletal muscle [83]. REDD1 inhibits 
mTOR by inhibiting Rheb, whereas KLF-15 diminishes mTOR activation by amino acids 
by increasing BCAT and thus amino acid breakdown. Interestingly, reports indicate that 
GC-induced muscle atrophy was prevented by administration of branched chain amino 
acids, which restored mTOR activity, making it a potential therapeutic mechanism [147]. 
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Besides increasing the expression of BCAT, KLF-15 also cooperates with FoxO protein 
to upregulate the promotor activity of atrogin-1 and MuRF-1. These findings illustrate 
that GC decrease protein synthesis and enhance protein degradation through both 
Akt/mTOR-dependent and -independent mechanisms.  
Another downstream target of insulin/IGF-1/Akt signaling is glycogen synthase 
kinase 3β (GSK3β). Akt typically inhibits GSK3β under insulin stimulation, thereby 
leading to increased activity of glycogen synthase, thus promoting glycogen synthesis. 
However, it is suggested that GSK3β may also be involved in GC-mediated inhibition of 
protein synthesis by inhibiting eukaryotic transcription factor 2B-dependent translation. 
Moreover, in vitro and in vivo studies show that inhibition of GSK3β prevents muscle 
protein degradation and cell atrophy [158-161]. Although the exact mechanisms of action 
for GSK3β-mediated muscle atrophy are not entirely clear, it has been suggested to 
involve the increased expression of atrogenes and promoting the degradation of β-
catenin, an important stimulator of muscle growth [160, 161].  
1.2.4.4. Glucocorticoid-induced upregulation of proteolytic pathways 
The intricate crosstalk between proteolytic and synthetic pathways has been 
clearly illustrated in the previous sections. Through the above described pathways, GC 
will interfere with Akt activation, and consequently this will result in decreased 
phosphorylation of FoxO transcription factors, leading to the upregulation of the UPP by 
increasing the expression of atrogin-1 and MuRF-1 (Figure 1.3). Furthermore, FoxO 
expression, particularly FoxO1 and FoxO3a, in myotubes and skeletal muscle was 
increased by GC treatment [162]. Moreover, in vitro inhibition of FoxO3a reduced 
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atrogin-1 expression and prevented muscle cell atrophy [111]. However, it should be 
noted that the contribution of FoxO in GC-mediated atrophy has been shown 
predominately with in vitro studies; therefore further research in a more complex 
physiological system is necessary to verify this in vivo. While FoxO proteins are key 
regulators of atrogene expression, it has also been illustrated that the GR is also capable 
of directly upregulating MuRF-1 expression, providing a FoxO-independent stimulation 
of the UPP [163].  
As mentioned previously, GC also regulate the negative growth factor myostatin 
and increased myostatin expression is found in several GC-induced models of muscle 
atrophy [48]. Increased myostatin expression by GC treatment occurs both through 
genomic and post-transcriptional mechanisms (Figure 1.3). It has been reported that the 
myostatin gene has a functional GRE, allowing upregulation under stimulation of GC, but 
that this response is modest [164]. Therefore, additional post-transcriptional mechanisms 
play a role in increased myostatin expression, which have not been fully elucidated. It has 
been proposed that the downregulation of miR-27a by GC contributes to the stabilization 
of myostatin mRNA [165]. Other recent reports have suggested that GC-induced 
inhibition of Akt leads to an increase in CEBP phosphorylation (a transcription factor 
regulating maintenance and regeneration of skeletal muscle) and subsequently enhanced 
myostatin expression [166].  
In conclusion, the effects of GC on muscle protein metabolism are complex and 
involve both mTOR and other important regulatory systems. However, it is evident that 
excess GC do not only alter the balance between protein synthesis and degradation but 
also causes muscle dysfunction, which may cause weakness and reduced force. 
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Therefore, the consequences of prolonged GC use in horses could have a significant 
impact on their performance.  
1.2.4.5. Glucocorticoids and protein metabolism in horses 
Because of their potent anti-inflammatory effects, synthetic glucocorticoids, such 
as dexamethasone, are commonly used in the equine industry to treat a variety of clinical 
conditions including inflammatory airway diseases, immune-mediated diseases, recurrent 
airway obstruction and osteoarthritis [135, 167, 168]. Additionally, a single injection is 
commonly used to diagnose equine Cushing’s diseases (i.e. the dexamethasone 
suppression test) [169]. Despite its usefulness as an immuno-suppressive agent, the 
adverse effects of dexamethasone seen in horses are similar to those previously described 
in other species. GC have been implicated in the development of laminitis, a detrimental 
hoof condition, however, it has been illustrated that this likely only occurs in horses 
predisposed to the condition rather than healthy horses [134]. Most extensively reported, 
are the insulin desensitizing effects of GC administration, inducing a state of IR as early 
as 24 h after a single injection [170]. A more elaborate review on the effects of 
dexamethasone on glucose and insulin dynamics in horses will be presented in section 
1.3.4.1. Despite its well-described adverse effects on insulin action, the consequences of 
GC on muscle protein metabolism in horses have not received much attention. One study 
reported a decrease in the phosphorylation of GSK3α and GSK3β in insulin-stimulated 
equine skeletal muscle samples obtained after 21 days of dexamethasone treatment [33]. 
Although the horses were clearly IR after 21 days of dexamethasone treatment, as 
measured by an EHC (euglycemic hyperinsulinemic clamp) procedure, no effects of GC 
were observed on insulin-stimulated Akt phosphorylation or GLUT-4 content in the 
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muscle. As previously discussed, GSK3β is thought to play a key role in GC-mediated 
muscle atrophy and its decreased phosphorylation therefore suggests increased activation 
which could indicate that protein synthetic capacity was decreased. However, no other 
markers for protein synthesis or degradation were measured in this study. Despite its 
frequent use, often for several consecutive weeks, and clear evidence of its proteolytic 
action in the skeletal muscle of other species, little information is available of the effects 
of GC in equine muscle. Furthermore, the abundance, expression and regulation of 
components in muscle protein degradation pathways in horses have not yet been 
investigated. Taken together, prolonged GC administration in horses could result in 
muscle atrophy, which could provide a useful model to elucidate some of the underlying 
mechanisms involved in protein degradation in horses.  
 
1.3. INSULIN DYSREGULATION AND WHOLE-BODY PROTEIN 
METABOLISM 
Insulin plays an essential anabolic role in protein metabolism, stimulating 
postprandial amino acid uptake into tissues and promoting their conversion into body 
protein by activating intracellular enzymes and signaling molecules involved in the 
anabolic pathways, while also inhibiting those involved protein catabolic pathways. 
Consequently, abnormal insulin function will affect amino acid dynamics and tissue 
protein metabolism. The following sections will focus on the relationship between insulin 
and protein metabolism, starting with a definition of the term “insulin dysregulation” 
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followed by a brief overview of normal insulin function, from secretion to peripheral 
action and how ID affects these steps in relation to protein metabolism. 
1.3.1. Definition of insulin dysregulation   
 
“Insulin dysregulation” is a collective term for abnormalities in insulin 
metabolism and function, which include aberrations in insulin biosynthesis, release 
and/or clearance, as well as alterations in insulin action due to tissue insulin resistance 
(IR). An ID state therefore is typically characterized by basal hyperinsulinemia and an 
increased insulin response to an oral and/or intravenous glycemic challenge. Although IR 
and ID are often used interchangeably in the literature, they do not exactly describe the 
same condition. IR is referred to as a decreased sensitivity or response of insulin-sensitive 
tissues, such as muscle, adipose and liver, to insulin stimulation [171]. However, other 
physiological systems besides peripheral tissues can modulate insulin action and 
therefore contribute to the development of ID. More specifically, circulating insulin 
levels are function of pancreatic secretion and hepatic clearance, which respond to stimuli 
from digested nutrients and incretins, as well as counter-regulatory hormones. 
Consequently, dysfunction in any of these organs and regulatory mechanisms can lead to 
ID, regardless of existing peripheral IR. Additionally, a multitude of other factors, such 
as dyslipidemia and inflammation play a role in the development of ID. Therefore, 
although IR is a common symptom of ID, it is important to distinguish between the two 
terms and acknowledge the different pathophysiological processes and end-phase 
manifestations of the condition we simply call “insulin dysregulation”. A detailed 
description of the different aspects and physiological systems involved in this 
multifactorial disease goes beyond the scope of this review but has been covered 
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extensively elsewhere [3, 24, 172-174]. Further review will focus on the impact of ID on 
protein metabolisms and likewise, how changes in amino acid dynamics may contribute 
to ID.  
1.3.2. Insulin biosynthesis and secretion 
Insulin is a potent anabolic hormone secreted by the pancreatic β-cells and plays a 
pivotal role in maintaining blood glucose levels by stimulating cellular glucose uptake 
and regulating carbohydrate, lipid and protein metabolism. Containing an A and B chain 
linked by disulphide bridges, this 51 amino acid-long dipeptide is synthesized in the 
rough endoplasmatic reticulum, forming pre-proinsulin and consequently proinsulin. 
After its transportation through the Golgi apparatus, proinsulin is stored in secretory 
vesicles where it is then converted to insulin and C-peptide [3]. In response to a stimulus, 
insulin is released from the pancreatic β-cells into the portal vein in a pulsatile, and 
typically biphasic, manner with a rapid initial phase of secretion followed by a less 
intense, more sustained insulin release [175]. This biphasic response has also been 
observed in horses following ingestion of a carbohydrate rich meal [176].  
Because of its essential role in maintaining glucose homeostasis, insulin 
biosynthesis and secretion is largely regulated by glucose, however other factors 
including amino acids, fatty acids and gut incretins, among others, also influence these 
processes [3, 177]. Glucose-stimulated insulin secretion is mediated by glucose 
metabolism in the pancreatic β-cells thereby generating ATP. Consequently, closure of 
the K+-ATP-dependent channels will result in membrane depolarization and opening of 
the calcium channels, leading to increased intracellular calcium levels, which will trigger 
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insulin release from the secretory granules in the β-cells [3]. Other insulinotropic 
mediators such as incretins [178] and neural stimuli [179] induce insulin secretion 
through activation of phospholipases, protein kinases or adenylyl cyclase. Conversely, 
insulin secretion is inhibited by hormones including somatostatin [180], and leptin [181].  
Similar to other species, both plasma glucose and insulin have circadian rhythms 
in horses and insulin dynamics are also known to change with season [182-184]. It has 
been well illustrated that blood insulin levels rise following consumption of a concentrate 
feed in horses, due to an increase in postprandial blood glucose concentrations. It has also 
been shown that this response varies depending on the level and source of carbohydrates 
in the feed, as well as feed processing methods [176, 185-189]. Other factors influencing 
insulin secretion and function in horses include surgery, exercise, stress and diseases such 
as equine metabolic syndrome and polysaccharide-storage myopathy [17, 24, 190-193]. 
In line with the focus of this review, the contribution of amino acids, in particular, on 
insulin secretion will be further elaborated. 
1.3.2.1. Amino acid-mediated insulin secretion 
Although the major stimulus for insulin secretion is glucose, the insulinotropic 
effects of amino acids have been well-established. Ingestion of a protein rich meal has 
shown to result in elevated plasma insulin levels in several species [194], including 
horses [57, 195]. However, the extent of this secretory effect on insulin secretion seems 
to vary depending on the protein source, indicating that this response is affected by the 
amino acid profile of the diet. Several studies in humans and animals, including horses, 
have illustrated that both oral ingestion and intravenous infusion of amino acids results in 
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increased plasma insulin concentrations [177, 196-200]. However, as several of these 
studies provided amino acid concentrations well above physiological levels, caution 
should be given in the interpretation of these results. In vitro studies have illustrated that 
insulin secretion was not induced when individual amino acids were added at 
physiological concentrations but only at high concentrations, when given in mixtures 
with other amino acids or in the presence of glucose [199, 201]. For example, it is well-
known that arginine is capable of depolarizing the cell membrane thereby stimulating 
insulin release from the β-cells, however as this amino acid is typically only found at 
very low concentrations in the plasma, its contribution in vivo might be minimal. Indeed, 
a study in humans reported that most amino acids with exception of histidine, tyrosine 
and arginine resulted in increased insulin circulations when consumed by healthy humans 
at a dose that represents the amount of a single amino acid that might be ingested in a 
high protein meal [202]. Additionally, the route of delivery of amino acids plays an 
important role in assessing insulin response, as gut and liver metabolism as well as 
digestive hormones will contribute to the overall stimulatory effect of ingested amino 
acids, which is unaccounted for by intravenous delivery. Furthermore, it is known that 
different amino acids have the potential to stimulate insulin secretion through different 
mechanisms and that the magnitude of this response is influenced by other physiological 
factors such as the presence of glucose and the release of other hormones including 
glucagon. For example, it has been clearly illustrated that amino acids and glucose have a 
synergistic effect on insulin secretion [203, 204]. In particular leucine seems to have a 
strong insulinotropic effect when ingested with glucose, which has also been documented 
in horses [195, 205]. This synergistic effect has also been observed at the molecular level, 
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where the presence of glucose in an in vitro pancreatic β-cell line enhanced the 
insulinotropic effect of amino acids, indicating that the fuel provided by glucose 
metabolism may complement the uptake and use of certain amino acids and consequently 
their stimulation of insulin release [199].  
The complexity of the effects of amino acids on insulin secretion is the cause of 
the controversy in the literature pertaining to the capacity of individual amino acids to 
stimulate insulin secretion. However, the stimulatory action of amino acids on insulin 
secretion is thought occur through mechanisms including depolarization of the plasma 
membrane by cationic amino acid uptake or by amino acids co-transported with sodium, 
changes in cellular ATP status by pancreatic metabolism of amino acids and amino acid-
induced release of insulinotropic incretins [199]. In depth review of these mechanisms is 
beyond the scope of this review is published elsewhere [199, 201, 206]. Although their 
effects vary based on the reasons discussed earlier, insulinotropic effects have been 
reported for most amino acids but in particular arginine, leucine, lysine, proline, glycine, 
glutamate/glutamine, alanine, phenylalanine and serine.  
In conclusion, amino acids can stimulate insulin secretion through glucose-
independent mechanisms; however, their insulinotropic effects act in concert with several 
other postprandial anabolic mechanisms and are enhanced in the presence of glucose. 
With this knowledge, it is clear that these mechanisms could be affected in a state of ID, 
in particular as it has been shown that pancreatic sensitivity to glucose in decreased in 
certain cases of diabetes in humans [207]. The effects of ID on insulin secretion will be 
discussed in greater detail in the next section.  
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1.3.2.2. The effects of insulin dysregulation on amino acid-stimulated  
insulin secretion 
Abnormalities in insulin secretion have been well studied in individuals with type 
2 diabetes or conditions associated with impaired glucose tolerance, and are often related 
to progressive insensitivity of the β-cells to glucose stimulation [208]. However, despite 
potential pancreatic defects in glucose-sensing and –signaling pathways, it has been 
shown that the synergistic effect of amino acids and glucose is maintained and often even 
enhanced in humans with type 2 diabetes compared to healthy individuals [207, 209]. 
Additionally, it is known that the intravenous infusion of amino acids in type 2 diabetic 
humans resulted in increased plasma insulin levels [210]. It has therefore been suggested 
that despite diminished glucose-stimulated insulin secretion, pancreatic sensitivity to 
amino acids might be maintained or enhanced under conditions of ID. This hypothesis 
seems plausible considering that amino acids are able to stimulate insulin release through 
glucose-independent mechanisms, as described earlier.  
The insulin stimulatory effect of amino acids in conditions associated with ID has 
been primarily investigated in humans, in particular in relation to nutritional intervention 
strategies in subjects with obesity and type 2 diabetes. High protein diets have gained 
popularity with regard to their potential to induce weight loss by increasing energy 
expenditure [211]. Additionally, it has been suggested that the intake of high amounts of 
protein promotes insulin secretion and reduces glycaemia in diabetic humans, making it 
an attractive strategy in the management of the disease [212, 213]. Despite its popularity, 
several studies have illustrated that the prolonged intake of excess protein also 
contributes to the development of ID, which will be discussed later [43]. It must also be 
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noted, that human diabetes is not entirely similar to equine ID, because horses rarely 
suffer from reduced insulin production, a characteristic typical of human type 1 diabetes. 
In a state of tissue IR, horses typically show compensatory insulin secretion, which is 
evident from basal hyperinsulinemia as well as an increased insulin response to an oral 
glycemic challenge [214-217]. Whether the altered pancreatic sensitivity to the 
stimulation of amino acids plays a role in equine ID, or could potentially aggravate the 
condition, is currently unknown but warrants further investigation.  
1.3.3. Insulin action 
 
Insulin mediates its physiological effects via its binding to membrane insulin 
receptors present on various tissues including adipose, liver and skeletal muscle. The 
insulin receptor consists of 2 α- and 2 β-glycoprotein subunits, which are linked by a 
disulphide bond. The binding of insulin to the α-subunit of its receptor will induce a 
conformational change allowing ATP binding to the intracellular component of the β-
subunit. This will trigger the activation of the tyrosine kinase activity of β-subunit, 
resulting in autophosphorylation of the receptor. This reaction will subsequently lead to 
tyrosine phosphorylation of the IRS, which will mediate insulin action by triggering an 
intracellular signaling cascade that controls several processes as described in section 
1.2.2.2 [2]. Phosphorylated IRS will interact with PI3K resulting in subsequent activation 
of Akt. Akt in turn will stimulate GLUT-4 mediated glucose uptake in fat and muscle 
tissue, which forms the major pathway for insulin to maintain blood glucose within 
normal levels. The presence of GLUT-4 transporters has also been established in equine 
skeletal muscle and reduced active cell-surface GLUT-4 has been implicated in horses 
with IR [218-220]. Besides activation of glucose uptake, insulin signaling through PI3K 
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will also promote glycolysis, glycogen synthesis, fatty acid synthesis and protein 
synthesis (as described earlier) by controlling expression and activity (by modulating 
phosphorylation and/or dephosphorylation) of enzymes and signaling molecules involved 
in these pathways. Through similar mechanisms, insulin simultaneously suppresses 
lipolysis, gluconeogenesis, glycogenolysis and proteolysis, thereby further promoting 
anabolic pathways [3].  
In the skeletal muscle, postprandial elevations in circulating insulin will promote 
transmembrane uptake of amino acids and trigger protein synthetic pathways, thereby 
increasing the demand for amino acids, which will further enhance their transport into 
cells [221]. Therefore, insulin’s key anabolic role is mediated by both providing 
necessary building blocks and as the metabolic switch required to activate protein 
synthetic pathways. ID is known to affect both of these factors, not only altering skeletal 
muscle protein metabolism, but also whole body amino acid dynamics. Interestingly, 
elevated levels of circulating amino acids have also shown to induce ID [222], 
emphasizing again the intricate and complex relationship between protein metabolism 
and insulin regulation. 
1.3.3.1. Effects of insulin dysregulation on protein and amino acid 
dynamics 
 
There is a vast amount of research illustrating that amino acid metabolism is 
altered in subjects with ID [223, 224]. Elevated levels of plasma amino acids are 
commonly observed in obese and diabetic humans and have been associated with reduced 
insulin sensitivity [45, 225]. More specifically, changes in plasma concentrations of 
branched chain amino acids (BCAA), sulfur amino acids, tyrosine and phenylalanine are 
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commonly reported in obesity and insulin resistance, often before the onset of clinically 
diagnosed diabetes in humans [226]. The correlation between ID and abnormal amino 
acid metabolism has also been reported in more recent metabolomics-based studies, 
which further illustrated the relationship between elevated concentrations of certain 
plasma amino acids and the risk of developing diabetes in the future [227]. In particular, 
BCAA and their metabolites seem to be most strongly associated with ID and studies 
have proposed their potential use as biomarker to diagnose early diabetes [228]. Despite 
these associations, an exact causative relationship between altered amino acid profiles 
and dysregulation of insulin action has not been fully elucidated. The complexity of inter-
organ amino acid dynamics also introduces limitations in accurately defining the 
underlying causes for subtle shifts in blood amino acid patterns. However, based on 
information described in the previous sections, the underlying mechanisms may involve 
increased protein turnover, decreased oxidation and excretion of amino acids or their 
derivatives and/or decreased insulin-stimulated amino acid uptake and use for protein 
synthesis due to tissue IR.  
Changes in protein turnover have been reported in obese, IR and diabetic humans 
and could contribute to elevated blood amino acids concentrations. However, the 
literature is conflicting with some reports indicating lower nitrogen balance and greater 
protein turnover, while other studies reported no effects in obese and/or diabetic humans 
[44, 223]. Other studies have reported blunted protein anabolism during 
isoaminoacidemic and/or hyperinsulinemic-euglycemic clamp studies, however, when 
clamping insulin, amino acids and glycaemia at postprandial concentrations, the protein 
anabolic response did not differ in diabetic compared to healthy men [229]. This suggests 
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that there might be a difference in protein anabolic response depending on the levels of 
available amino acids, with diminished response to insulin stimulus when protein intake 
is lower in ID individuals. Therefore, protein requirements may be increased in subjects 
with ID, including horses, in particular when metabolic control is poor, caloric intake is 
reduced and the individual is sedentary. Further research regarding the protein anabolic 
response to insulin is necessary in horses suffering from ID, in order optimize dietary 
needs and maintain muscle mass. Collectively, the controversy in the literature 
emphasizes that the underlying pathophysiology of ID is complex and varies greatly 
between individuals depending on lifestyle, gender, diet, body weight and consequently 
the degree of metabolic dysregulation and homeostatic control.  
To exclude the potential impact of changes in protein synthetic capacity, most 
amino acid data reported in ID humans are concentrations in a fasted state. Although the 
literature is somewhat controversial, it has been proposed that alterations in intracellular 
amino acid metabolism seem to be the most likely reason for elevated circulating amino 
acid concentrations in a postabsorptive state. It has been suggested that changes in the 
activity of enzymes involved in amino acid metabolism, in particular that of the 
branched-chain α-ketoacid dehydrogenase complex (BCKD), could be a potential 
underlying mechanism. An excellent review on the contribution of BCKD in ID can be 
found elsewhere [226], however, decreased activity of BCKD in subjects with ID has 
been reported in several studies [230, 231]. Briefly, the BCKD is the rate-limiting step in 
BCAA oxidation and is typically inhibited under the influence on insulin. Additionally, it 
has been shown that protein and BCAA oxidation are inversely proportional to free fatty 
acid (FFA) oxidation, with obese rodents and humans displaying reduced use of protein 
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for energy when fasted. This is further explained by a reduction of intra-mitochondrial 
redox state during increased FAA oxidation, resulting in inhibition of the BCKD by the 
generated NADH [232]. Although a detailed review of lipid metabolism is beyond the 
scope of this dissertation, it is well-known that ID is often associated with dyslipidemia, 
in particular in obese subjects. This relationship has also been illustrated in obese horses 
and those with equine metabolic syndrome [22, 233]. Taken together these findings 
support that altered metabolic status (i.e. cellular FFA and redox status), such as what is 
seen with obesity and ID, could decrease BCAA breakdown leading to elevated blood 
concentrations of specific amino acids.  
Perspectives on amino acid-induced ID 
Although it is still unclear if elevations in blood amino acid levels are a cause or 
consequence of ID, it has been reported that high levels of circulating amino acids can 
induce cellular IR. As mentioned previously, amino acids are insulin secretagogues and it 
has been suggested that pancreatic sensitivity to amino acids is increased in subjects with 
ID. Several studies have reported that the intake of high protein diets in diabetic humans 
decreased overall insulin sensitivity and consequently decreased glucose uptake [234]. 
Additionally, chronic high protein intake in otherwise healthy humans and rodents has 
been shown to increase fasting glucose levels by decreasing hepatic suppression of 
gluconeogenesis by insulin and reduced insulin-mediated glucose disposal [235, 236]. 
Furthermore, amino acid infusion reflecting basal or twice basal concentrations during a 
hyperinsulinemic-euglycemic clamp, decreased whole-body glucose disposal and induced 
an IR state in healthy individuals [95]. This inhibitory impact of amino acids on insulin 
sensitivity seems to involve a direct action on the muscle cells thereby decreasing 
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peripheral glucose uptake. In vitro studies illustrated that basal and insulin-stimulated 
glucose transport in muscle cells was inhibited by both prolonged and acute amino acids 
exposure [94].  
Although several mechanisms have been described by which amino acids regulate 
cellular signaling, as reviewed elsewhere [43], the pathway by which excess amino acids 
are proposed to induce IR, involves the hyperactivation of mTOR and subsequently 
S6K1. As mentioned earlier, S6K1 is a key player in the activation of a negative feedback 
mechanism during overstimulation by nutrients, leading to serine phosphorylation of 
IRS-1, thereby inhibiting its signaling potential. Consequently, diminished IRS-1 
signaling will reduce insulin-mediated Akt activation and thus decrease GLUT-4 
mobilization to the cell membrane, explaining the observed decrease in glucose uptake 
[43]. In support of this, studies in humans and animals have illustrated that oral 
administration of leucine or infusion of amino acids induced IRS-1 serine 
phosphorylation at different sites and blunted PI3K activation in skeletal muscle [95, 
237]. Further evidence that this negative feedback loop plays an important role in IR is 
illustrated by the finding that the S6K1-IRS-1 pathway is also activated in obese animals 
and that S6K1 deficiency protects against diet-induced IR [238].   
In conclusion, it is clear that altered insulin function impacts a multitude of 
metabolic pathways (i.e. glucose, lipid and protein) leading to improper anabolism and 
catabolism of nutrients. Consequently, accumulation of intra- and extracellular 
concentrations of nutrients or their metabolites, whether that is caused by ID or through 
dietary imbalance, will trigger protective feedback mechanisms that will further decrease 
cellular sensitivity to insulin and attenuates normal metabolism. Although the 
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understanding of the underlying mechanisms responsible for changes in blood amino acid 
profiles in IR states is in its infancy, it is clear that changes in protein metabolism should 
be taken into consideration in subjects with ID.  
 
1.4. INSULIN DYSREGULATION IN HORSES 
 
In modern equine management practices where feed is always available and 
exercise often limited, the genetic traits that were once essential for horses to survive in 
harsh environments, are now often one of the causes of metabolic disorders. 
Consequently, the prevalence of diseases associated with ID is ever increasing, the most 
common and troublesome being laminitis. The often detrimental outcome of laminitis and 
its association with ID, has spurred the majority of equine research conducted in the last 
few decades to focus on management and preventative strategies to reduce obesity and 
ID. Although a vast amount of studies have evaluated the effects of ID on glucose and 
insulin dynamics, little is known of its effects on protein metabolism in horses.  
As is evident from the previous sections, the underlying mechanisms of ID are 
extremely complex and similar end-stage manifestations of the condition can occur 
through completely different pathophysiological processes. The development of ID in 
horses has been associated with a multitude of causative factors including genetics, 
degree of adiposity, inflammation, dietary management, and drug administrations. 
Because managing horses for a steady state of metabolic disease is difficult, many 
researchers have used experimentally induced models of ID and obesity to study 
underlying physiological and molecular changes. These models have included diet-
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induced obesity and ID [27, 239], insulin, lipid and lipopolysaccharide infusions [240-
243] and GC administration [29, 244].  
Despite their practical use in a research-type setting, the often non-physiological nature 
of experimental model limits interpretation and caution should be taken when making 
inferences relevant to naturally occurring ID. The following section will give a brief 
overview of relevant knowledge on equine ID, common measurement techniques to 
assess insulin sensitivity and discuss two equine models used to study ID that are relevant 
to this PhD work, namely, GC-induced IR and naturally occurring equine metabolic 
syndrome.   
1.4.1. The manifestations of insulin dysregulation in horses 
As described earlier, abnormal insulin function includes more than just peripheral 
IR, therefore, the term insulin dysregulation has also been adopted in the equine 
literature. In particular, after recent studies illustrated that not all horses with ID 
necessarily have peripheral IR, equine research has focused on the role of other systems 
contributing to the symptoms of ID, such as the gut and adipose tissue [172]. For 
example, it has been shown that horses can have a hyperinsulinemic response to oral non-
structural carbohydrates without showing a change in peripheral glucose uptake when 
subjected to both an oral and intravenous glucose tolerance test, indicating the 
involvement of the GI tract in the disease [245]. Similarly, despite a strong correlation 
between increased adiposity and changes in insulin sensitivity, some obese animals have 
normal insulin levels and conversely, hyperinsulinemia has been detected in lean horses 
and ponies [172].    
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As mentioned previously, several internal and external factors may lead to the 
development of ID, however, similar to humans, the most common contributors are both 
excessive and prolonged intake of high energy diets and lack of exercise in horses [27, 
215]. As described earlier, chronic nutrient excess and altered metabolism of endogenous 
glucose, fat and protein triggers negative feedback mechanisms resulting in decreased 
insulin sensitivity in various tissues and may alter gut, pancreatic and hepatic insulin 
metabolism. Although it is assumed that these mechanisms, work in similar ways as 
reported in other species, they have not yet been thoroughly investigated at the molecular 
level in horses. However, it is suggested that repeated, chronic postprandial 
hyperinsulinemia triggers cellular adaptive mechanisms that will ultimately lead to tissue 
IR. Previous studies in healthy horses illustrated that insulin infusion resulted in 
decreased GLUT-4, GLUT-1 and insulin receptor mRNA in adipose tissue, increased 
GLUT-1 mRNA but decreased GLUT-1 and insulin receptor protein expression in 
skeletal muscle [246, 247]. Additionally, insulin infusion increased fatty acid transporter 
and lipoprotein lipase in skeletal muscle. Another study reported decreased cell-surface 
GLUT-4 expression in skeletal muscle of IR horses [220]. Although no further pathway 
signaling components were identified, based on our knowledge in other species, this 
suggests that the IRS-1/Akt stimulated translocation of GLUT-4 is decreased in horses 
with ID.  
Although not always the case, most horses with substantial ID have fasting 
hyperinsulinemia [27, 172, 248], which is likely attributed to both a persistent pancreatic 
secretion in response to elevated levels of circulating glucose, fatty acids, amino acids or 
other insulinotropic stimuli and/or decreased hepatic clearance. Insulin clearance can be 
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assessed by determining the ratio of C-peptide to insulin, and a low ratio has been 
previously reported in horses with equine metabolic syndrome, providing evidence that 
hepatic clearance of insulin might be impaired in horses with ID [214]. Despite 
compensatory insulin secretion to maintain glycemic control in the face of IR, there have 
been reports of increased glucose concentrations in horses with EMS. Glucotoxicity, 
which is known cause serious tissue damage in humans, has also been implicated in the 
development of laminitis [249].    
In addition to fasting hyperinsulinemia, the most common concern in horses with 
ID is an exacerbated insulinemic response to feed intake, which could be attributed to 
compensatory insulin secretion in response to tissue IR, altered pancreatic sensitivity to 
the stimulus of nutrients/incretins and/or delayed hepatic insulin clearance. Because 
glucose is considered the most potent stimulator for insulin release, most research has 
focused on glycemic and insulinemic responses to ingestion of pasture and concentrates 
rich in non-structural carbohydrates. As metabolic responses to high energy feedstuffs 
have been implicated in laminitis, this has led to the exclusion of high glycemic 
feedstuffs in the management of ID prone horses [215, 250, 251]. However, despite 
recent interest in the role of the gut incretins in hyperinsulinemia [245], the contribution 
of other strong insulinotropic nutrients, such as amino acids, in these horses has received 
little attention. Similarly, despite forage being the main component in equine diets, little 
is known on the influence of microbial end-products or alterations in the gut microbiome 
on ID.  
In conclusion, although the manifestation of ID in horses have been extensively 
described, very little is known on the underlying molecular mechanisms at the tissue 
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level. Moreover, the majority of research has focused on the insulin responses to high 
glycemic diets, yet little attention has been given to the contribution of other nutrients in 
the development of ID.  
1.4.2. Measurements to assess insulin sensitivity in horses 
 
In line with the previously discussed manifestations of ID, the diagnosis of the 
condition typically involves measurement of basal insulin levels and a dynamic test to 
assess peripheral insulin sensitivity. However, with recent evidence of the contribution of 
the enteroinsular axis, it is now commonly recommended that such dynamic testing also 
include an oral challenge to determine the insulin response to ingestion of feed.  
The first step in diagnosis of equine ID typically involves determination of basal 
insulin concentrations, with levels >20 µIU/mL being the common cut-off value for 
suspected ID. Although caution should be given in in the interpretation of a single fasting 
blood sample, it has been shown that basal insulin levels correlate to the results of more 
specific tests, such as the EHC procedure [19]. However, insulin and glucose 
concentrations can vary significantly in an individual over time due to diurnal 
fluctuations and other factors such as diet, season and stress. Therefore, it is warranted to 
conduct a more dynamic test such as glucose and/or insulin tolerance test or clamps in 
addition to a fasting blood sample. Detailed description of various glucose-insulin 
tolerance tests commonly applied in horses have been reviewed elsewhere [19]. 
Therefore, the following section will discuss two tests relevant to the research for this 
PhD work, which are the EHC and the oral sugar test.  
48 
 
1.4.2.1. The euglycemic-hyperinsulinemic clamp procedure 
Because fluctuations in endogenous insulin secretion interfere with interpretations 
from of single blood sample or with tolerance testing, accurate determination of tissue 
insulin sensitivity is impossible. Therefore, the clamp technique was first introduced in 
human medicine by DeFronzo et al [252], and has been successfully applied in horses 
[32, 191]. By infusing a predetermined concentration of insulin, the EHC induces a 
supra-maximal steady state in insulin levels (i.e. “clamp”), thereby eliminating 
endogenous interference. Simultaneously, glucose is infused at a rate to maintain 
euglycemia, based on blood glucose levels assessed from frequently obtained venous 
blood samples. When glucose infusion reaches a steady plateau, the infusion rate is 
assumed to equal the rate of glucose disposal, and therefore provides an indication of 
tissue sensitivity to insulin-stimulated glucose uptake [253]. A slightly modified method 
is the isoglycemic-hyperinsulinemic clamp procedure where glucose levels are 
maintained at basal levels for each individual horse, rather than a preset fasted glucose 
level (e.g. 5 mmol/L) [254]. Despite the criticism of its non-physiological nature, the 
EHC remains the “gold standard” for accurate diagnosis of IR and has shown to be more 
repeatable than other measures such as the frequently sampled intravenous glucose 
tolerance test in horses [255]. Additionally, the EHC also provides the advantage of 
inducing a steady insulin state, which allows investigation of insulin-stimulated 
metabolic pathways in tissues such as skeletal muscle. However, because the clamp 
procedures are labor-intensive, their use is limited to research and not feasible for clinical 
diagnosis of ID. This has led to the development of several more practical, though not as 
accurate, tests for assessing ID in the field. One of such tests is the oral sugar test.   
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1.4.2.2. The oral sugar test 
  
The oral sugar test (OST) falls under the glucose tolerance tests and was 
originally developed in humans to assess carbohydrate tolerance, as it measures plasma 
glucose response to an oral administration of a specified dose of glucose. Because plasma 
insulin and glucose concentrations following an oral glycemic challenge also reflect in 
part the pancreatic response to glucose and consequently the clearance of glucose, it has 
also been used in the diagnosis of insulin sensitivity. However, as mentioned several 
times, the response to an oral sugar test is complex and besides peripheral insulin 
sensitivity, it depends on rate of gastric emptying, small intestinal absorption, endocrine 
function of the pancreas and hepatic glucose metabolism. Therefore, although the OST 
might be an indication of underlying tissue IR it also suggests abnormalities in other 
tissues might be contributing to the insulin response. However, because the main concern 
in horses with ID is the response to intake of carbohydrate-rich feed, the OST will reflect 
this response more closely than an intravenous test.  
Although several oral glucose tests have been applied in horses [15, 19, 256], both 
through in-feed or nasogastric intubation, a simpler method has been developed using a 
commercially available corn syrup [217]. This test allow both horse owners and 
veterinarians to rapidly asses ID in the field. This test involves taking a baseline venous 
blood sample, after which the horse is given 0.15 mL/kg BW of Karo light corn syrup 
(ACH Food Companies) directly into the mouth with an oral dosing syringe. This dose is 
estimated to provide ~150mg/kg BW of dextrose-derived digestible sugars. An additional 
venous blood sample is obtained between 60-90 min post-sugar administration. Blood 
insulin concentrations >60µIU/mL, 60-90min after administration of the OST is typically 
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considered to be an indication of ID. The OST has shown to be closely correlated to 
intravenous glucose tolerance tests and although it does not provide a definite diagnosis 
of IR, it remains a useful tool to quickly assess overall insulin status of horses in the field 
[217].  
1.4.3. Glucocorticoid-induced insulin resistance 
 
Although insulin is considered a major anabolic hormone in a fed state, it acts in 
concert with other hormones including growth hormone and IGF-1 to drive metabolic 
processes. Conversely, counter-regulatory hormones including glucagon, 
cathecholamines and corticosteroids, balance these potent anabolic stimuli. Because their 
function is to oppose the actions of insulin, excess secretion or dysregulation of these 
counter-regulatory hormones can induce a state of IR. With this knowledge, it has been 
well documented that the administration of synthetic glucocorticoids has a similar effect 
on insulin function and is a cause of severe IR [257]. Therefore, the use of 
glucocorticoids, such as dexamethasone, has proven to be an easy model to study 
underlying molecular changes associated with IR. However, as discussed in Chapter 
1.2.4, GC modulate a variety of cellular signaling molecules through both insulin-
dependent and -independent mechanisms, which limits the interpretation of the results as 
they might not necessarily be a consequence of IR but rather of direct GC-mediated 
changes. GC are known to induce IR by reducing peripheral tissue insulin sensitivity and 
promoting gluconeogenic pathways [258]. It has been shown that hepatic sensitivity to 
insulin is decreased after cortisol infusion in men, thereby reducing its suppressive action 
on gluconeogenic pathways [259]. In peripheral insulin-sensitive tissues, the molecular 
effects are complex and affect both glucose, lipid and protein metabolism. As described 
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earlier, a major pathway affecting peripheral insulin sensitivity is a GC-mediated 
decrease in signaling through IRS-1/PI3K and consequently a reduction in GLUT-4 
translocation. Additional pathways involve the activation of similar feedback 
mechanisms as explained in 1.3.3.1, where GC-induced alterations in amino acid and 
lipid metabolism consequently affect insulin signal transduction (for in detail review, 
please refer to [257]). In addition to the impairment of insulin-mediated glucose 
homeostasis, GC have also shown to increase pancreatic insulin secretion and lower 
hepatic insulin clearance. Enhanced pancreatic secretion has been attributed to increased 
β-cell response to glucose stimulation. The proposed underlying mechanisms for these 
pancreatic adaptations include, increased β-cell mass, increased mitochondrial function, 
Ca2+ signaling and PLC/PKC activity (pathways essential for insulin secretion) [260]. 
Although reduced hepatic clearance has been reported in several studies after GC 
treatment, a recent study elucidated that this is likely due to decreased activity of insulin-
degrading enzyme in the liver as was observed in dexamethasone treated rodents [261]. 
Together these findings illustrate some of the underlying molecular mechanisms for GC-
induced ID and its associated hyperinsulinemia and hyperglycemia. With this knowledge 
in mind, the following section will give a brief overview of the research pertaining GC 
use and its known adverse effects in horses.  
1.4.3.1. Pharmacokinetics and –dynamics of dexamethasone in horses 
 
Dexamethasone is a potent steroidal anti-inflammatory drug and is suggested to 
be 30 times as potent as endogenous cortisol. Published dosages for dexamethasone use 
in horses range from 0.005 to 0.164 mg/kg BW, depending on the bioavailability of the 
formula used and its administrative route [135]. However, a dose of 0.1 mg/kg BW is 
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commonly used in the treatment of recurrent airway obstruction in horses (RAO, an 
environmentally-induced inflammatory obstructive airway disease), and is typically 
administered for several days to weeks via intermittent bolus dosing to minimize 
potential metabolic side effects [262]. The half-life of intravenous dexamethasone is 
2.63h and both intravenous and oral administration has shown to suppress endogenous 
cortisol secretion as early as 1h after delivery and is continued for 48-72h [263-265]. In 
the treatment of RAO, significant improvement in lung function was observed within 2-6 
hours after intravenous or oral dexamethasone administration, suggesting that 
transcriptional downregulation of inflammatory mediators occurs within a few hours after 
treatment [135]. Interestingly, these authors reported that the effects of oral 
dexamethasone administration tended to have a longer duration than intravenous 
administration, but that feeding horses prior to GC treatment decreased its bioavailability 
and efficacy [135]. Another study illustrated that a single dose of 0.05 mg/kg of either 
powdered or injectable dexamethasone both given orally, or a single dose of 0.05 mg/kg 
given intravenously resulted in an immediate rise in plasma dexamethasone 
concentrations, which fell below detectable ranges within 8-12h for all routes of 
administration [265]. Interestingly, although dexamethasone is cleared from the blood 
after 12h, its suppressive effects on cortisol secretion are maintained long after that (up to 
72h). The authors suggested that this was due to effects of intracellular dexamethasone 
and/or the natural lag of genomic effects [265].  
While treatment with dexamethasone and other glucocorticoids typically starts out 
with intravenous administration for the first few days, this is typically followed by 
tapering doses of oral administered medication for several days to weeks. Despite the fact 
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that oral dexamethasone power is commercially produced and FDA approved, it is 
common practice to orally administer the injectable formulation of dexamethasone 
solution. It is reported that this is due variable availability of the powered FDA-approved 
formulation, leading to substitution with compounded formulas or other human drugs. 
However, these may not be as well absorbed by horses or can be too costly for extended 
use. Studies have illustrated that oral administration of the dexamethasone solution was 
effective against inflammatory conditions, making the injectable formula a convenient 
and economical means of GC delivery. Furthermore, comparison between the efficacy of 
oral administration of the injectable formula and the powered formula showed that both 
treatments resulted in equal suppression of cortisol secretion. Additionally, the 
bioavailability of both formulas ranged from 28 to 66%, but were not different between 
treatments [135, 265].  
1.4.3.2. The effects of glucocorticoids on insulin and glucose dynamics in 
horses 
Studies evaluating dexamethasone-induced alterations in glucose and insulin 
dynamics in horses have mainly been a consequence of its implication in laminitis, one of 
the most common and troublesome clinical presentations in equine veterinary practice. 
However, the mechanisms by which GC may induce detachment of the hoof lamellae is 
not entirely clear and several theories have been proposed and described elsewhere [134]. 
However, of interest pertaining to the research in this dissertation, is the theory that GC 
may alter intestinal permeability, therefore allowing absorption of toxic factors that could 
trigger laminitis. Although this has not been proven in horses, there is considerable 
evidence in other animal models that permeability of the mucosal lining increases after 
treatment with GC, which warrants further investigation in horses [266, 267]. However, 
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because laminitis has been associated hyperinsulinemia, GC-mediated alterations in 
glucose and insulin dynamics have received considerable attention. A single intravenous 
dose of dexamethasone (40µg/kg BW) decreased the insulin response to a glucose-insulin 
tolerance test as early as 2h and resulted in IR at 24h [170]. Intramuscular injection with 
dexamethasone (125 µg/kg BW) for 4 days resulted in increased plasma glucose and 
insulin within 24h, which kept increasing until treatment was ceased and only returned to 
pretreatment values 19 days after initial injection [31]. Interestingly, these authors also 
reported an increase in plasma IGF-1 concentration, but this was only visible several days 
after treatment had ended. Prolonged dexamethasone treatment (15 to 21 days at doses of 
0.08 mg/kg BW every 48h, 20 mg/ day or 0.04 mg/kg BW/day) also resulted in 
significant elevations in insulin and glucose concentrations and markedly decreased 
insulin sensitivity as measured by the EHC or the frequently sampled intravenous glucose 
tolerance test [29, 32, 191, 244]. The effects of prolonged dexamethasone treatment have 
also shown to be sustained for several days to weeks, with glucose and insulin 
concentrations normalizing within 3 days after ending of treatment, but proxy measures 
for insulin sensitivity (i.e. the reciprocal of the square root of insulin) not returning to 
pretreatment values until 2 weeks post cessation of treatment [268].  
Besides their adverse effects on insulin and glucose dynamics, other side effects 
seen with exogenous GC administration in horses include suppression of the 
hypothalamic-pituitary-adrenal axis and immunosuppression [269, 270]. Additionally 
both short and prolonged treatment in mares in late dioestrus may lead to inhibition of 
follicular development and ovulation and reduces normal behavior associated with 
oestrus [264, 271].  
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In conclusion, it has been clearly illustrated that dexamethasone administration 
both acutely and chronically alters glucose and insulin dynamics in horses and induces a 
state of IR within 24 after treatment is started. However, as mentioned previously, less is 
known on the effects of GC-induced IR on other insulin-mediated pathways, including 
protein metabolism.  
1.4.4. Equine metabolic syndrome 
 
Similar to humans, horses, in particular those breeds closely related to their wild 
relatives, develop metabolic diseases due to lack of proper exercise, continuous 
availability of high energy feed and a genotype not yet adapted to deal with this 
nutritional abundance. Consequently, there is an increasing prevalence of health issues 
related to obesity in horses. Equine metabolic syndrome (EMS), named after a similar 
condition in obese humans, is now an officially accepted term to describe a cluster of 
symptoms associated with endocrinopathic laminitis. The three core components of EMS 
are increased adiposity (general and regional), insulin dysregulation and a predisposition 
toward laminitis [272]. Other factors associated with the disease may also include 
dyslipidemia [27, 40], altered blood adipokine concentrations [216, 273], systemic 
inflammation [22], and reproductive dysfunction [274].  All of these risk factors, in 
particular those associated with laminitis, have received considerable research attention 
in an attempt to improve treatment strategies and identify markers for early diagnosis [41, 
275, 276].   
In many species, there is a strong correlation between obesity, systemic IR, and 
inflammation [277-279]. The adipose tissue, in particular the white adipose tissue, is not 
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only an energy storage depot, but also one of the largest endocrine organs, and secretes a 
cohort of adipokines, including pro-inflammatory cytokines [280, 281]. Prolonged, 
excessive energy intake will result in expansion of adipocytes, which may lead to a local 
inflammatory response due to macrophage infiltration and local hypoxia.  This shift 
towards a more pro-inflammatory state will in turn affect various other metabolic 
pathways, including hepatic and peripheral glucose and insulin dynamics [174, 282-285]. 
Additionally, lipotoxicity, due to dysfunctional adipose tissue will alter the blood lipid 
profile in humans and horses with metabolic syndrome, and can lead to a typical increase 
in circulating levels of free fatty acids (FFA) [40, 233, 286]. Infiltration of FFA and 
adipokines into peripheral tissues, such as muscle, will affect insulin-mediated signaling, 
and can potentially cause IR by directly interfering with the phosphorylation of IRS-1, or 
by affecting downstream signaling. Accumulation of intracellular lipids and/or pro-
inflammatory cytokines can alter the function of signaling proteins and transcription 
factors involved in regulation of the protein translation machinery, glucose uptake and 
inflammatory responses [287]. For example, it has been shown that FFA are able to 
trigger the innate immune system through activation of toll-like receptor-4 (TLR-4) 
signaling, which in turn activates inflammatory signaling factors, such as NF-κB, c-jun 
aminoterminal kinases (JNK), and suppressor of cytokine signaling proteins (SOCS), 
ultimately leading to increased expression of pro-inflammatory cytokines [284, 288]. 
TNF-α is probably the best characterized pro-inflammatory cytokine, and is able to 
directly cause skeletal muscle IR through modifications of insulin signaling, involving 
similar proteins as previously mentioned (i.e. impaired IRS-1 tyrosine phosphorylation, 
NF-κB, JNK) [289].   
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Although there are consistent reports in obese people of elevated expression of 
pro-inflammatory cytokines in plasma and peripheral blood mononuclear cells (PBMC’s) 
[277, 290], research in horses evaluating interrelationships between obesity and 
inflammation is somewhat equivocal. Equine obesity is described as a chronic, low grade 
inflammatory state, and IR has been correlated with increased expression of TNF-α, and 
IL-1β in the blood [22].  Hyperinsulinemic, previously laminitic horses have increased 
serum TNF-α levels in comparison to their healthy counter parts [216, 291].  
Additionally, induced hyperinsulinemia, caused by a 6h insulin infusion, altered IL-6 and 
TNF-α plasma concentrations [292]. Conversely, other studies in obese, hyperinsulinemic 
horses showed that gene expression of endogenous pro-inflammatory cytokines in 
PBMC’s was reduced or unchanged before and after immune stimulation in comparison 
to normo-insulinemic horses. Furthermore, no differences were seen in production and 
expression of cytokines in PBMC’s of horses with EMS versus control [233, 293]. These 
findings suggest that there may be distinct species differences that explain the different 
outcomes of metabolic syndrome.   
Interestingly, there also seems a distinct species differences in inflammatory 
status of various tissues within the body.  In humans, the impact of obesity related 
disorders is dependent on the anatomic distribution of the adipose tissue, with the visceral 
fat depot being a particularly strong indicator for IR [294].  In contrast, however, the 
nuchal ligament depot (generating the typical “cresty neck” in EMS horses) may 
contribute the most to the pathogenesis of obesity related disorders in horses. This fat 
region has shown to have a greater expression of inflammatory genes in comparison to 
other fat depots [295]. IR has also been associated with elevated protein expression of 
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TLR-4 and SOCS-3 in both visceral adipose and skeletal muscle tissue of horses [296].  
Furthermore, this study showed positive correlations between TLR-4 and SOCS-3 and 
SOCS-3 and GLUT-4 trafficking, further supporting the close relationship between 
inflammation, IR, and impaired glucose metabolism. Conversely, hyperinsulinemia 
induced by means of a prolonged EHC clamp procedure did not result in an increased 
expression of the same proteins in skeletal muscle, indicating the importance of studying 
the mechanisms of this disease in its natural development [292]. 
Similar to human studies, the majority of equine research in the field of metabolic 
disease have focused on strategies to induce weight loss and improve insulin sensitivity 
and glycemic control. However, little attention has been given to the potential role of 
altered amino acid dynamics in the development of EMS or how the disease might affect 
whole-body protein metabolism. Based on the previously discussed literature there is 
clear evidence in other species that both amino acid and protein metabolism is altered in 
the face of ID and that excess protein intake might have a potential role in the 
development of the disease. Considering horses are often fed high levels of protein, 
further investigation of these mechanisms in relation to EMS is warranted.  
 
 
 
 
 
 
 
 
 
 
Copyright © Caroline M. M. Loos 2018  
59 
 
1.5. HYPOTHESES AND OBJECTIVES 
 
1.5.1. Scope of the dissertation 
 
The overall aims of the research presented in this dissertation were to evaluate the 
effects of ID on whole-body protein metabolism in horses. More specifically, looking at 
the effects of ID on amino acid dynamics and skeletal muscle protein synthetic and 
proteolytic pathways in a post-absorptive state and after an anabolic stimulus. We 
evaluated these effects in two groups of ID horses, one group included mature horses that 
were made IR by both short-term or prolonged GC administration, whereas the other 
group of horses were diagnosed with naturally occurring equine metabolic syndrome. The 
overall hypothesis of this research was that horses with ID, whether experimentally 
induced or naturally occurring, would have different blood amino acid profiles compared 
to healthy horses and that muscle protein synthetic capacity would be reduced while 
muscle proteolytic pathways would be upregulated.  
1.5.2. Specific hypotheses and objectives 
 
1.5.2.1. First research hypothesis and objectives 
To determine the effects of prolonged dexamethasone treatment in mature horses 
on insulin-stimulated plasma amino acid dynamics and activation of muscle protein 
synthetic and proteolytic signaling pathways. We hypothesized that 21 days of 
dexamethasone treatment would alter plasma amino acid concentrations, decrease 
insulin-mediated activation of signaling components involved protein synthesis and 
increase markers of protein degradation.  
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1.5.2.2. Second research hypothesis and objectives 
To determine the effects of short-term DEX treatment on plasma glucose, insulin 
and amino acid dynamics and muscle signaling pathways in response to the consumption 
of a high protein meal in mature horses. We hypothesized that 7 days of dexamethasone 
treatment would increase basal plasma glucose, insulin and amino acid concentrations, 
induce a state of tissue IR and therefore, decrease postprandial insulin-mediated signaling 
pathways and increase proteolytic markers. We also hypothesized that the intake of a 
high protein meal might maintain mTOR signaling through insulin-independent 
mechanisms. Lastly, we hypothesized that most of these effects would disappear after 7 
days of recovery from treatment.   
1.5.2.3. Third research hypothesis and objectives 
To determine the effects of short-term DEX treatment on plasma glucose, insulin 
and amino acid dynamics and muscle signaling pathways in response to an oral sugar test 
in mature horses. We hypothesized that 7 days of dexamethasone treatment would 
increase basal plasma glucose and insulin concentrations, induce a state of tissue IR and 
therefore, decrease the insulin-mediated anabolic response of muscle signaling pathways 
and increase proteolytic markers. Secondly, we hypothesized that most of these effects 
would disappear after 7 days of recovery from treatment.   
1.5.2.4. Fourth research hypothesis and objectives 
To evaluate the effects of naturally occurring ID on plasma glucose, insulin and 
amino acid dynamics before and after consumption of a meal high in protein, in horses 
with equine metabolic syndrome. We hypothesized that horses with EMS would have 
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different pre- and postprandial plasma amino acid profiles, compared to healthy horses. 
Secondly, we hypothesized that underlying ID would alter the amino acid and insulin 
responses to a meal high in protein in horses with EMS.  
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1.6. FIGURES 
 
 
Figure 1. 1 Signaling pathways contributing to muscle protein synthesis 
This figure is a simplified overview of signaling molecules involved in protein synthesis, that are 
relevant to the research presented in this dissertation. 
Abbreviations: IRS-1, insulin receptor substrate-1; PI3K, phosphoinositide 3-kinase; Akt, protein 
kinase B; GLUT-4, glucose transporter 4; GSK-3β, glucose synthase kinase 3β; TSC1/2, tuberous 
sclerosis complex 1,2; Rheb, Ras homologue enriched in brain; mTOR, mammalian target of 
rapamycin; GβL, mammalian lethal with SEC13 protein 8; Raptor, regulatory-associated protein 
of mTOR; PRAS40, 40 kDa pro-rich Akt substrate; Deptor, DEP domain-containing mTOR-
interacting protein; S6K11, 70 kDa S6 kinase 1; 4E-BP1, eukaryotic initiation factor 4 binding 
protein 1; rpS6, ribosomal protein S6; eIF, eukaryotic initiation factor (4E, 4G); Rags, Rag 
GTPases. An arrow indicates activation, a broken line indicates a negative feedback mechanism, 
a perpendicular line indicates inhibition, lines marked with a cross indicate that the action of this 
signaling molecule on its target is lifted under anabolic conditions. 
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Figure 1. 2 Signaling pathways contributing to muscle protein degradation 
This figure is a simplified overview of signaling molecules involved in protein degradation, that 
are relevant to the research presented in this dissertation. 
Abbreviations: IRS-1, insulin receptor substrate-1; PI3K, phosphoinositide 3-kinase; Akt, protein 
kinase B; GLUT-4, glucose transporter 4; GSK-3β, glucose synthase kinase 3β; TSC1/2, tuberous 
sclerosis complex 1,2; Rheb, Ras homologue enriched in brain; mTOR, mammalian target of 
rapamycin; Raptor, regulatory-associated protein of mTOR; S6K11, 70 kDa S6 kinase 1; 4E-BP1, 
eukaryotic initiation factor 4 binding protein 1; rpS6, ribosomal protein S6; REDD1, Regulated in 
development and DNA damage response 1; AMPK, adenosine monophosphate kinase; ULK, 
Unc-51-like kinase; UPP, ubiquitin proteasome pathway; FoxO, forkhead box O; NF-κB, nuclear 
factor kappa B; MuRF-1, muscle ring finger-1; An arrow indicates activation and a perpendicular 
line indicates inhibition, lines marked with a cross indicated that the action of this signaling 
molecule on its target is lifted under catabolic conditions.  
 
 
 
 
 
64 
 
 
 
 
Figure 1. 3 Pathways for glucocorticoid-mediated interference with muscle protein 
metabolism 
This figure is a simplified overview of signaling molecules involved in GC-mediated muscle 
atrophy, that are relevant to the research presented in this dissertation. 
Abbreviations: GR, glucocorticoid receptor; IGF-1, insulin-like growth factor 1;IRS-1, insulin 
receptor substrate-1; PI3K, phosphoinositide 3-kinase; p85α, subunit of PI3K; Akt, protein kinase 
B; GLUT-4, glucose transporter 4; GSK-3β, glucose synthase kinase 3β; mTOR, mammalian 
target of rapamycin; REDD1, Regulated in development and DNA damage response 1; KLF-15, 
Krüppel-like factor 15; BCAT, Branched-chain amino acid transferase; HSP70. Heatshock 
protein 70; UPP, ubiquitin proteasome pathway; FoxO, forkhead box O. A black arrow indicates 
activation and a perpendicular line indicates inhibition, upward and downward facing arrows 
indicate increased and decreased protein expression, respectively, lines marked with a cross 
indicated that the action of this signaling molecule on its target is lifted in the face of excess GC. 
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CHAPTER 2  
PROLONGED DEXAMETHASON TREATMENT AFFECTS PROTEIN 
METABOLISM IN EQUINE SKELETAL MUSCLE 
 
Abstract 
Prolonged dexamethasone (DEX) treatment has been shown to induce insulin resistance 
(IR) and interfere with insulin-mediated signaling pathways in equine skeletal muscle. 
High doses of glucocorticoids (GC) are known to contribute to muscle atrophy by 
downregulating synthetic and upregulating proteolytic pathways. Although horses 
commonly suffer from conditions associated with IR, there is a paucity of data on IR-
induced alterations in muscle protein metabolism. Therefore, the objective of this study 
was to determine whether DEX-induced IR affects protein signaling pathways in skeletal 
muscle. Eight mature horses were fed twice daily to meet maintenance requirements. An 
initial (pre-DEX) percutaneous biopsy of the gluteus medius muscle was performed, after 
an isoglycemic-hyperinsulinemic clamp procedure (IHC). After 21d, during which all 
horses received 0.04 mg/kg BW/day of oral DEX, the IHC was repeated and a post-DEX 
muscle sample was obtained. Plasma amino acid concentrations were determined and 
muscle samples were analyzed using Western immunoblot procedures to determine the 
relative abundance or phosphorylation of protein signaling components. Data were 
analyzed using the mixed procedure of SAS with period, time and their interaction as the 
fixed effect and horse as the random subject. Twenty-one days of DEX treatment resulted 
in increased basal plasma methionine, alanine and glutamine concentrations (P < 0.05) 
and resulted in overall higher plasma amino acid levels during the post-DEX IHC 
compared to pre-DEX IHC (P < 0.05). Insulin-stimulated activation of rpS6 and 4E-BP1 
decreased as expected, however FoxO1 phosphorylation increased after 21 days of DEX 
treatment (P < 0.05 and 0.05 < P < 0.1). Additionally, total abundance of atrogin-1 and 
myostatin, markers for protein breakdown, were increased and decreased after GC 
treatment, respectively (0.05 < P < 0.1). Collectively, these results indicate that 
prolonged GC administration resulted in muscle resistance to insulin-stimulated amino 
acid uptake and activation of protein synthetic machinery and upregulated muscle 
degradation pathways.  
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2.1. INTRODUCTION 
Endogenous glucocorticoids (GC) are important modulators of metabolic 
homeostasis, mediating inflammatory responses and regulating several cellular processes, 
including glucose metabolism and proteolytic pathways in the muscle under catabolic 
conditions [129, 130, 297]. Although GC-stimulated protective mechanisms are essential 
in certain cases such as injury or acute phases of illness, they can have undesired effects 
in other circumstances [298]. Crosstalk between GC and regulatory pathways of protein 
metabolism lead to increased muscle atrophy seen in metabolic diseases, aging, fasting 
and with the administration of exogenous GC [147, 153, 164, 299-301]. Consequently, 
the acute catabolic effects and relative ease of use have made GC-induced wasting a 
frequently used model for muscle atrophy to investigate underlying molecular 
mechanisms [302]. Because of their long lifespan, horses suffer from diseases similar to 
humans and experience age-related muscle wasting, however, little is known of the 
proteolytic mechanisms responsible. GC-induced muscle wasting could therefore be a 
useful model to elucidate the function and regulation of protein degradation pathways in 
horses.   
Synthetic GC, such as dexamethasone, are frequently used in equine veterinary 
medicine to treat a variety of medical conditions including inflammatory airway diseases, 
immune-mediated diseases, recurrent airway obstruction and osteoarthritis [135, 167, 
168]. A single injection is also used in the diagnosis of Equine Cushing’s [169]. Despite 
its useful immunosuppressive action, both short and long-term administration of 
dexamethasone has undesired pleiotropic effects in multiple species including horses. In 
vitro and in vivo experiments in multiple species have illustrated that administration of 
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GC’s inhibit muscle glucose uptake, elevate blood glucose levels, reduce insulin 
sensitivity, decrease muscle mass and cause muscle dysfunction and weakness [47, 48, 
83, 136, 164, 303-307]. In horses, dexamethasone is known to increase blood glucose 
levels and lower insulin sensitivity as early as 2 hours after administration, creating a 
state of insulin resistance (IR) by 24h [30]. Additionally, GC administration has been 
associated to the acute development of laminitis in predisposed animals [134, 308]. 
Prolonged administration of dexamethasone in horses has also been shown to induce 
substantial peripheral IR and reduce insulin-stimulated muscle glucose metabolism [29, 
32, 33, 191]. In addition to regulating glucose homeostasis, insulin and insulin-like 
growth factor-1(IGF-1)-mediated signaling pathways are known to be major stimuli of 
muscle protein synthesis and the maintenance of muscle mass in multiple species, 
including horses. Therefore, the detrimental effects of GC on muscle mass are partially 
due to inducing a state of IR, which could result in decreased protein synthetic capacity. 
A key regulator of skeletal muscle protein metabolism is the mechanistic target of 
rapamycin (mTOR), which is highly sensitive to the anabolic stimulus of growth factors 
such as insulin and IGF-1, as previously reviewed [4, 309, 310]. Briefly, the binding of 
insulin or IGF-1 to their membrane receptors will trigger an intracellular signaling 
cascade involving recruitment of the insulin receptor substrate and subsequent activation 
of phosphatodinositol-3 kinase (PI3K), eventually leading to the phosphorylation of Akt 
[76]. Akt in turn will phosphorylate tuberous sclerosis complex (TSC) 1/2 at multiple 
sites, thereby lifting its inhibitory effect on Rheb, allowing its interaction with mTOR [4, 
77]. Phosphorylation of mTOR will eventually lead to the activation of protein synthetic 
machinery through the activation of several downstream signaling components including 
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4E-BP1, S6K1 and ribosomal protein S6 (rpS6) [66, 90, 309, 311]. In addition to 
stimulating protein synthesis, activation of the Akt/mTOR pathway also has an inhibitory 
effect on transcription factor Forkhead Box-O1 (FoxO1) thereby blocking the synthesis 
of components of proteolytic pathways such as atrogin-1 and muscle RING-finger1 
(MuRF-1).  
In contrast, low energy availability, stress or pathological conditions induce a 
metabolic shift towards a more catabolic state. Downregulation of the mTOR/Akt 
pathway can occur through several mechanisms including the activation of energy-
sensitive AMP protein kinase (AMPK) and upregulation of myostatin, a major negative 
regulator of muscle growth. Additionally, catabolic hormones, including GC, regulate 
muscle protein degradation pathways through binding glucocorticoid response elements 
(GRE) of genes responsible for activating catabolic pathways and mTOR downregulation 
[147]. Similar effects are seen with the administration of exogenous GC, for example, the 
presence of a GRE on the myostatin promotor is cause of direct upregulation of muscle 
atrophy after administration of dexamethasone [164, 312].  
Although the effects of dexamethasone on components in the initial steps of insulin 
signaling have been studied in horses [33], less is known of its effects on muscle protein 
synthetic and proteolytic pathways. Therefore, the objective of this study was to further 
characterize the effects of prolonged dexamethasone treatment on insulin-mediated 
activation of muscle protein synthetic and proteolytic signaling pathways in otherwise 
healthy mature horses. 
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2.1. MATERIALS AND METHODS 
 
2.1.1. Animals and housing 
Eight mature horses of mixed breed and gender were used. Within this group 
there were three quarter horse crosses and five thoroughbreds of which there were four 
mares and four geldings (6-12 years old; 543 ± 16 kg BW). All horses were turned out 
into a paddock in group for approximately 8h/day and were stalled overnight to allow for 
individual feeding. Horses had ad libitum access to water and mixed-grass hay and were 
fed a commercial pelleted concentrate at the maintenance-level recommendations (Table 
2.1). All diets were formulated to meet the requirements for mature, idle horses. All 
procedures were approved by the Alltech Institutional Animal Care and Use Committee. 
2.1.2. Experimental procedures 
Each horse was studied before and after a 21-day period of dexamethasone (DEX) 
treatment where each horse served as its own control. DEX was administered orally at a 
daily dose of 0.04 mg/kg BW, which has previously been shown to result in insulin 
dysregulation [244]. A muscle biopsy was collected from each horse before (Pre-DEX) 
and after (Post-DEX) the 21 day treatment period. To study the effects of DEX on insulin 
mediated signaling pathways, all muscle samples were collected in an insulin-stimulated 
state at the end of a 2h isoglycemic-hyperinsulinemic clamp (IHC) procedure. All horses 
had access to water and hay overnight and during the IHC procedure. Each IHC was 
conducted before the horses’ morning meal, according to previously described methods 
by Urschel et al [254]. Briefly, after basal blood samples were collected from a venous 
catheter, horses were given a priming dose of insulin (0.4 mU/kg BW) after which insulin 
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and dextrose (50% dextrose solution) infusions were started. Insulin infusion was held 
constant at a rate of 1.2 mU/kg BW/min, while dextrose infusions were adjusted to 
maintain blood glucose concentrations within 10% of each horse’s resting value. This 
insulin infusion rate has previously shown to activate signaling components in the mTOR 
pathways in the gluteus medius muscle of horses [6]. Additional venous blood samples 
were collected every 15 min throughout the procedure. Once equilibrium was obtained, 
blood samples collected during the last 30 min were used to determine measures of 
insulin sensitivity, and these results are published elsewhere [32]. During the final part of 
the clamp procedure, horses were lightly sedated with 3mL of xylazine hydrochloride and 
biopsy sites aseptically scrubbed and anesthetized with Lidocaine (13 ml of 12% 
lidocaine). Through a single incision, a percutaneous biopsy sample of the gluteus medius 
muscle was collected using the Bergstrom needle technique as previously described [57]. 
After muscle sample collection, the IHC was stopped and horses were returned to their 
stalls and received 2 g of non-steroidal anti-inflammatory phenylbutazone paste 
(ButaPaste, Butler Animal Health Supply, Dublin, OH), with additional doses given for 2 
days following the procedures. After the initial IHC horses started their daily treatment of 
oral dexamethasone (DexaJet SPc), which was top dressed on their afternoon feed. After 
21 days of DEX treatments, the IHC was repeated and a second muscle biopsy sample 
was collected from the gluteus medius muscle. 
2.1.3. Western immunoblot analysis 
Approximately 100 mg of freshly collected muscle tissue was weighed out and 
immediately homogenized in a cell lysis buffer (20 mM HEPES, 2 mM EGTA, 50 mM 
NaF, 100 mM KCL, 0.2 mM EDTA, 50 mM β-glycerophosphate) containing 20µl/ml of 
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a protease inhibitor using a handheld tissue homogenizer. Homogenates were then 
centrifuged at 10,000 x g for 10 min and the supernatant removed and frozen at -80°C 
until further analysis.  
The abundance and phosphorylation of proteins of interest in the muscle samples 
were analyzed for by western immunoblotting based on previously described methods 
[14, 21]. Briefly, total protein content was determined using a Bradford assay after which 
samples were diluted in laemmli buffer (62.5 mM Tris-Base, pH 6.8; 3% SDS; 30% 
glycerol, 1% 2-mercaptoethanol) to a final concentration of 2μg/µl. Ten µl of each 
sample was loaded into a polyacrylamide gel in duplicate. After separation by 
electrophoresis, proteins were transferred to a 0.45 µm polyvinylidene deflouride 
membrane (Millipore Sigma, St. Louis, MO). Membranes were blocked by incubation 
with either a 5% fat-free milk or BSA (bovine serum albumin) solution after which they 
were probed with the appropriate primary antibody overnight at 4 °C (Akt, rpS6, 4E-BP1, 
FoxO1, myostatin, NF-κB and AMPK) or for 1h at room temperature (atrogin-1, MuRF-
1). Rabbit polyclonal antibodies were used against total and ser473 Akt (1:2000 dilutions 
for both, Cell Signaling Technology, Inc., Boston, MA); ser235/236 and ser240/244 rpS6 
(1:2000 dilutions each, Cell Signaling Technology); atrogin-1 (1:1000 dilution, ECM 
Biosciences, Versailles, KY); MuRF-1 (1:1000 dilution, ECM Biosciences); total AMPK 
(1:1000 dilution, Cell Signaling Technology) and myostatin (1:1000 dilution, Abcam, 
Cambridge, MA). Rabbit monoclonal antibodies were used specific to total rpS6 
(1:10,000 dilution, Signaling Technology); total and thr37/46 of 4E-BP1 (1:1000 dilution 
for each, Cell Signaling Technology); total and ser256 FoxO1 (1:4000 and 1:5000 
dilutions, Santa Cruz Biotechnology, Dallas, TX); α-tubulin (1:1000 dilution, Cell 
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Signaling Technology); thr172 AMPK (1:1000 dilution, Cell Signaling Technology) and 
total and ser536 NF-κB p65 were used (1:4000 and 1:1000 dilutions, Cell Signaling 
Technology). Antibodies were raised against human (total and phosphorylated rpS6, NF-
κB, AMPK; total 4E-BP1, MuRF-1, α-tubulin and myostatin) or mouse proteins (total 
and phosphorylated Akt; phosphorylated 4E-BP1 and total atrogin-1). The FoxO1 
antibody used for this study has been discontinued and protein source was unavailable at 
this time. All antibodies used were either previously validated in our lab for use with 
equine muscle tissue or validated before the start of the current analysis (Appendix A.1).  
After removing the primary antibody, membranes were washed and incubated 
with a goat anti-rabbit antibody conjugated with horseradish peroxidase (dilution specific 
to each primary antibody, Bio-Rad, Hercules, CA) for 1h at room temperature. 
Membranes were developed using a chemiluminescent kit (Amersham ECL Plus western 
blotting detection reagent, GE Healthcare Bio-Sciences, Pittsburgh, PA) and visualized 
on x-ray film using a film processor (Kodak X-OMAT film processor, Kodak Health 
Imaging Division, Rochester, NY). After developing, the membranes were stripped for 
10 min with stripping buffer (2% SDS, 62.5 mM Tris-Base, 0.1 M β-mercaptoethanol), 
re-blocked with appropriate blocking solution and re-probed with an antibody against 
total form of each phosphorylated protein measured (Akt, rpS6, 4E-BP1, AMPK, NF- κB 
and FoxO1) and procedures repeated as described. When only the total form of the 
protein was determined (MuRF-1, atrogin-1 and myostatin ) the membranes were 
incubated with α-tubulin which has been previously used to standardize protein 
abundance in equine muscle [21]. All gels were run in duplicate and results are expressed 
as an average of two gels.  
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The band densities captured on x-ray film where then digitalized using a charge 
coupled device camera on a VersaDoc™ imager (Bio-Rad Laboratories, Inc., Hercules, 
CA) and quantified using a densitometry software (ImageJ, National Institutes of Mental 
Health Bethesda, MD). To control for intra-assay variation, each sample band was 
normalized to the band density of a positive control (pooled muscle homogenate 
samples), which was loaded onto each gel. The band density of phosphorylated Akt, 
rpS6, 4E-BP1, AMPK, NF- κB and FoxO1 was then normalized to that of the total 
abundance of the respective protein. MuRF-1, atrogin-1 and myostatin were normalized 
to the band densities of α-tubulin. All obtained values are expressed as relative 
abundances in arbitrary units.  
2.1.4. Plasma amino acids 
Plasma free amino acid concentrations of blood samples collected during the IHC 
procedure were determined by reserve-phase HPLC of phenyisothiocyanate derivatives 
as previously described [57].  
2.1.5. Data analysis 
Data were analyzed using mixed procedures of SAS (version 9.4; SAS Institute, 
Cary, NC) with significance considered at P < 0.05 and trends at 0.05 < P < 0.1.  Baseline 
amino acid concentrations were analyzed with a one-way ANOVA using period as the 
fixed effect and horse as the random subject. Amino acid data from the IHC were 
analyzed using repeated measures, with time, period and their interaction as the fixed 
effects and horse as the random subject. A variance-covariance matrix was chosen based 
on lowest values for respective fit statistics for each amino acid. Differences in protein 
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expression between sample periods (PRE vs POST DEX) were determined using a one-
way ANOVA with period as the fixed effect and horse as the random subject. All western 
blot data were analyzed for normality and outliers identified as > 2 standard deviations 
from the mean were removed from the dataset. All data are presented as least square 
means ± pooled SE. 
 
2.2. RESULTS 
 
The glucose and insulin data for this study has been published elsewhere [32]. 
Briefly, basal glucose and insulin concentrations were increased after 21 days of 
dexamethasone treatment (P < 0.05). Proxy measurements for insulin sensitivity (RISQI, 
the reciprocal of the square root of the insulin concentration) and pancreatic β-cell 
responsiveness (MIRGP, modified insulin-to-glucose ratio for ponies) were decreased 
and increased, respectively, after dexamethasone treatment (P < 0.001). Additionally, 
calculations based on the insulin and glucose data from the EHC procedure indicated that 
insulin-mediated glucose uptake was decreased after dexamethasone treatment (P < 
0.001). Together these data clearly illustrate that all horses were insulin resistant after the 
21-day dexamethasone treatment period.  
2.2.1. Plasma amino acids 
Basal concentrations of plasma methionine (P = 0.04), alanine (P = 0.005) and 
glutamine (P = 0.02) were 28%, 64% and 40% higher after dexamethasone treatment, 
respectively (Figure 2.1, Table 2.2). Regardless of treatment period, there was a 
significant effect of time for three amino acids, showing a general decrease in 
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concentrations from baseline levels by 90 min for plasma arginine (P = 0.003), leucine (P 
= 0.02) and lysine (P < 0.0001) during the IHC (Table 2.2). Additionally, concentrations 
also tended to be lower than basal at 30 min for plasma glutamate (P = 0.07) and at 90 
min for isoleucine (P = 0.1), regardless of treatment period (Figure 2.2). There was no 
significant interaction between treatment period and time for any of the amino acids. 
However, there was a significant effect of treatment period for most amino acids. 
Twenty-one days of dexamethasone treatment resulted in overall higher amino acid levels 
during the IHC (P < 0.05), with exception of aspartate, glutamate, histidine, isoleucine, 
tryptophan and ornithine (P > 0.05). Conversely, overall citrulline concentrations during 
the IHC were lower post DEX versus pre DEX (P = 0.01) (Figure 2.3).  
2.2.2. Western blots 
Twenty-one days of dexamethasone treatment resulted in a 1.5 fold decrease in 
insulin-stimulated activation of rpS6 at Ser235/236 & 240/244 (P = 0.04), tended to increase 
phosphorylation of FoxO1 at Ser256 (P = 0.08) and tended to decrease activation of 4E-
BP1 at Thr37/46 (P = 0.08) as measured by the ratio of phosphorylated to total protein 
(Figure 2.4 ). Dexamethasone treatment had no effect on Akt, AMPK or NF- κB 
phosphorylation (P > 0.05) (Figures 2.4, 2.5). There was a 1.6 fold increase in total 
abudance of atrogin-1 (P = 0.05) after 21 days of dexamethasone treatment, however 
myostatin expression tended to decrease (P = 0.07). No treatment effects were observed 
for abundance of MuRF-1 or α-tubulin, which was used to normalize myostatin, atrogin-1 
and MuRF-1 (P > 0.05) (Figure 2.6). 
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2.3. DISCUSSION 
Prolonged dexamethasone treatment has been previously shown to cause IR and 
interfere with insulin-mediated muscle signaling in horses [33]. This study confirms these 
findings, showing decreased activation of rpS6 and 4E-BP1, signaling components 
involved in the activation of the protein synthetic machinery. Additionally, 
dexamethasone treatment altered the abundance and activation of signaling of molecules 
involved in proteolytic pathways, with increased abundance of atrogin-1 and a tendency 
for increased phosphorylation of the transcription factor FoxO1. Conversely, myostatin 
tended to decrease after 21 days of dexamethasone treatment. In addition to aberrations in 
insulin-stimulated protein signaling, dexamethasone treatment also affected plasma 
amino acid levels and resulted in overall higher concentrations during the IHC and 
elevated basal plasma methionine, glutamine and alanine concentrations.  
Because of their importance in glucose homeostasis, immune function and inter-
organ nitrogen balance, plasma alanine and glutamine levels are typically elevated in 
post-absorptive and catabolic states. The synthesis of these amino acids mainly occurs 
through transamination reactions with other amino acids, in particular by accepting 
nitrogen from branched-chain amino acid breakdown. Therefore, the body’s increased 
metabolism of glutamine and alanine, and associated catabolism of BCAA, play a major 
role in skeletal muscle atrophy under catabolic conditions [313]. Considering the 
proteolytic effects of GC’s, elevation of plasma glutamine and alanine in the current 
study suggests that there was increased muscle protein degradation. This hypothesis was 
further supported by an increase in atrogin-1 abundance, a marker for protein breakdown, 
in the muscle of dexamethasone treated horses. Similarly, previous data reported a 
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significant rise in glutamine and alanine release from the skeletal muscle of 
dexamethasone-treated dogs and rats [138, 143]. Additionally, another study observed 
increased gastrointestinal extraction of glutamine and increased release of alanine from 
the gut in dexamethasone treated dogs [144]. Together these data indicates that GC’s 
induce a catabolic state associated with a significant shift in whole body amino acid 
metabolism. 
Insulin is known to stimulate amino acid uptake into tissues and a decline in 
plasma concentrations of essential amino acids was previously reported in healthy horses 
during a IHC procedure [6]. A decrease was seen for levels of arginine, leucine, lysine, 
glutamate and isoleucine during the IHC, which was not affected by dexamethasone 
treatment. Because it is known that insulin reduces activity of enzymes involved in 
oxidative disposal of essential amino acids, it is unlikely that amino acid degradation was 
the reason for the observed decline in plasma levels. This indicates that despite 
dexamethasone induced IR, insulin was still able to stimulate uptake of these amino acids 
into tissues. A lack of decrease in other amino acids over time could be due to the 
relatively low amount of insulin infused (1.2 mU/kg BW/min). In the previous study, a 
rapid decline in levels of essential amino acids was only seen at higher rates of insulin 
infusion (i.e. 3 mU/kg BW/min and 6 mU/kg BW/min). For the rate of insulin infusion 
similar to the one used in the current study, differences from baseline levels were only 
visible at 120 min [6]. It could therefore be possible that more differences might have 
been visible after 120 min in the current study. Alternatively, overall amino acid levels 
during the post-dexamethasone IHC were significantly higher, suggesting diminished 
insulin-mediated amino acid uptake, which could have affected overall time effects. GC’s 
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are known to decrease insulin’s anabolic action on insulin-sensitive tissues such as the 
muscle, creating a state of IR, thereby decreasing insulin-mediated amino acid uptake 
into muscle tissue and blunting the stimulatory effect of IGF-1, insulin and amino acids 
on protein anabolism [137, 314-318]. Decreased glucose disposal determined by the IHC 
data [32] together with elevated plasma amino acid levels, clearly illustrated horses were 
IR after the 21 days of dexamethasone treatment. Because protein synthesis relies on the 
availability of amino acids as well as an anabolic stimulus, this study provides evidence 
that prolonged dexamethasone treatment reduced both these components thereby 
decreasing muscle protein synthetic capacity and potentially muscle loss. 
Muscle mass is maintained by the balance between protein synthesis and protein 
degradation, which is in part mediated by the presence of positive and negative growth 
regulators. Insulin and IGF-1 are growth factors with strong stimulatory effects on mTOR 
pathway activation [10, 319]. To evaluate whether prolonged dexamethasone 
administration affects the ability of insulin to stimulate muscle protein metabolism, 
muscle samples were obtained after a 2h IHC procedure. Insulin infusion rates similar to 
those used in the current study have previously been shown to result in activation of 
mTOR signaling components, including Akt, 4E-BP1 and rpS6, compared to a saline 
infusion [6]. However, in the present study, after horses were given dexamethasone for 
21 days, there was a significant decrease in rpS6 phosphorylation and a tendency for 
lowered 4E-BP1 activation. This could have been the result of GC-induced IR, thereby 
reducing muscle sensitivity to the anabolic stimulus of insulin and a subsequent decrease 
in mTOR pathway activation. A blunted response to insulin-induced muscle protein 
anabolism has previously been shown in healthy men treated with GC [317]. GC’s 
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mechanisms of action on insulin signaling is multifactorial and can be mediated through 
genomic pathways involving binding of the GC receptor (GR) to the GRE of a variety of 
genes thereby altering protein expression and consequently cellular signaling [4, 83]. In 
vitro studies in muscle cells previously reported that dexamethasone treatment inhibited 
IGF-1 stimulated phosphorylation of Akt. It was suggested to be the result of GC 
stimulated increase in the expression of the PI3K subunit p85α, which competes for PI3K 
binding with IRS-1 leading to decreased phosphorylation of IRS-1 and subsequently Akt 
activation [306]. Decreased PI3K-mediated phosphorylation of Akt could have explained 
decreased downstream stimulation of protein synthetic machinery in the current study. 
However, we did not detect a significant difference in Akt activation after dexamethasone 
treatment, which was similar to previously reported data in horses [33]. It could be 
speculated that despite potential dexamethasone-induced changes, elevated levels of 
circulating insulin during the IHC in the current study were able to maintain Akt 
activation. This is supported by previous studies showing that the addition of insulin or 
IGF-1 to dexamethasone treated cells overcame its catabolic effects and increased Akt, 
S6K1 and 4E-BP1 phosphorylation, indicative of increase protein synthesis activation 
[47, 320]. 
Despite the lack of change in Akt activation, we observed a significant decrease in 
insulin-mediated phosphorylation in rpS6 and tendency for decrease in 4E-BP1 
phosphorylation. This suggests that dexamethasone might have interfered with protein 
signaling pathways in an Akt-independent manner. It is known that GC effects can be 
mediated through pathways independent of insulin/IGF-1 signaling involving non- 
genomic interference of the GR with the function of cell-signaling molecules, including 
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phosphatases and kinases [48, 126, 153]. This is in accordance with data from a study in 
rats reporting acute dephosphorylation of 4E-BP1 and S6K1 (responsible for activation of 
rpS6) after dexamethasone administration leading to inhibition of proper assembly of 
protein synthetic machinery. The authors suggested that GC’s modulate phosphatases 
and/or kinases specific to S6K1 and 4E-BP1 or its signaling target, eukaryotic initiation 
factor 4E, thereby interfering with skeletal muscle protein translation initiation [307]. 
Interestingly, although often coordinately regulated, S6K1 is reported to be more 
sensitive to the inhibitory effects of GC’s than 4E-BP1, even under growth-promoting 
conditions [321]. This is supports the current findings, revealing a more significant 
decrease in rpS6, a direct downstream target of S6K1, compared to 4E-BP1. 
As mentioned earlier, muscle mass is maintained by positive and negative 
regulators of muscle growth. An important negative regulator of muscle cell 
differentiation and development is myostatin, a member of the transforming growth 
factor-β family [322]. Increased expression of myostatin will result in decreased muscle 
growth and increased muscle breakdown through mechanisms involving: 1) decreased 
phosphorylation of Akt; 2) reducing mTOR/S6K1/rpS6 signaling and 3) inhibiting 
muscle differentiation-inducing genes [122, 125, 126]. Due to the presence of a GRE 
(glucocorticoid response element) on its promotor, myostatin plays a major role in GC-
induced muscle proteolysis by direct upregulation of its expression after GC 
administration [164]. Unexpectedly, there was trend for myostatin to decrease after 21 
days of dexamethasone treatment in the current study. There is evidence that the effect of 
GC on myostatin expression is transient, showing that the protein expression was 
returned to basal level after prolonged treatment. It is therefore possible we were unable 
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to pick up changes in myostatin levels that may have occurred in the acute phase of 
dexamethasone treatment. Additionally, it has been suggested that molecular adaptations 
occur during chronic GC excess that may prevent continued loss of muscle mass [164]. 
In addition to myostatin, muscle differentiation genes are also regulated by 
nuclear transcription factor kappa B (NF- κB), which is mostly known for its 
upregulation of pro-inflammatory and cell survival genes [97]. Evidence shows that NF- 
κB plays a role in muscle atrophy through mechanisms including: 1) interference with the 
process of skeletal muscle differentiation, 2) promoting the expression of muscle wasting 
inducing inflammatory molecules and 3) inducing transcription of the ubiquitin-
proteasome pathway (UPP) component MuRF-1 [98, 119, 121, 323]. In particular, the 
NF- κB family member, p65, which was measured in the current study, has been shown 
to be responsible for the downregulation of differentiation genes [121]. However, no 
difference was seen in NF- κB activation between pre- and post-dexamethasone treatment 
periods. Upregulation of NF- κB typically occurs in an inflammatory state, therefore the 
combination of insulin’s anabolic action with the anti-inflammatory effect of GC’s may 
have prevented any changes in the phosphorylation status of NF- κB. This is in 
accordance with other data showing the potent inhibitory effect of GC on NF- κB 
function [324, 325]. This may in part also explain the lack of increase in MuRF-1 during 
prolonged dexamethasone treatment. 
FoxO1, another important proteolytic signaling molecule, is typically activated 
under GC-stimulated conditions and induces transcription of muscle specific E3 UPP 
ligases, atrogin-1 and MuRF-1, which are responsible for tagging regulatory and 
structural proteins for degradation [99, 111, 162].  However, FoxO1 phosphorylation was 
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increased, indicating that it was downregulated and sequestered in the cytosol preventing 
its entry into the nucleus. Because insulin is known to suppress proteolysis, high levels of 
circulating insulin at the time of biopsy [32], may have masked dexamethasone-induced 
upregulation of proteolytic components. This is supported by in vitro and in vivo data in 
rodents illustrating that the effects of dexamethasone on muscle protein degradation are 
easily blocked by the addition or injection of IGF-1 or insulin [102, 111]. Because Akt 
phosphorylation was maintained in an insulin-stimulated state, this would have 
subsequently inactivated FoxO1 and provides a mechanism behind the IGF-1/insulin-
mediated rescue from muscle atrophy [79]. However, this does not explain why FoxO1 
phosphorylation was increased to a greater extent in muscle biopsies collected after 21 
days of dexamethasone treatment. As mentioned previously, it is possible that protective 
mechanisms are activated during prolonged GC excess, which could lead to molecular 
adaptations reflected by the unexpected results for myostatin and FoxO1 in the current 
study. Additionally, the regulation of protein metabolic pathways is incredibly complex 
and many components potentially impacting mTOR signaling are yet unknown. It is 
therefore possible that GC administration altered other physiological factors and 
pathways that may have contributed to the observations in the current study. For 
example, there is evidence that AMP-activated protein kinase (AMPK), a major cellular 
energy sensor, is involved in the regulation of muscle mass by interfering with mTOR 
signaling and upregulation of protein degradation [107, 326]. In vitro studies have shown 
that activation of AMPK leads to increased expression of FoxO transcription factors and 
consequently atrogin-1 and MuRF-1 [112]. Because of overlapping biological actions 
AMPK activity is naturally intertwined with GC mediated cellular mechanisms and it has 
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been shown more recently that AMPK regulates transcriptional activity of the GR [327]. 
As a mediator in catabolic pathways, AMPK is strongly inhibited by insulin, reflected by 
reduced phosphorylation at Thr172, which was the site measured in the current study 
[328]. Elevated levels of insulin during the IHC might have therefore repressed AMPK 
activity regardless of any potential dexamethasone effect. This may also in part have 
contributed to the lack of FoxO1 upregulation under these conditions. 
While Akt/AMPK-mediated inactivation of FoxO1 supports the lack of change 
seen in MuRF-1 expression with dexamethasone treatment, there was still a significant 
increase in the abundance of atrogin-1. Although FoxO transcription factors are major 
regulators of the expression of both these ligases, they are both affected by factors other 
than FoxO molecules and differences in the abundance of atrogin-1 and MuRF-1 have 
been previously reported [102, 162]. It is also known that different members of the FoxO 
family have different actions. For example, while FoxO3 is a major player in Akt-
mediated inhibition of atrogin-1 expression [103], FoxO4 can increase atrogin-1 
expression independently of Akt [329]. This suggests that components other than FoxO1 
might have been responsible for increased abundance of atrogin-1 seen in this study. 
Additionally, most previously reported data illustrate dexamethasone or IGF-1 induced 
changes in mRNA expression of Atrogin-1 or MuRF-1 after 24h but little is known on 
the immediate effects. It is known that cells quickly respond to changes in cellular 
environment. It could therefore be speculated that while high levels of insulin during the 
IHC may have shifted the phosphorylation status of Akt and subsequently FoxO1, these 
rapid posttranslational modifications might not necessarily be reflected by protein 
expression levels of downstream target genes. Therefore, increased abundance of atrogin-
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1 in the post-dexamethasone muscle samples was likely a genomic effect of prolonged 
GC treatment and indicative of upregulation of proteolytic mechanisms. 
Although a non-insulin-stimulated muscle sample might have provided additional 
information on the effects of dexamethasone on basal states of protein expression and 
activation status, it has been reported that GC do not seem to alter skeletal muscle protein 
synthesis in a post-absorptive, non-stimulated state. This is likely due to a basal 
hyperinsulinemic state caused by prolonged dexamethasone treatment [315]. 
Additionally, previous data in horses has shown detectible treatment differences on 
insulin-mediated muscle signaling components following an IHC [6, 33]. Furthermore, 
the selected insulin infusion rate has previously shown to approximate plasma insulin 
concentrations after a high starch meal in horses [254]. However, it should be noted that 
despite using similar rates of insulin infusion, both basal and plasma insulin levels during 
the IHC were significantly greater during the post-DEX period compared to pre-DEX 
[32]. Therefore, such supraphysiological insulin levels create difficulties with 
interpretation of the data and make drawing inferences related to postprandial anabolic 
response complicated. An additional limitation of the study was the lack of a non-
dexamethasone treated control group, which might have provided a better comparison 
and accounted for any potential effects of external factors. However, because the horses 
were studied within a narrow time window and were not growing or exercised, we 
believe the observed effects were due to dexamethasone treatment. 
In conclusion, 21 days of dexamethasone treatment increased plasma levels of 
glutamine and alanine and resulted in overall higher plasma amino acid concentrations in 
an insulin-stimulated state. Additionally, activation of downstream mTOR signaling 
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components, rpS6 and 4E-BP1, was decreased while abundance of atrogin-1 was 
increased. Together these results indicate that prolonged GC treatment resulted in muscle 
resistance to insulin-stimulated amino acid uptake and activation of protein synthetic 
machinery. Consequently, GC antagonized insulin’s antiproteolytic action and 
upregulated muscle protein degradation pathways. The majority of published data on the 
mechanisms of proteolytic pathways comes from in vitro models. However, the 
discrepancy between our results and those previously reported emphasizes the need for in 
vivo models to understand the complexity and adaptability of cellular regulatory 
mechanisms in a biological system. This study was the first to investigate the effects of 
GC on signaling molecules involved in proteolytic pathways in horses and suggests that 
prolonged dexamethasone treatment could decrease muscle integrity. 
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2.4. TABLES 
 
 
Table 2.1 As-fed nutrient composition of the concentrate and mixed-grass hay  
Nutrient Concentrate a Hay 
Dry matter (%) 90.5 ± 0.14 93.4 ± 0.15 
Digestible energy (Mcal/kg) 2.53± 0.00 1.91 ± 0.04 
   
Crude protein (%) 13.5± 0.30 8.75 ± 0.55 
Acid detergent fiber (%) 14.5± 0.35 37.6 ± 0.45 
Neutral detergent fiber (%) 31.3± 0.70 58.4 ± 0.80 
Non-structural Carbohydrates 
(%) 
32.9± 0.30 16.9 ± 0.75 
Crude fiber (%) 4.25± 0.15 2.15 ± 0.15 
Ash 8.1± 0.20 7.2 ± 0.30 
Values represent the means ± SEM for two samples. a Reliance Pelleted horse feed, Southern 
States, Inc. Non-structural carbohydrates (NSC, % = 100 - moisture % -CP % - CF % - NDF % - 
ash%) 
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Table 2. 2 Mean plasma amino acid concentrations during a 120 min IHC 
procedure before (Pre) and after 21 days (Post) of daily dexamethasone treatment 
(0.04 mg/kg/BW) in 8 mature horses.  
  Time (min) P-value 
 Period 0 30 60 90 120 Period Time Period*Time 
Asp Pre 21 ± 4.8 17 ± 3.3 17 ± 3.3 16 ± 4 12 ± 1.9 NS NS NS 
 
Post 14 ± 2.4 12 ± 2.1 12 ± 2 12 ± 2.2 11 ± 1.6   
 
  
Glu Pre 106 ± 22.1 83 ± 11.6 79 ± 8.7 74 ± 7.8 66 ± 3.6 NS 0.07 NS 
 
Post 111 ± 17.3 81 ± 9.7 82 ± 11.2 71 ± 8.3 81 ± 20.9   
 
  
Ser Pre 233 ± 15.1 209 ± 14.4 203 ± 11 188 ± 13.8 180 ± 11.7 0.003 NS NS 
 
Post 273 ± 17.8 292 ± 22.2 307 ± 28.5 281 ± 25.3 280 ± 32.9   
 
  
Asn Pre 42 ± 5.5 38 ± 5.5 41 ± 5.5 34 ± 5.5 32 ± 6.2 0.01 NS NS 
 
Post 54 ± 5.5 59 ± 5.5 57 ± 5.5 51 ± 5.5 53 ± 5.5   
 
  
Gly Pre 389 ± 31.1 364 ± 25.4 367 ± 23.9 348 ± 16.3 355 ± 18.9 0.03 NS NS 
 
Post 467 ± 59.4 419 ± 29.7 443 ± 37.6 413 ± 31.6 432 ± 45.5   
 
  
Gln Pre 386 ± 31.5 388 ± 31.5 389 ± 28.3 354 ± 24.7 341 ± 35.8 0.003 NS NS 
 
Post 538 ± 59 571 ± 51.6 600 ± 68.4 542 ± 53.3 566 ± 76.9   
 
  
His Pre 75 ± 3.7 71 ± 3.7 68 ± 3.4 64 ± 5.1 61 ± 3.4 NS NS NS 
 
Post 82 ± 11 73 ± 6.1 76 ± 6.1 71 ± 5.5 71 ± 5.5   
 
  
Cit Pre 107 ± 10 104 ± 9.8 105 ± 9.9 97 ± 7.4 89 ± 4.7 0.01 NS NS 
 
Post 93 ± 14.6 76 ± 5.8 79 ± 6.9 74 ± 8 74 ± 7   
 
  
Thr Pre 148 ± 18.4 139 ± 12.4 134 ± 14.1 122 ± 13.8 107 ± 6.1 0.04 NS NS 
 
Post 164 ± 9.2 165 ± 20.1 172 ± 18.9 163 ± 21.1 160 ± 15.6   
 
  
Ala Pre 216 ± 20.3 202 ± 14.5 211 ± 11 202 ± 14 204 ± 14 < .0001 NS NS 
 
Post 353 ± 34 369 ± 32.2 389 ± 31.4 372 ± 29.2 384 ± 54.6   
 
  
Arg Pre 95 ± 7.9 87 ± 7.9 84 ± 7.9 78 ± 7.9 73 ± 8.1 0.0004 0.003 NS 
 
Post 97 ± 7.9 110 ± 7.9 112 ± 7.9 101 ± 7.9 102 ± 7.9   
 
  
Pro Pre 98 ± 8 88 ± 8 87 ± 5.3 81 ± 8 79 ± 6.5 0.06 NS NS 
 
Post 115 ± 12.6 128 ± 16.6 137 ± 21.6 122 ± 18.3 120 ± 19.5   
 
  
Tyr Pre 84 ± 10.4 72 ± 10.4 76 ± 10.4 72 ± 10.4 66 ± 10.7 < .0001 NS NS 
 
Post 98 ± 10.4 116 ± 10.4 116 ± 10.4 102 ± 10.4 108 ± 10.4   
 
  
Val Pre 213 ± 11.9 197 ± 12.4 197 ± 10.6 181 ± 10.8 169 ± 6.3 0.005 NS NS 
 
Post 250 ± 29.1 239 ± 16.7 254 ± 22 234 ± 16.9 231 ± 21.7   
 
  
Met Pre 31 ± 2 28 ± 1.6 28 ± 1.3 25 ± 1.3 22 ± 1.6 0.0001 NS NS 
 
Post 39 ± 3.4 42 ± 3.9 45 ± 3.6 40 ± 3.1 39 ± 5.4   
 
  
Ile Pre 68 ± 6.1 60 ± 6.1 57 ± 5.1 49 ± 5.8 42 ± 3.4 NS NS NS 
 
Post 73 ± 8.1 81 ± 6.2 57 ± 11.8 53 ± 11.6 58 ± 8.9   
 
  
Leu Pre 120 ± 10.4 110 ± 10.4 103 ± 10.4 89 ± 10.4 79 ± 10.9 < .0001 0.02 NS 
 
Post 126 ± 10.4 133 ± 10.4 137 ± 10.4 123 ± 10.4 118 ± 10.4   
 
  
Phe Pre 69 ± 3.9 65 ± 2.8 64 ± 2.1 60 ± 3.9 57 ± 3.6 0.05 NS NS 
 
Post 73 ± 9.5 72 ± 4.3 76 ± 4.8 69 ± 3.1 69 ± 6.3   
 
  
Trp Pre 6 ± 1.1 6 ± 0.8 6 ± 1 5 ± 0.6 6 ± 1.1 NS NS NS 
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Abbreviations: ASP, aspartate; GLU, glutamate; SER, serine; ASN, asparagine; GLY, glycine; GLN, 
glutamine; HIS, histidine; CIT, citrulline; THR, threonine; ALA, alanine; ARG, arginine; PRO, proline; 
TYR, tyrosine; VAL, valine; MET, methionine; ILE, isoleucine; LEU, leucine; PHE, phenylalanine; TRP, 
tryptophan; ORN, ornithine; LYS, lysine; PRE, pre-dexamethasone; POST, post-dexamethasone; NS, not 
significant. Data analyzed with repeated measures analysis using an autoregression variance-covariance 
structure for histidine, alanine, methionine, phenylalanine, a compound symmetry structure for leucine and 
tyrosine, a Toeplitz structure for asparagine, arginine, lysine and an antedependence structure for all other 
amino acids. Data are presented as least square means ± standard error of the mean. N = 8 horses   
 
Post 7 ± 1.1 8 ± 1.1 20 ± 11.8 18 ± 10 7 ± 1.9   
 
  
Orn Pre 64 ± 5.6 59 ± 4.6 58 ± 4.5 51 ± 3.7 48 ± 3.4 NS NS NS 
 
Post 62 ± 4.2 59 ± 9.3 59 ± 9.2 57 ± 10.7 58 ± 5.1   
 
  
Lys Pre 91 ± 7.8 83 ± 7.8 76 ± 7.8 67 ± 7.8 62 ± 7.8 0.03 < .0001 NS 
 
Post 90 ± 7.8 96 ± 7.8 100 ± 7.8 91 ± 7.8 83 ± 7.8       
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2.5. FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 1 Mean baseline plasma concentrations (μmol/L) for amino acids 
significantly affected by dexamethasone treatment. 
Values are least squared means ± SE of baseline amino acid levels that differed significantly 
between pre-DEX (white bars) and post-DEX (black bars) sample periods (P < 0.05). Data 
analyzed with repeated measures analysis using an autoregression variance-covariance structure 
for alanine and methionine, phenylalanine and an antedependence structure for glutamine. N = 8 
horses.  
  
Methionine Alanine Glutamine
0
100
200
300
400
500
600
Pre DEX
Post DEX
B
a
s
e
li
n
e
 p
la
s
m
a
 a
m
in
o
 a
c
id
c
o
n
c
e
n
tr
a
ti
o
n
s
 µ
m
o
l/
L
Post DEX 
Pre DEX 
90 
 
 
 
 
 
 
 
Figure 2. 2 Mean plasma concentrations (μmol/L) during the IHC for amino acids 
significantly affected by time 
Values are least squared means ± SE of amino acid concentrations that changed significantly over 
time (P< 0.05). Data analyzed with repeated measures analysis using a autoregression-
heterogenous variance-covariance structure for histidine, alanine, methionine and phenylalanine, 
a toeplitz structure for asparagine, arginine and lysine, a compound symmetry structure for 
tyrosine and leucine and an antedependence variance-covariance structure for all other amino 
acids. Abbreviations: Glu: glutamate, Arg: arginine, Ile: isoleucine, Leu: leucine, Lys: lysine. N = 
8 horses. 
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Figure 2. 3 Mean plasma concentrations (μmol/L) during the IHC for amino acids 
significantly affected by dexamethasone treatment  
Values are least squared means ± SE of amino acid concentrations during the IHC that differed 
significantly between pre-DEX (white bars) and post-DEX (black bars) sample periods (P < 
0.05). Data are averaged across all time points and analyzed with repeated measures analysis 
using a autoregression-heterogenous variance-covariance structure for histidine, alanine, 
methionine and phenylalanine, a toeplitz structure for asparagine, arginine and lysine, a 
compound symmetry structure for tyrosine and leucine and an antedependence variance-
covariance structure for all other amino acids. Abbreviations: Ser: serine, Asn: asparagine, Gly: 
glycine, Cit: citrulline, Thr: threonine, Ala: alanine, Pro: proline, Try: tryrosine, Val: valine, Met: 
methionine, Leu: leucine, Phe: phenylalanine, Lys: lysine. N = 8 horses.  
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Figure 2. 4 Insulin-stimulated phosphorylation of factors involved in the 
upregulation of muscle protein synthesis 
Values are least squared means ± SE of protein expression levels of Akt at Ser473, rpS6 at 
Ser235/236 & 240/244 and 4E-BP1 at Thr37/46 in  pre-DEX (white bars) and post-DEX (black bars) 
gluteus medius muscle samples. Phosphorylated form of each protein was normalized to their 
respective total form abundance. Data were analyzed using a one-way ANOVA. Representative 
images of the immunoblots are shown above. *Significant difference between pre and post 
dexamethasone treatment (P < 0.05). N = 8 horses. 
  
Akt 4EBP-1 Rps6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Pre DEX
Post DEX
4EBP has a tendency to be
lower P = 0.0842
RpS6 p = 0.0418
*
Akt P = 0.14
P
h
o
s
p
h
o
ry
la
te
d
/T
o
ta
l 
p
ro
te
in
 a
b
u
n
d
a
n
c
e
A
rb
it
ra
ry
 u
n
it
s
Post DEX 
Pre DEX 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 5 Insulin-stimulated phosphorylation of factors involved in the 
upregulation of muscle protein degradation  
Values are least squared means ± SE of protein expression levels of AMPK at Thr172 , FoxO1 at 
Ser256  and NF-κB p65 Ser536 in  pre-DEX (white bars) and post-DEX (black bars) gluteus medius 
muscle samples. Phosphorylated form of each protein was normalized to their respective total 
form abundance. Data were analyzed using a one-way ANOVA. Dexamethasone treatment 
tended to increase FoxO1 phosphorylation (P = 0.08) but did not affect activation of AMPK or 
NF-κB p65 (P > 0.05). Representative images of the immunoblots are shown above. N = 8 
horses. 
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Figure 2. 6 Relative abundance of factors involved in the upregulation of muscle 
protein degradation 
Values are least squared means ± SE of protein expression levels of myostatin, atrogin-1 and 
MuRF-1 in pre-DEX (white bars) and post-DEX (black bars) gluteus medius muscle samples. 
The abundance of each protein was normalized to the total abundance of housekeeping protein, α-
tubulin. Representative images of the immunoblots are shown above. Data were analyzed using a 
one-way ANOVA *Significant difference between pre and post dexamethasone treatment (P < 
0.05). N = 8 horses. 
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Protein  Phosphorylated form Total form 
 MW (kDa) Pre DEX Post DEX Pre DEX Post DEX 
Akt 60   
rpS6 32   
4E-BP1 15-20   
AMPK 62   
FoxO1 80  NA 
Atrogin-1 41 NA  
Myostatin 42 NA  
NF-κB 65   
MuRF-1 38 NA  
α-Tubulin 52 NA  
 
Figure 2. 7 Representative images of the immunoblots 
The images represent phosphorylated (left two columns) and total form (right two columns) of 
each protein before and after 21 days of dexamethasone treatment.  
Akt phosphorylated at ser473, rpS6 phosphorylated at Ser235/236 and Ser240/244, 4E-BP1 
phosphorylated at Thr37/46, AMPK phosphorylated at Thr172, FoxO1 phosphorylated at Ser253, NF-
κB p65 phosphorylated at Ser536 . NA: not applicable; MW: molecular weight; kDa, kilodalton. 
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CHAPTER 3  
EFFECTS OF SHORT-TERM DEXAMETHASONE ADMINISTRATION ON 
GLUCOSE AND INSULIN DYNAMICS AND MUSCLE PROTEIN SIGNALING 
IN HORSES AFTER THE CONSUMPTION OF A HIGH PROTEIN MEAL 
 
Abstract 
Long-term dexamethasone (DEX) administration results in peripheral insulin resistance 
and interferes with protein synthetic pathways in equine skeletal muscle. The anabolic 
response to dietary amino acids is mediated through their insulinotropic effects and their 
ability to stimulate muscle protein synthesis through insulin-independent mechanisms. 
The objective of this study was to determine the effects of short-term DEX treatment on 
plasma glucose, insulin and amino acid dynamics and muscle signaling pathways in 
response to the consumption of a high protein meal. Twelve mature, thoroughbred mares 
were used in this study: 6 horses received oral DEX (0.04 mg/kg BW/day) for 7 days and 
6 served as control, receiving no DEX. Each horse was sampled 3 times: prior to DEX 
administration (DAY 1), following the 7 day DEX treatment period (DAY 7), and 7 days 
after cessation of treatment (DAY 14). On each sampling day, blood and gluteus medius 
muscle samples were collected before and 90 min after feeding 4g/kg BW of a high 
protein feed (30% CP). Plasma glucose, insulin, amino acid and urea concentrations were 
determined, and muscle samples were analyzed by Western immunoblot procedures to 
determine the relative abundance and phosphorylation of muscle signaling molecules. 
Data were analyzed using mixed procedures in SAS with block, treatment, day and their 
interactions as the fixed effects and horse nested within block as the random subject. 
Feeding increased plasma glucose, insulin and amino acids and activated or increased 
abundance of muscle Akt, rpS6, 4E-BP1, mTOR, IRS-1 and ULK-1, regardless of 
treatment or day (P < 0.05). Seven days of DEX treatment increase basal concentrations 
of plasma glucose, insulin, several amino acids and tended to lower PUN (P < 0.05; 0.05 
< P < 0.1). Regardless of sample day, the basal activation of mTOR and total abundance 
of IRS-1 were lower and higher in DEX horses, respectively (P < 0.1). DEX treated 
horses had a 3-fold greater insulin response but a generally lower amino acid response to 
a high protein meal (P < 0.05). Postprandial activation of rpS6 was higher and lower in 
DEX treated horses compared to the control group on DAY 7 and 14, respectively (P < 
0.05). In response to feeding, activation of AMPK and ULK-1 tended to be higher in 
DEX treated horses on DAY 7 (P <0.1). Differences in glucose and insulin responses 
between groups disappeared by DAY 14 (P > 0.05), however aberrations in amino acid 
dynamics and muscle signaling were still evident after 7 days of recovery from DEX 
treatment. Collectively, these results indicate the 7 days of DEX administration resulted 
in transient insulin dysregulation, caused alterations in amino acid metabolism and 
interfered with muscle protein signaling pathways in response to a high protein meal in 
mature, healthy horses. 
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3.1. INTRODUCTION 
Glucocorticoids (GC’s) are fundamental modulators of immune function and 
metabolism under pathophysiological conditions and are known to affect whole body 
glucose and insulin dynamics, as well as skeletal muscle carbohydrate and protein 
metabolism [128, 129, 257]. Despite their useful anti-inflammatory effects, 
administration of synthetic GC’s, such as dexamethasone, is known to have adverse 
effects in several species including horses. Both short and long-term dexamethasone 
treatment in horses has been shown to result in a significant decrease in peripheral insulin 
sensitivity, increase blood glucose levels and interfere with skeletal muscle signaling 
pathways (Chapter 2 and [29, 30, 32, 33, 244]). GC-induced muscle atrophy has been 
extensively studied in relation to stress-associated pathologies and has also proven to be a 
useful model to investigate the molecular mechanism underlying skeletal muscle 
degradation [48]. GC’s catabolic action on skeletal muscle is largely mediated through 
interference with the mammalian target of rapamycin (mTOR), a key regulator of the 
delicate balance between protein synthesis and degradation. 
Activation of protein synthetic machinery by mTOR relies upon the presence of 
anabolic growth and nutritional factors, including insulin, insulin-like growth factor-1 
(IGF-1) and amino acids. Insulin-mediated activation of mTOR works through an 
intracellular signaling cascade involving phosphorylation of insulin receptor substrates 
and Akt [76]. Once activated mTOR will phosphorylate downstream targets 4E-BP1 and 
S6K1 and subsequently rpS6, eventually leading to protein translation initiation [90]. 
Amino acids play a unique role in protein synthesis because they do not only function as 
substrates but also stimulate mTOR activation in an insulin-independent manner [66, 
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330]. In humans and rodents it has been illustrated that the adverse effects of GC’s on 
muscle mass are mediated through both interference with these anabolic signal 
transduction pathways and decreasing amino acid uptake into the muscle, thereby 
limiting substrate supply for protein translation [48, 257, 307, 318]. Additionally, 
mechanisms underlying GC-induced muscle protein degradation in these species include 
upregulation of genes involved in proteolytic pathways and reducing cellular energy 
status due to decreased glucose uptake [103, 136, 312, 327]. 
Ingestion of a meal rich in protein, in particular one that is high in essential amino 
acids, is known to stimulate muscle protein synthesis in several species including horses 
[14, 57, 331-333]. In addition to the direct stimulatory effects of certain amino acids on 
mTOR, dietary amino acids are also known to induce pancreatic insulin release thereby 
enhancing the anabolic effects of feeding [177, 203]. Conversely, it is known that amino 
acid and insulin metabolism is altered in a state of insulin dysregulation [45, 225], 
potentially reducing postprandial muscle anabolic responses [44, 46, 334]. In horses, it is 
known that the activation of protein translation initiation factors in response to a high 
protein meal changes with age, which might be associated with developmental alterations 
in muscle sensitivity to the anabolic stimulus of insulin and amino acids [14, 59]. 
Previous in vivo and in vitro studies clearly illustrate that dexamethasone 
administration rapidly decreases insulin sensitivity and reduces muscle protein synthetic 
responses to insulin, IGF-1 and amino acids [83, 303, 335-337]. We have previously 
illustrated that 21-days of dexamethasone administration in horses resulted in significant 
insulin dysregulation associated with decreased insulin-stimulated activation of mTOR 
signaling components (Chapter 2). However, the acute effects of dexamethasone on 
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postprandial metabolic responses in horses is still unknown. Therefore, the objective of 
the current study was to evaluate the effects of short-term dexamethasone treatment on 
glucose, insulin and amino acid dynamics and muscle protein signaling pathways before 
and after consumption of a meal high in protein. 
3.2. MATERIALS AND METHODS 
3.2.1. Animals and housing 
Twelve healthy, mature, thoroughbred mares from University of Kentucky Maine 
Chance farm were selected for the study (age 16 ± 3 years old; 563 ± 35 kg BW; mean ± 
SD). For the duration of the study, all horses were housed in 3 x 15 m, partially covered, 
dry-lot pens with crushed limestone footing having ad libitum access to water and a salt 
block. With exception of sample days, all horses were turned out in group into grass lot 
pens for approximately 8h each day wearing muzzles. Horses remained in their individual 
pens overnight and on sampling days to allow for individual feeding and handling during 
experimental procedures. All horses were acclimated to the housing and turnout paddocks 
and monitored for water intake while wearing the muzzles for 1 week prior to any sample 
collection. Horses had ad libitum access to water and a salt block in their individual 
overnight pens and were fed alfalfa hay and a commercial ration balancer twice daily (at 
0700 and 1600) at 1.85 and 0.15 % of their BW on as-fed basis, respectively, to meet 
requirement for mature, idle horses. Samples of the hay and ration balancer were sent to 
Dairy One Forage Laboratory (Ithaca, NY) for analysis (Table 3.1). The University of 
Kentucky Institutional Animal Care and Use Committee approved all procedures. 
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3.2.2. Experimental procedures 
Twelve horses were randomly assigned to receive either 7 days of dexamethasone 
(DEX) or an equivalent amount of saline (CON). Each horse was studied for 15 days and 
underwent sampling procedures before (DAY 1) and after 7 days of treatment (DAY 7), 
and following a 7-day recovery period from their respective treatments (DAY 14). This 
timeline was based on the results of a pilot study showing differences in postprandial 
insulin response and mTOR signaling pathways after 7 days of DEX treatment (See 
Appendix A.3). To facilitate sampling procedures, the 12 horses were divided into two 
consecutive 21-day blocks. Because it is known that mTOR signaling and consequently 
protein synthesis can be activated by both insulin and amino acids, the response of each 
horse to two different anabolic challenges, the ingestion of a high protein meal and an 
oral sugar test, were studied on consecutive days. Horses received the anabolic challenges 
in a randomly determined order on three sample periods during the study: 1) a pre DEX 
two-day sample period (DAY 1), 2) a post DEX two-day sample period (DAY 7) and 3) a 
two-day sample period following 7 days of recovery from treatment (DAY 14). 
Description and results of the oral sugar test will be presented separately in Chapter 4 and 
this Chapter will focus solely on the response to feeding a high protein meal.  
To study the effects of DEX on postprandial activation of mTOR signaling 
pathways, blood and muscle samples were collected before and 90 min after ingestion of 
a commercially available high protein balancer pellet (CP 33%, Table 3.2) on each 
sample day (DAY 1, DAY 7, DAY 14). This feeding strategy has been previously shown 
to activate the muscle protein signaling pathways in horses [57]. On the days prior to 
sample collection, horses received their allotted evening hay and concentrate portions 18h 
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before initiation of sampling procedures [14]. Any remaining hay was removed 
approximately 14h before sample collection to ensure horses were in a post-absorptive 
state. Ad libitum access to water was maintained at all times. On the morning of 
collection, a baseline blood sample (10 mL, pre feeding) was collected via venipuncture 
into evacuated tubes containing sodium heparin, after which horses were lightly sedated 
with 3 mL of xylazine hydrochloride. Biopsy sites were aseptically scrubbed and 
anesthetized with lidocaine (13 ml of 12% lidocaine). A percutaneous biopsy of the 
gluteus medius muscle was collected through a single incision, using the bergstrom 
needle technique as previously described [57]. After the basal muscle sample collection 
(pre feeding), horses were allowed to recover from the sedation in their stalls until they 
were visually alert (~30-45 min) after which they received 2g/kg BW of the high protein 
pellet at t = 0 and 30 min, for a total of 4g/kg BW of feed (Table 2). At t = 90 min after 
feeding the first meal, a second blood sample was collected via venipuncture and biopsy 
procedures were repeated as previously described (referred to as post feeding). Muscle 
biopsies collected on the same day were obtained from contralateral sides. After the 
second biopsy, horses were allowed to recover in their individual pens until sedation 
wore off after which they received their daily hay portion. After the last biopsy collection 
in each sample period (i.e. Feed day or OST day) horses received 2g of non-steroidal 
anti-inflammatory phenylbutazone paste (ButaPaste, Butler Animal Health Supply, 
Dublin, OH) for 2 days. After sample collections on DAY 1, horses received a daily dose 
of dexamethasone (DexaJet SPc; 0.04 mg/kg/BW), or an equal volume of 0.9% saline, for 
7 days which was top-dressed on their evening concentrate. This dose has previously 
shown to result in substantial insulin dysregulation after 7-21 days [29, 32, 244]. All 
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sample procedures were repeated after 7 days of DEX  (DAY 7) treatment and following 
a 7-day recovery period (DAY 14).  
Blood samples were processed immediately and centrifuged at 2000 x g for 10 
min at 4 °C after which plasma was removed and stored at -20 °C until further analysis. 
Approximately 100 mg of freshly collected muscle tissue was weighed out and 
immediately homogenized in a cell lysis buffer (20 mM HEPES, 2 mM EGTA, 50 mM 
NaF, 100 mM KCL, 0.2 mM EDTA, 50 mM β-glycerophosphate) containing 20µl/ml of 
a protease inhibitor using a handheld tissue homogenizer. Homogenates were then 
centrifuged at 10,000 x g for 10 min and the supernatant removed and frozen at -80°C 
until further analysis. 
3.2.3. Western immunoblot analysis 
The abundance and phosphorylation of proteins of interest in the muscle samples 
were analyzed for by western immunoblotting based on previously described methods 
[14, 21]. Briefly, total protein content was determined using a Bradford assay and 2μl of 
phosphatase inhibitor (Cell Signaling Technology) was added to every 200μl of muscle 
homogenate to improve stability of phosphorylated protein. Samples were then diluted in 
laemmli buffer (30% glycerol; 6% SDS; 180 mM Tris Base, pH 6.8; 536 mM 2-
mercaptoethanol; 0.03% bromophenol blue) to a final concentration of 2μg/µl. Ten µl of 
each sample was loaded into a polyacrylamide gel in duplicate. After separation by 
electrophoresis, proteins were transferred to a 0.45 µm polyvinylidene deflouride 
membrane (Millipore Sigma, St. Louis, MO). Immediately after transfer, both 
membranes were stained with Fast Green Stain (1% fast green, 50% methanol, 1% glacial 
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acetic acid), which binds to all protein bound to the membrane. A picture of the fast green 
stained membranes was obtained using a digitalized using a charge coupled device 
camera on a VersaDoc™ imager (Bio-Rad Laboratories, Inc., Hercules, CA). This image 
was used as a measure of ‘total protein’ for normalization of each protein. Fast Green was 
removed with destain (50% methanol, 1% glacial acetic acid) after which the membranes 
were blocked by incubation with either 5% (w/v) fat-free milk or BSA (bovine serum 
albumin) buffer for 1h at room temperature. After the blocking solution was removed, 
membranes were probed with the appropriate primary antibody overnight at 4 °C (Akt, 
rpS6, 4E-BP1, FoxO3, IRS-1, mTOR, ULK, myostatin, NF-κB and AMPK) or for 1h at 
room temperature (atrogin-1). Rabbit polyclonal antibodies were used against total and 
ser473 Akt (1:2000 dilutions for both, Cell Signaling Technology, Inc., Boston, MA); 
Ser235/236 and Ser240/244 rpS6 (1:2000 dilutions each, Cell Signaling Technology); atrogin-
1 (1:1000 dilution, ECM Biosciences, Versailles, KY); total AMPK (1:1000 dilution, 
Cell Signaling Technology), total and Ser2448 mTOR (1:1000 dilution each, Cell 
Signaling Technology), Ser757 ULK (1:5000 dilution, Cell Signaling Technology) and 
myostatin (1:500 dilution, Abcam, Cambridge, MA). Rabbit monoclonal antibodies were 
used specific to total rpS6 (1:10,000 dilution, Signaling Technology); total and Thr37/46 of 
4E-BP1 (1:1000 dilution for each, Cell Signaling Technology); total and Ser253 FoxO3 
(1:2000 and 1:3000 dilutions,  Cell Signaling Technology); α-tubulin (1:1000 dilution, 
Cell Signaling Technology); Thr172 AMPK (1:1000 dilution, Cell Signaling Technology), 
total IRS-1 (1:1000 dilution, Cell Signaling Technology) and Ser536 NF-κB p65 were 
used (1:1000 dilutions, Cell Signaling Technology). Antibodies were raised against 
human (total and phosphorylated rpS6, NF-κB, AMPK, FoxO3, mTOR; total IRS-1, 4E-
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BP1, myostatin; and phosphorylated ULK-1) or mouse proteins (total and phosphorylated 
Akt; phosphorylated 4E-BP1 and atrogin-1). All antibodies used were either previously 
validated in our lab for use with equine muscle tissue or validated before the start of the 
current analysis (Appendix A.1).  
After removing the primary antibody, membranes were washed and incubated 
with a goat anti-rabbit IgG antibody conjugated to horseradish peroxidase (dilution 
specific to each primary antibody, Cell Signaling Technology) for 1h at room 
temperature. Membranes were developed using a chemiluminescent kit (Amersham ECL 
Plus western blotting detection reagent, GE Healthcare Bio-Sciences, Pittsburgh, PA) and 
visualized using a digital imager (Azure c600, Azure biosystems, Dublin, CA). After 
developing, the membranes were stripped for 10 min with stripping buffer (2% SDS, 62.5 
mM Tris-Base, 0.1 M β-mercaptoethanol), re-blocked with appropriate blocking solution 
and re-probed with an antibody against total form of each phosphorylated protein 
measured (Akt, rpS6, 4E-BP1, AMPK, FoxO3 and mTOR) and procedures repeated as 
described.  
All gels were run in duplicate and results are expressed as an average of two gels. 
Band densities of all blots and Fast Green stained membranes were quantified using a 
densitometry software (AzureSpot, Azure Biosystems, Dublin, CA). To control for intra-
assay variation, each sample band was normalized to the band density of a positive 
control (pooled muscle homogenate samples), which was loaded onto each gel. To 
correct for possible gel loading errors, all band densities (phosphorylated and total 
protein abundance) were normalized to the value of total protein in each respective lane, 
determined by the densitometry software as “total lane volume” of the Fast Green stained 
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membranes (For more information see Appendix A.2). The band density of 
phosphorylated forms of Akt, rpS6, 4E-BP1, AMPK, mTOR and FoxO3 was also 
normalized to that of the total abundance of each respective protein. The calculated ratio 
of phosphorylated to total protein will serve as a measure for activation of Akt, rpS6, 4E-
BP1, AMPK, mTOR and FoxO3. In addition to the activation status of these proteins, 
relevant differences in phosphorylated and total protein abundance will also be discussed. 
Results for IRS-1, myostatin and atrogin-1 will only refer to total abundance of each 
protein and results for ULK and NF-κB represent only their respective phosphorylated 
forms. All obtained values are expressed as relative abundances in arbitrary units. 
3.2.4. Plasma glucose and insulin 
Plasma glucose concentrations were determined enzymatically using an 
automated analyzer (YSI 2700 Select Analyzer, YSI Inc. Life Sciences). Plasma insulin 
levels were assayed using a commercially available radioimmunoassay kit (Porcine 
insulin RIA, Millipore Sigma) which has previously been used for analysis of equine 
insulin and validated in our lab by running parallelisms. The inhibition curves produced 
by adding decremental volumes of diluted plasma were parallel to the insulin standards. 
All samples for each assay were run in duplicate and within the same day. Insulin intra-
assay coefficient of variation for low and high quality controls was 0.5% and 18.6%, 
respectively. 
3.2.5. Plasma amino acids 
Plasma free amino acid concentrations and feed amino acid content were 
determined by reserve-phase HPLC of phenyisothiocyanate derivatives as previously 
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described [57]. Methionine content of the feed was determined by performic acid 
oxidation prior to acid hydrolysis procedures as previously described [338]. 
3.2.6. Plasma urea 
Plasma urea nitrogen (PUN) concentrations were assayed using a 
spectrophotometric enzymatic assay as previously described (Millipore Sigma) [339], 
with an intra-assay coefficient of variation of 4.6 %. All samples were run as a single 
batch to avoid any effects of inter-assay variation. 
3.2.7. Data analysis 
All data were analyzed using mixed or glimmix procedures of SAS version 9.3 
(SAS Institute Inc.) with significance set at P < 0.05. Statistical trends were considered 
when 0.05 < P < 0.10. Normality of the data was assessed by visual inspection of the 
distribution of studentized residuals and the Shapiro-Wilk test (P < 0.05). If necessary, 
outliers identified as > 2 standard deviations from the mean were removed from the 
dataset to obtain normality. The response to the consumption of a high protein meal was 
analyzed as the delta (post -pre) of the 90 min post values and the baseline (0 min) values 
of each dependent variable. Baseline and response data were analyzed using repeated 
measures analysis with an appropriate variance-covariance matrix chosen based on 
lowest values for respective fit statistics. Block, treatment (DEX vs CON), sample day 
(DAY 1, DAY 7, DAY 14) and their interactions were considered fixed effects and horse 
nested within block as the random subject. In addition to the comparison of baseline and 
response to feeding, western blot data was also analyzed for overall effects of time (0 min 
vs 90 min) and treatment (DEX vs CON) with block, treatment, day, time and their 
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interaction as the fixed effects and horse nested within block as the random subject. 
When fixed effects were significant, least square means were compared using a pdiff test. 
All data are presented as least square means ± SE. 
3.3. RESULTS 
No differences were observed in average age (DEX 15 ± 1 and CON 16 ± 1 years 
old; P > 0.05) or bodyweight (DEX 558 ± 15 and CON 567 ± 16 kg; P > 0.05) between 
the treatment groups. Bodyweight also did not change significantly throughout the study 
in either treatment group (P > 0.05). 
3.3.1. Plasma glucose 
Baseline plasma glucose concentrations were significantly affected by a treatment 
by day interaction (P = 0.0002). Basal glucose levels did not differ between treatment 
groups on DAY 1 and 14, however on DAY 7 glucose concentrations were 1.2-fold 
higher in dexamethasone treated horses compared to the control group (Figure 3.1 A). 
There was no difference in basal levels within the control group but glucose 
concentrations were significantly higher on DAY 7 compared to DAY 1 and DAY 14 in 
the dexamethasone treated group (Figure 3.1 A).  
Feeding a high protein meal resulted in an increase in glucose concentrations in 
all horses (P < 0.0001). However, the postprandial glucose response was not different 
between or within each treatment groups on any day (P > 0.05, Figure 3.1 B).  
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3.3.2. Plasma insulin 
Basal plasma insulin levels were significantly affected by a treatment by day 
interaction (P = 0.0002). Basal insulin concentrations were 4.5-fold higher in 
dexamethasone treated horses on DAY 7 compared to the control group, with insulin 
concentrations of 5.8 ± 2.8 and 26.3 ± 2.8 µIU/mL in control and dexamethasone treated 
horses, respectively (Figure 3.2 A). No differences between treatment groups were 
detected on any other sample days (P > 0.05). There was no difference in basal levels 
within the control group but dexamethasone treated horses had a 5-and 4-fold increase in 
insulin concentrations on DAY 7 compared to DAY 1 and DAY 14, respectively (Figure 
3.2 A). 
Insulin levels increased in all horses after eating a high protein pelleted meal, 
regardless of sample day (i.e. overall effect of time, P < 0.0001). The insulin response to 
feeding was affected by a significant treatment by day interaction (P < 0.0001) which 
showed that the postprandial insulin response was 3-fold greater in dexamethasone 
treated horses compared to the control group on DAY 7 (Figure 3.2 B). Insulin responses 
did not differ between groups on any other days (P > 0.05). There was no difference in 
postprandial insulin responses within the control group during the entire study (P > 0.05, 
Figure 3.2B). Within the dexamethasone treated horses insulin responses to a high protein 
were 3 and 2- fold greater on DAY 7 compared to DAY 1 and DAY 14, respectively (P < 
0.05, Figure 3.2 B). 
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3.3.3. Plasma urea nitrogen 
Basal PUN was affected by day (P = 0.01) and there was a tendency for a day by 
treatment interaction (P = 0.08). Overall basal PUN concentrations on DAY 7 were 
significantly lower than DAY 14 (P = 0.004) and tended (P = 0.09) to be lower than 
DAY 1 (Figure 3.3A). Analysis of the treatment by day interaction showed no difference 
in basal PUN in the control horses, however baseline PUN was significantly lower on 
DAY 7 compared to DAY 1 and DAY 14 in the dexamethasone group (P < 0.05) (Figure 
3.3B).  There was no difference in PUN response to feeding between days or treatment 
groups (P > 0.05, Figure 3.4). 
3.3.4. Plasma amino acids 
There was significant effect of treatment on basal concentrations of plasma serine, 
asparagine, glycine, glutamine, threonine, alanine, proline, tyrosine, phenylalanine, 
tryptophan and lysine (P < 0.05, Table 3.3, Figure 3.5) and trend for treatment to affect 
plasma arginine levels (P = 0.06, Table 3.3, Figure 3.5). Basal concentrations of plasma 
histidine, citrulline, tyrosine, phenylalanine, tryptophan, ornithine and lysine were 
affected by day (P < 0.05,) and plasma glutamate tended (P = 0.1) to be affected by day 
(Table 3.3). There was a significant treatment by day interaction for basal values of 
plasma serine, asparagine, glutamine, alanine, proline and isoleucine (P < 0.05, Table 
3.3, Figure 3.6) and a tendency for baseline plasma concentrations of glycine (P = 0.09, 
Figure 3.6) and arginine (P = 0.1, Table 3.3, Figure 3.6) to be affected by the interaction. 
Baseline plasma amino acids affected by treatment were significantly elevated in 
dexamethasone treated horses, regardless of sample day (P < 0.05, Table 3.3, Figure 3.5). 
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An effect of sample day was seen for basal plasma histidine and phenylalanine where 
concentrations were higher on DAY 7 compared to DAY 1 and 14. Basal citrulline 
concentrations on DAY 7 and 14 were higher than DAY 1 but not different from each 
other. Baseline plasma tyrosine and tryptophan concentrations were higher on DAY 7 
than DAY 1, but not different from DAY 14. Baseline plasma ornithine and lysine 
concentrations were higher on DAY 7 compared to day 14 but not different from DAY 1. 
Conversely, basal plasma glutamate on DAY 7 was lower than DAY 14, but not different 
from DAY 1. As result of a treatment by day effect, baseline levels of serine, asparagine, 
glutamine, alanine, proline, isoleucine, arginine and glycine were significantly higher in 
dexamethasone treated horses on DAY 7 compared to the control horses (Figure 3.6). For 
these amino acids, there were no differences between the treatment groups on DAY 1 or 
DAY 14, with the exception of asparagine, which was also higher in dexamethasone 
treated horses on DAY 14. There were no differences in basal concentrations for any of 
these amino acids within the control group. Within the dexamethasone group, basal levels 
of serine, asparagine, glutamine, alanine, proline, isoleucine, arginine and glycine were 
generally increased on DAY 7 in comparison to DAY 1 and/or DAY 14 (Figure 3.6). 
Feeding a high protein meal increased plasma concentrations of all amino acids 
over baseline levels (P < 0.05). There was a significant effect of treatment on the 
response to feeding for plasma serine, glycine and histidine (P < 0.05) and a tendency of 
a treatment effect for plasma aspartate (P = 0.06), glutamine (P = 0.07) and ornithine (P 
= 0.06) (Table 3.4, Figure 3.7). Postprandial plasma histidine, citrulline, arginine and 
leucine responses were affected by day (P < 0.05) and tended to be different by day in 
plasma threonine (P = 0.09), phenylalanine (P = 0.1) and ornithine (P = 0.1) (Table 3.4). 
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There was a significant interaction between treatment and day for plasma serine, 
glutamine and proline responses (P < 0.05) and a trend this interaction in plasma 
responses of aspartate (P = 0.09), glutamate (P = 0.09) and lysine (P = 0.1) (Table 3.4 
and Figure 3.8). Plasma amino acids affected by treatment showed an overall lower 
response to feeding in horses treated with dexamethasone (Figure 3.7). Postprandial 
histidine and threonine (tendency) response was lower on DAY 7 versus DAYS 1 and 14. 
Citrulline response was lower on DAY 7 and 14 compared to DAY 1. Arginine and 
leucine response was lower on DAY 1 and 7 versus DAY 14. Ornithine response tended 
to be greater on DAY 1 and 14 compared to DAY 7. Phenylalanine response tended to be 
greater on DAY 14 versus DAY 7 but DAY 1 and 7 were not different. For plasma amino 
acids affected by a treatment by day interaction, the ingestion of a high protein meal 
resulted in significantly lower plasma response of aspartate (trend), serine, glutamine and 
proline on DAY 7 in the dexamethasone treated horses (Figure 3.8). There were no 
differences in postprandial amino acid response between days within the control group, 
with exception of proline, which was lower on DAY 7 (Figure 3.8). Within the 
dexamethasone treated group, postprandial amino acid responses of aspartate, glutamate, 
serine, glutamine, proline and lysine were generally decreased on DAY 7 in comparison 
to DAY 1 and/or DAY 14 (Figure 3.8). 
3.3.5. Western blots 
Regardless of day or treatment, feeding a high protein meal increased activation 
of Akt (P < 0.0001), rpS6 (P < 0.0001), 4E-BP1 (P = 0.002) and mTOR (P < 0.0001) 
and increased overall abundance of IRS-1 (P = 0.05) and the phosphorylated form of 
ULK (P < 0.0001) (Table 3.4 and Figure 3.9). 
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For the following section, data regarding treatment effects on activation, 
phosphorylated form and total form of each protein can be found in Table 3.4, 3.5 and 
3.6, respectively.  
Regardless of sample day or time of biopsy, there was an overall effect of 
treatment on the activation of FoxO3 (phosphorylated/total FoxO3) (P = 0.05) and the 
total abundance of IRS-1 (IRS-1/ total protein stain) (P = 0.09) (Table 3.4 and Figure 
3.10). FoxO3 phosphorylation was overall greater in control versus dexamethasone 
treated horses (P = 0.05, Table 3.4, Figure 3.10A). There was an overall trend for greater 
abundance of IRS-1 in dexamethasone treated horses compared to control horses (P = 
0.09, Table 3.6, Figure 3.10A). Regardless of sample day, there was also an effect of 
treatment on basal levels of activated mTOR (phosphorylated/total mTOR) (P = 0.06) 
and basal levels of IRS-1 (IRS-1/ total protein stain) (P = 0.06) (Figure 3.10B). There 
was a trend for basal levels of activated mTOR to be lower and levels of IRS-1 to be 
higher in dexamethasone treated horses compared to control horses (Tables 3.4 and 3.6).  
A treatment by day interaction was observed for the activation (ratio of 
phosphorylated to total protein abundance) of rpS6 (P = 0.02), AMPK (P = 0.05) and 
phosphorylation of ULK (P = 0.09) in response to feeding and for baseline levels of IRS-
1 (P = 0.08) (Figure 3.11). Activation (ratio of phosphorylated to total protein 
abundance) of rpS6 in response to feeding was significantly higher (P = 0.04) and tended 
(P = 0.09) to be higher on DAY 7 versus DAY 14 and DAY 1, respectively, within the 
dexamethasone treated horses (Table 3.4, Figure 3.11 B). However, compared to the 
control horses rpS6 activation in response to feeding tended (P = 0.09) to be greater in 
the dexamethasone group on DAY 7 but was significantly lower in this group versus 
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control horses on DAY 14 (P = 0.03). Activation of AMPK in response to feeding was 
significantly higher on DAY 7 (P = 0.008) and 14 (P = 0.01) compared to DAY 1 within 
the dexamethasone treated horses (Table 3.4, Figure 3.11 D). There were no differences 
between groups or within the control horses for AMPK response (P > 0.05). In response 
to feeding, abundance of phosphorylated ULK increased to a greater extent on DAY 7 
compared to DAY 1 (P = 0.02) within the dexamethasone treated horses but the response 
on DAY 7 did not differ from that on DAY 14 (P = 0.2) (Table 3.5, Figure 3.11 C). 
There was a tendency for a greater ULK response to feeding in the dexamethasone group 
versus the control group on DAY 7 (P = 0.1) (Table 3.5). Within the control group, 
postprandial abundance of phosphorylated ULK tended to be greater on DAY 14 
compared to DAY 1 (P = 0.09) and 7 (P = 0.09). Basal levels of IRS-1 were higher in 
dexamethasone treated horses on DAY 14 (P = 0.004, Table 3.6, Figure 3.11 A). Within 
the control group, basal IRS-1 levels also tended to be higher on DAY 1 (P = 0.04) and 
DAY 7 (P = 0.05) compared to DAY 14.  
Regardless of treatment, sample day affected activation (phosphorylated to total 
protein ratio, P = 0.06) and total levels (P = 0.1) of FoxO3 and levels of phosphorylated 
(P = 0.07) and total forms of mTOR (P = 0.02) in response to feeding (Table 3.4). 
FoxO3 activation decreased in response to feeding, however this decrease was smaller on 
DAY 7 compared to DAY 14 (P = 0.02) (Table 3.4). Postprandial response of total 
FoxO3 abundance was greater on DAY 14 compared to DAY 7 but not different from 
DAY 1 (P = 0.04) (Table 3.6). Levels of phosphorylated were mTOR higher on DAY 7 
compared to DAY 14 (P = 0.04) and a trend for phosphorylation to be higher on DAY 7 
compared to DAY 1 (P = 0.06), in response to feeding (Table 3.5). In response to the 
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high protein meal, abundance of the total form of mTOR was significantly lower on DAY 
14 compared to  DAY 7 (P = 0.004) and tended to be lower than DAY 1 (P = 0.09) 
Table 3.6).  
Regardless of treatment, sample day also affected basal levels of activated 4E-
BP1 (P = 0.01), phosphorylated forms of NF- κB (P= 0.03) and ULK-P (P = 0.02) and 
total abundance of AMPK (P = 0.07), mTOR (P = 0.09), FoxO3 (P = 0.03) and 
myostatin (P = 0.0007) (Table 3.4). Basal levels of activated 4E-BP1 were significantly 
higher on DAY 14 compared to DAY 1 (P = 0.04) and 7 (P = 0.003) (Table 3.4). 
Baseline levels of phosphorylated NF- κB were significantly higher on DAY 7 compared 
to DAY 1 (P = 0.007) but did not differ from those on DAY 14 (P > 0.05) (Table 3.5). 
Baseline levels of phosphorylated ULK were significantly lower on DAY 1 compared to 
DAY 7 (P = 0.03) and 14 (P = 0.003) (Table 3.5). Total AMPK levels at baseline were 
lower on DAY 14 compared to DAY 1 (P = 0.05) and 7 (P = 0.04), but DAY 1 and 7 did 
not differ (P > 0.05) (Table 3.6). Basal total abundance of mTOR was lower on DAY 14 
versus DAY 1 (P = 0.03), however there was no difference between DAY 7 and 14 or 1 
and 7 (P > 0.05) (Table 3.6). Total abundance of FoxO3 at baseline was higher on DAY 
7 compared to DAY 14 (P = 0.02) and DAY 1 (P = 0.01) (Table 3.6). Lastly, basal 
myostatin levels were significantly higher on DAY 7 compared to DAY 1 (P = 0.01) and 
14 (P = 0.002) (Table 3.6). 
Interestingly, there was also an effect of block on overall activation of AMPK (P 
= 0.04), mTOR (P = 0.03), FoxO3 (P = 0.002) and IRS-1 (P < 0.0001). Block also 
affected activation of rpS6 (P = 0.01) and phosphorylation of Akt (P = 0.03) in response 
to feeding and basal levels of total rpS6 abundance (P = 0.008). There was a significantly 
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treatment by block interaction for atrogin-1 (P < 0.05) and phosphorylated NF- κB (P= 
0.04). Horses in block 1 had higher levels of activated rpS6 but lower Akt 
phosphorylation in response to feeding and overall greater activation of mTOR and 
FoxO3 (regardless of day or time of biopsy) compared to those in block 2. Conversely, 
horses in block 2 had greater overall activation of AMPK and levels of IRS-1. Atrogin 
levels were overall higher in the control horses in block 1 but not different between 
groups in block 2. Dexamethasone treated horses had significantly lower levels of NF- 
κB compared to control horses in block 2, however this difference was not observed in 
block 1. Additionally, this interaction illustrated that dexamethasone treated horses in 
block 1 had higher levels of NF- κB compared to dexamethasone treated horses in block. 
3.4. DISCUSSION 
Despite its useful anti-inflammatory action, undesired pleiotropic effects of 
dexamethasone in horses include an acute increase in circulating glucose levels and a 
decrease in insulin sensitivity, inducing a state of insulin resistance (IR) by 24h [29, 170]. 
Additionally, 21 days of treatment has been shown to modulate amino acids metabolism 
and insulin stimulated signaling pathways in skeletal muscle (Chapter 2). Because 
veterinary GC treatment commonly spans a few days to weeks, it was of interest to 
investigate if similar changes would be seen in the early stages of GC treatment and 
whether this would have implications on the metabolic response to an anabolic stimulus. 
This study confirms that horses treated with dexamethasone show acute signs of insulin 
dysregulation and is the first to illustrate that GC also affect amino acid metabolism and 
skeletal muscle protein signaling after short-term administration. Seven days of 
dexamethasone treatment significantly increased basal plasma glucose, insulin, serine, 
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asparagine, glutamine, alanine, proline, isoleucine, arginine and glycine concentrations 
and tended to decreased baseline PUN. Overall, activation of FoxO3 and total abundance 
of IRS-1 were increased and basal activation of mTOR was decreased in skeletal muscle 
samples of dexamethasone treated horses. Dexamethasone treatment significantly 
increased plasma insulin, but decreased plasma serine, glycine, histidine, aspartate, 
glutamate, glutamine, ornithine, proline and lysine responses to a high protein meal. 
Additionally, the activation of rpS6, AMPK and ULK in response to feeding were 
significantly altered after 7 days of dexamethasone treatment. As previously illustrated 
[268], dexamethasone effects on plasma insulin and glucose were transient and returned 
to pre-treatment levels after 7 days of recovery. However, differences in plasma amino 
acid dynamics and skeletal muscle protein signaling were still visible on DAY 14, 
indicating GC-induced changes in protein metabolism might take longer to recover. 
GC’s play an essential role in energy homeostasis in a catabolic state, increasing 
liver gluconeogenesis and counter-acting the actions of insulin in attempt to prioritize 
energy supply for essential tissues and immune cells. The observed increase in plasma 
glucose and insulin concentrations on DAY 7 was therefore expected and in line with 
previous data in horses [29]. Basal insulin concentrations in dexamethasone treated 
horses were >20 µIU/mL on DAY 7, a commonly used threshold level in horses 
suspected of having insulin dysregulation (ID) [23]. Additionally, the insulin response to 
a high protein meal was 3-fold greater in dexamethasone treated horses compared to 
control horses, suggesting an excessive insulin response to the stimulus of nutrients. 
Although insulin sensitivity was not directly measured, our results are in line with 
previously published data in horses [29, 32] and therefore indicate that the 
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dexamethasone treated horses in the current study were IR on DAY 7. Circulating insulin 
concentration is function of pancreatic secretion and hepatic clearance and although we 
did not assess these fluxes, there is a vast body of evidence illustrating that GC-
associated hyperinsulinemia is both the result of compensatory pancreatic secretion and 
reduced hepatic clearance to overcome IR [29, 37, 257, 260, 261]. Although little is 
known on the role of liver function in horses with IR, we believe that the basal and 
postprandial hyperinsulinemia in the current study was likely the result increased 
pancreatic insulin release and reduced hepatic clearance in the face of GC-induced IR. 
It has previously been reported that dexamethasone administration enhances 
glucose-stimulated insulin release, which could explain an excessive insulin response to 
dietary glucose [304, 340]. However, the feed in the current study supplied only a very 
limited amount of carbohydrates (ethanol soluble carbohydrates, 11% and starch, 2%) but 
was intended to provide the total daily protein requirement for each horse. The 
insulinotropic effect of effect of amino acids is well-known [177, 196, 197] and 
consumption of a high protein meal has previously shown to induce insulin secretion in 
horses ([14] and Chapter 5). We therefore believe that ingestion of amino acids 
contributed significantly to the insulin response in all horses in the current study. 
Whether dexamethasone alters amino-stimulated insulin secretion in adult horses is 
unknown, but it has been shown that arginine-stimulated insulin secretion was altered in 
foals born to mares treated with GC in late gestation [341]. Amino acid infusion in 
dexamethasone treated men induced a significant increase in plasma insulin 
concentrations, whereas this increase was not observed in the control group [318]. While 
the exact mechanism for this response is not entirely clear, it has been suggested that 
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pancreatic sensitivity to the insulinotropic effects of amino acid under conditions of 
reduced glucose sensitivity is increased [207]. Furthermore, GC’s are known to modulate 
gene expression of uncoupling proteins, which are known negative regulators of insulin 
secretion and have been implicated in IR and diabetes in humans [342]. Dexamethasone-
mediated downregulation of these protein in the pancreas could explain enhanced insulin 
release. Interestingly, a similar hyperinsulinemic response to the same high protein feed 
was observed in horses with natural ID (Chapter 5). This suggests that the insulin 
response to dietary nutrients, whether from glucose and/or amino acids, is altered in 
horses with natural or experimentally induced IR. 
In addition to their anabolic effects, amino acids play a key role in several 
essential metabolic pathways and alterations in whole body homeostasis elicit rapid shifts 
in their inter-organ flux and use. In the postabsorptive state, we observed overall higher 
levels of plasma serine, asparagine, glycine, glutamine, threonine, alanine, proline, 
tyrosine, phenylalanine, tryptophan, arginine, isoleucine and lysine in dexamethasone 
treated horses. An increase in alanine and glutamine was expected, as the demand for 
these important modulators in whole body energy and nitrogen balance increases in 
postabsorptive and catabolic conditions. Because their synthesis relies largely upon 
nitrogen liberated from branched-chain amino acid (BCAA) breakdown, catabolic states 
are typically associated with muscle protein breakdown [313]. With the knowledge of the 
proteolytic actions of GC, elevated levels of alanine and glutamine in a postabsorptive 
state on DAY 7, suggest that dexamethasone treated horses may have had increased 
muscle protein degradation. A rise in glutamine and/or alanine has been previously 
reported in GC-treated humans, dogs and rats [138, 139, 143] and similar results were 
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obtained after prolonged dexamethasone treatment in horses (Chapter 2). In further 
support of this hypothesis, there is evidence that GC directly upregulate transcription 
factor KLF-15 in skeletal muscle, a protein directly responsible for the upregulation of 
branched chain aminotransferase (BCAT). Considering BCAT mediates intracellular 
BCAA degradation, its upregulation by KLF-15 has shown to diminish amino acid 
stimulated activation of mTOR and could have contributed to muscle protein breakdown 
[147]. Further indication that dexamethasone altered whole body protein metabolism was 
evident from increased levels of asparagine and arginine, amino acids with key roles in 
nitrogen disposal. Regulated by substrate availability [55], altered metabolism of urea 
cycle components may impact urea formation, which is a possible explanation for the 
observed tendency for lower PUN on DAY 7 within the dexamethasone group. 
Elevated levels of other basal amino acids could be due to decreased tissue uptake 
and use, increased protein catabolism/ release of amino acids into circulation, decreased 
protein synthesis rates or decreased excretion of amino acids and their catabolic end 
products. Although previous data is somewhat equivocal, increased plasma levels of 
several amino acids have been observed in dexamethasone treated infants [140], GC 
treated fasted men [141] and mice [142]. Considering the horses were in a post-
absorptive state, basal elevations were likely due to decreased tissue uptake or altered 
tissue amino acid metabolism and release into circulation rather than rate of protein 
synthesis and excretion. Although the complexity of the metabolic response to steroid 
treatment makes identification of underlying mechanisms difficult, the genomic and non-
genomic effects of GC’s affect several metabolic pathways and it is plausible that GC’s 
affects tissue metabolism of amino acids and/or their products or precursors by altering 
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enzymatic activity. This hypothesis is supported by evidence that GC’s induce alterations 
in muscle [143] and liver [146] amino acid metabolism. Additionally, it has been 
previously shown that enzymes involved in the catabolic pathways of BCAA, sulfur-
containing amino acids, phenylalanine, tyrosine and histidine, are altered in humans and 
rodents with IR, resulting in plasma elevations of these amino acids [226, 228]. Similar 
plasma elevations were also seen in horses with equine metabolic syndrome (Chapter 5). 
The combination between GC interference with biochemical pathways and an IR state in 
dexamethasone treated horses might therefore have contributed to the elevation in basal 
plasma amino acid concentrations in the current study. 
As expected, feeding a high protein meal increased plasma amino acid 
concentrations above baseline levels in all horses throughout the study. Both baseline and 
90 min post feeding concentrations of all amino acid were in range with previously 
reported data in horses, using a similar feeding challenge [57]. Interestingly, the absolute 
increment of plasma glutamate, aspartate, glutamine, serine, glycine, histidine, proline, 
ornithine, and lysine repsonse to the high protein meal was less in dexamethasone treated 
horses. Considering this response was determined by the delta of the 90 min and 0 min 
concentrations, elevated basal concentrations alone does not explain this lag of 
postprandial increase of these amino acids in GC treated animals. This suggests that 
dexamethasone may affect the extent or rate of dietary amino acid absorption, increase 
postprandial extraction into tissues or affect the use or oxidation of these amino acids. 
Similar results have been reported in men showing that the absolute increment in BCAA 
after infusion of an amino acid mixture was significantly less in the dexamethasone 
group, which was attributed to increased GC-mediated BCAA oxidation [318]. However, 
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in the current study, with exception of lysine and histidine, the differences were mostly 
seen in non-essential amino acids of which five were also elevated in a postabsorptive 
state. This indicates that dexamethasone might have a more pronounced effects on 
endogenous amino acid metabolism rather than dietary amino acid uptake. Lower 
postprandial glutamate concentrations were previously reported in adult, less insulin 
sensitive, horses when compared to their younger counter parts [14] and in horses with 
ID (Chapter 5) using a similar feed challenge. Several amino acids, including glutamate, 
aspartate, glutamine, glycine, proline, ornithine are heavily metabolized by the intestinal 
mucosa, which regulates the entry of absorbed dietary amino acids into portal circulation 
[343]. It could be speculated that the lower postprandial increment of these amino acids 
in de dexamethasone treated horses could result from GC-induced alterations in normal 
gut metabolism. Indeed, evidence shows that exogenous GC administration alters the 
metabolism of amino acids in the small intestine by modulating expression of several 
enzymes, including those involved in glutamine, proline, arginine and ornithine 
catabolism [145]. 
The availability of amino acids and the presence of growth factors such as insulin, 
provide a major anabolic stimulus for the activation of muscle protein synthesis. 
Consequently, feeding a high protein meal after an overnight fast resulted in a significant 
postprandial activation of Akt, mTOR and its downstream signaling components rpS6 
and 4E-BP1, regardless of treatment. This illustrates that the postprandial elevation in 
circulating amino acids and insulin effectively triggered the mTOR pathway signaling 
cascade and activated protein synthetic machinery in all horses, similar to previous 
results [14, 57]. Interestingly, mTOR pathway activation in response to feeding was not 
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greatly altered by dexamethasone treatment as no difference was detected in activation of 
Akt, mTOR or 4E-BP1. This suggests that, despite lowered postprandial responses for 
several amino acids and an obvious IR state, GC- induced compensatory 
hyperinsulinemia might have maintained activation of Akt, mTOR and 4E-BP1, similar 
to previous results (Chapter 2). In vitro studies have illustrated that phosphorylation of 
Akt, S6K1 and 4E-BP1 increased in dexamethasone treated cells after addition of insulin 
or IGF-1, indicating that elevated levels of growth factors can overcome the catabolic 
effects of GC’s [47, 320]. Alternatively, BCAA amino acids, in particular leucine, are 
known to be potent stimulators of mTOR and muscle protein synthesis [344]. Although 
intramuscular amino acids were not measured, dexamethasone did not seem to alter 
postprandial plasma BCAA responses, suggesting their levels might have been adequate 
to stimulate mTOR activation. Similar results have been reported in humans, showing 
that the stimulatory of effect dietary amino acids on muscle protein synthesis was 
maintained in the face of acute hypercortisolemia [345]. In another study, infusion of an 
amino acid mixture in dexamethasone treated men was able to activate S6K1 but not 4E-
BP1, further indicating that certain catabolic effects of GC’s can be overcome by amino 
acid stimulation [318]. Although no effect of treatment was observed for postprandial 
Akt, mTOR and 4E-BP1 activation, the absolute increment in rpS6 activation post 
feeding was higher in dexamethasone treated horses compared to the control horses on 
DAY 7 but tended to be lower in this group on DAY 14. These results were unexpected 
as insulin-stimulated rpS6 activation was significantly decreased after 21-days of 
dexamethasone treatment (Chapter 2). As mentioned above, studies in humans reported 
that GC’s did not affect amino acid-induced S6K1 phosphorylation, the kinase 
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responsible to rpS6 activation [318]. Although these authors did not compare results 
between the treatment groups, visual assessment of the data suggests a slightly higher 
S6K1 response to amino acid infusion in the dexamethasone treated group [318]. 
Although it is unclear why this occurred, this would support elevation in rpS6 activation 
in GC-treated horses on DAY 7. One possible theory is that S6K1 is particularly sensitive 
to insulin [346], therefore the hyperinsulinemic response in the dexamethasone group 
may have triggered overactivation of S6K1 and consequently rpS6 phosphorylation. This 
could indicate there are other mechanisms at play that may contribute to a hypersensitive 
response to anabolic stimuli in the face of excess GC. Unexpectedly, rpS6 activation 
tended to be diminished in dexamethasone treated horses after 7 days of recovery from 
treatment. Effects of GC are mediated through genomic and non-genomic mechanisms 
and evidence exists that certain GC-induced alterations are evident long after cessation of 
treatment [133, 347]. Although glucose and insulin dynamics seem to be restored after 7 
days of recovery, it could be speculated that the consequences of genomic alterations due 
to GC treatment might persist for a longer time, potentially explaining the difference in 
rpS6 activation on DAY 14. 
Muscle mass is maintained by the balance between protein synthesis and 
degradation which is impacted by a variety of factors, including cellular energy status. In 
addition to mTOR, AMP-activated protein kinase (AMPK) is particularly sensitive to 
changes in energy levels, increasing its phosphorylation when the AMP/ATP ratio is high 
[348]. As reflected by the small or negative deltas, feeding decreased AMPK activation 
in control horses. However, postprandial AMPK activation was increased in 
dexamethasone treated horses on DAY 7 and DAY 14. Although these responses were 
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not significantly different from the control group on those days, these findings suggest 
subtle shifts in AMPK regulation due to GC-induced cellular IR as Thr172 
phosphorylation is known to occur with energy depletion. Increased muscle AMPK 
activity has been previously reported in dexamethasone treated rodents [349, 350]. 
Activated AMPK will reduce anabolic activities, including protein synthesis, and 
promote restoration of energy levels by activation proteolytic pathways including 
upregulation of the ubiquitin proteasomal pathway (UPP) and autophagy [108, 112]. 
Autophagy specifically is regulated by initiation factor ULK, which has several 
phosphorylation sites allowing for differential regulation by kinases including AMPK and 
mTOR depending on physiological conditions [108, 351]. Although phosphorylation of 
ULK at Ser757, a site specifically upregulated by mTOR when nutrients are plentiful, 
would be expected to increase post feeding, it was unclear why this response tended to be 
greater in the dexamethasone group. If postprandial mTOR activation was not diminished 
with dexamethasone treatment, it explains why ULK phosphorylation at Ser757 would be 
maintained but not why it increased. Although no difference was detected in mTOR 
activation at Ser2448 during GC treatment, it is known that mTOR has several 
phosphorylation sites, sensitive to different stimuli [352]. Additional research is 
necessary to verify whether phosphorylation of mTOR at different sites or activation of 
ULK by other kinases might have contributed to our results. It should be noted that ULK 
phosphorylation also increased by DAY 14 in the control group, indicating that other 
external factors might have had an influence. 
In the postabsorptive state, the total abundance of insulin receptor substrate-1 
(IRS-1) was overall higher in dexamethasone treated horses compared to the control 
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group. However, when looking at the day by treatment interaction it was evident that 
IRS-1 abundance did not significantly change within the dexamethasone group but rather 
decreased in the control group, which would have caused the significant difference on 
DAY 14. Why this would have occurred is unclear, suggesting that factors other than 
treatment might have affected the results. IRS-1 plays an essential role in the initial signal 
transduction when insulin or IGF-1 binds of to their membrane receptors. IRS-1 
activation will trigger an intracellular signaling cascade, eventually leading to the 
activation of Akt [353]. Total muscle IRS-1 abundance and its activation are typically 
decreased in response to GC treatment [151]. Studies have shown that GC increase 
expression of phosphatidylinositol-3-kinase (PI3K) subunit p85α, which competes for 
PI3K binding with IRS-1 leading to decreased phosphorylation and subsequent Akt 
activation [306]. Additionally, it is known that IRS-1 function can be inhibited through a 
negative feedback signal from downstream signaling component S6K1. This regulatory 
feedback is activated in in the face of amino acid or insulin overload, such as seen in 
obese, IR individuals and has shown result in skeletal muscle insulin resistance [96]. 
Unfortunately, we were unable to detect phosphorylated (activated) IRS-1 in the current 
study. Therefore, it is difficult to conclude whether dexamethasone did in fact decrease 
IRS-1 activation. However, since no effect was observed for postprandial activation of 
Akt, it could be speculated that signaling through IRS-1 was maintained in 
dexamethasone treated horses. In contrast to IRS-1, postabsorptive levels of activated 
mTOR (phosphorylated to total protein) were decreased in dexamethasone treated horses. 
Because no difference was detected in total levels of mTOR protein, this indicates that, 
despite basal hyperinsulinemia, GC induced a decrease in basal states of mTOR 
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phosphorylation. Although no treatment effect was observed for Akt, it is known that GC 
can directly downregulate mTOR, independent of Akt signaling, through a GC receptor-
mediated increase in the expression of several mTOR repressors [4, 83]. 
Regardless of sample day or time of biopsy, dexamethasone treatment resulted in 
overall greater activation of FoxO3 (phosphorylated to total abundance). In contrast to 
most other protein measured, decreased phosphorylation indicates increased activation 
for FoxO transcription factors [354]. Under catabolic conditions, including GC treatment, 
dephosphorylation of FoxO3 results in the upregulation of muscle specific E3 UPP 
ligases, atrogin-1 and MuRF-1, which are involved in the degradation of regulatory and 
structural muscle proteins [111, 162]. Conversely, increased phosphorylation of FoxO3 
by Akt will sequester it in the cytosol, inhibiting its transcriptional activity under anabolic 
conditions. Decreased FoxO3 phosphorylation has been previously reported after GC 
treatment and FoxO activation plays an important role in steroid-mediated muscle 
atrophy [48, 162]. Although downregulation of Akt activity is known to be an important 
contributor of GC-mediated activation of FoxO protein, we did not observe an effect of 
dexamethasone treatment on Akt activation. However, it is known that FoxO protein are 
modulated through various mechanisms, including direct upregulation of their expression 
by GC [162]. Additionally, AMPK is a known upregulator of FoxO transcription factors 
[112], and there was a trend for increased AMPK activation after short-term 
dexamethasone treatment in the current study. Despite the tendency for increased FoxO3 
activation after 7 days of dexamethasone treatment, we did not observe an increase in the 
abundance of E3 ligase atrogin-1, an important gene target of FoxO transcription factors 
[111]. This indicates that posttranslational changes in the phosphorylation status of 
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transcription factors do not necessarily result in upregulation of target genes or that other 
mechanisms interfered with the transcriptional and/or translational processes. Similarly, 
there was no effect of GC treatment on other proteins associated with proteolytic 
pathways, including myostatin and nuclear transcription factor kappa B (NF- κB).  
Myostatin, a member of the transforming growth factor-β family, is an important 
negative regulator of muscle mass through modulation of mTOR signaling and 
expression of differentiation-inducing genes [122, 126, 322]. Myostatin expression is 
typically increased with GC treatment due to the presence of a GC response element on 
its promotor which has shown to play a major role in GC-induced muscle atrophy [164]. 
However, myostatin expression was not affected by 7 days of dexamethasone treatment 
in horses, similar to previous reports (Chapter 2). This indicates that myostatin regulation 
could be different in horses or that other mechanisms might have interfered with its 
upregulation under the current study conditions. Alternatively, previous reports show that 
muscle myostatin expression was acutely increased after 5 days of dexamethasone 
treatment in rats but that levels returned to baseline values after 10 days of treatment 
[164]. Such transient effect might explain the lack of increase seen in the current study 
and indicate further research in necessary to elucidate the effect of potential protective 
mechanisms triggered by chronic GC excess. Similar to previous results (Chapter 2), no 
effect of dexamethasone treatment was observed for NF- κB p65. In addition to 
upregulation of pro-inflammatory and cell-survival genes, this transcription factor is also 
known to be involved in the upregulation of muscle atrophy [98, 119, 121, 323]. Similar 
to reasons discussed in Chapter 2, the anti-inflammatory effect of GC together with a 
hyperinsulinemic state could explain the lack of upregulation in NF- κB. 
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Overall, 7 days of dexamethasone treatment did not seem to have a significant 
impact on protein synthetic capacity in response to feeding or upregulation of muscle 
wasting pathways. Interestingly, regardless of treatment, the expression of several 
proteins were altered on different sample days which would suggest that external factors 
might have played a role in mTOR signaling. Most notably were increased basal levels of 
NF- κB on DAY 7 compared to DAY 1 and 14. This could suggest that muscle 
inflammatory processes were upregulated on DAY 7. To study the effects of 
dexamethasone on responses to feeding and an oral sugar test, biopsies were collected on 
2 consecutive days each sample period. Because these challenges were randomized, 
NSAID treatment was only started on the final day of each sample period to avoid any 
effects on metabolic responses. All horses received NSAID’s for 48h after each sample 
period and biopsy sites were monitored, cleaned and dressed with a topical anti-bacterial 
ointment as necessary. Although all biopsy sites were properly healed by the next sample 
period and new incisions were made ~2 cm from previous sites, a lack of initial 
suppression of potential inflammation from the 1st biopsy day might have prolonged 
certain inflammatory processes. Results from a previous study in our lab illustrated that 
muscle inflammation and mTOR signaling was not changed during repeated biopsies 
over 5 days as long as horses received a daily dose of NSAID’s. However, when not 
treated with NSAID’s, muscle inflammatory markers were increased, Akt activation 
decreased whereas activation of S6K1, rpS6 and 4E-BP1 increased in response to a high 
protein meal [355]. In the current study, basal levels of phosphorylated 4E-BP1 increased 
by DAY 14 and total mTOR levels decreased by DAY 14. Additionally, there was a trend 
for mTOR phosphorylation to increase in response to feeding on DAY 7. Sample day 
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also affected basal levels of myostatin and total FoxO3 abundance, which were increased 
on DAY 7. Associated with muscle protein degradation, elevations in these two protein 
could indicate an increased catabolic cellular environment, although this does not clearly 
explain why the changes disappeared by DAY 14. However, it could be speculated that 
despite 48h NSAID administration, repeated biopsies might have elicited some effect on 
mTOR signaling in the current study. 
In addition to the effects of sample day, a block effect was also observed for 
certain proteins. Although horses were randomly assigned to their treatments and no 
significant age or bodyweight differences were observed between the treatment groups, it 
is notable that the horses in block 1 were slightly older (18 ± 0.5, years ± SD) than those 
in block 2 (13 ± 1.9, years ± SD). Some interesting differences included higher levels of 
rpS6 but lower Akt activation in response to feeding for horses studied in the first block. 
Additionally, regardless of day or feeding status, horses in block 1 showed lower overall 
mTOR, AMPK and FoxO3 activation and lower levels of total IRS-1 abundance. 
Considering horses in block 1 were slightly older, these results could indicate subtle 
differences in protein synthetic capacity that might be related to aging. Developmental 
differences in the regulation of mTOR signaling has previously been illustrated in horses, 
consistent with some results in the current study [14]. Additionally, dexamethasone 
treated horses in block 2 had lower levels of NF- κB in comparison to control horses but 
this effect was not seen in block 1 horses. With the knowledge that NF- κB activation is 
decreased by GC treatment [325], but often increases with age due to “inflamm-aging” 
processes [356], elevated levels in the older horses in block 1 could have diminished a 
dexamethasone-induced decrease in NF- κB. 
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In summary, 7 days of dexamethasone administration caused transient insulin 
dysregulation reflected be a significant increase in basal and postprandial insulin 
concentrations. This study was the first to illustrate that in an experimental model of IR, 
intake of high levels of dietary amino acids resulted in a hyperinsulinemic response. 
Additionally, short-term GC administration also affected protein metabolism illustrated 
by elevated basal levels of several amino acids, lowered PUN and generally lowered 
amino acid responses to a high protein meal. Furthermore, dexamethasone treatment 
lowered mTOR activation at baseline levels and altered postprandial activation of rpS6, 
AMPK and ULK. Additionally, activation of proteolytic mediator, FoxO3, was increased 
with 7 days of GC treatment. Together these results indicate that short-term 
dexamethasone treatment resulted in substantial changes in plasma metabolic responses 
to an anabolic stimulus and subsequent alterations in signaling downstream of mTOR. 
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3.5. TABLES 
 
Table 3. 1 As-fed nutrient composition of the daily concentrate and hay1 
Nutrient Concentrate (%) Hay (%) 
Dry matter 89.25 ± 0.07 92.6 ± 0.14 
   
Crude protein 12.23 ± 0.12 17.18 ± 0.09 
   
Aspartate and asparagine 0.49 ± 0.08 1.38 ± 0.33 
Glutamate and glutamine 1.2 ± 0.75 1.13 ± 0.46 
Serine 0.39 ± 0.21 0.46 ± 0.2 
Glycine 0.37 ± 0.11 0.47 ± 0.18 
Histidine 0.27 ± 0.11 0.21 ± 0.1 
Arginine 0.66 ± 0.27 0.53 ± 0.25 
Threonine 0.31 ± 0.14 0.41 ± 0.18 
Alanine 0.41 ± 0.12 0.53 ± 0.2 
Proline 0.47 ± 0.17 0.52 ± 0.2 
Tyrosine 0.29 ± 0.13 0.32 ± 0.16 
Valine 0.44 ± 0.09 0.59 ± 0.18 
Methionine 0.18 ± 0.02 0.24 ± 0.09 
Isoleucine 0.36 ± 0.12 0.48 ± 0.16 
Leucine 0.67 ± 0.3 0.86 ± 0.37 
Phenylalanine 0.47 ± 0.21 0.63 ± 0.27 
Lysine 0.49 ± 0.35 0.65 ± 0.24 
  
 
Acid detergent fiber 10.4 ± 0.43 39.17 ± 0.07 
Neutral detergent fiber 22.98 ± 0.46 54.03 ± 0.38 
Water-soluble carbohydrates 10.22 ± 0.32 2.5 ± 0 
Ether-soluble carbohydrates 7.85 ± 1.38 1.62 ± 0.33 
Starch 15.08 ± 0.52 0.56 ± 0.26 
Non Fiber Carbohydrates 45.47 ± 0.28 10.28 ± 0.41 
  
 
Calcium 3.18 ± 0.03 1.03 ± 0.05 
Phosphorus 1.6 ± 0.01 0.4 ± 0.01 
Magnesium 0.5 ± 0 0.16 ± 0.01 
Potassium 1.17 ± 0 3.33 ± 0.14 
Sodium 0.72 ± 0.02 0.02 ± 0 
  
 
Iron 650.19 ± 6.43 207.89 ± 12.12 
Zinc 454.73 ± 48.95 19.91 ± 1.99 
Copper 176.27 ± 22.23 7.41 ± 0.01 
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Table 3.1 continued   
   
Manganese 376.64 ± 21.16 38.43 ± 0.71 
Molybdenum 1.87 ± 0.12 1.11 ± 0 
Values for concentrate composition are mean ± standard deviation of 4 samples measured in duplicate. 
Values for hay composition are mean ± standard deviation of 3 samples measured in triplicate 
NA = Not applicable 
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Table 3. 2 As-fed nutrient composition of the high protein pelleted feed and nutrient 
intake (mg/kg of body weight) from the diet fed after a 14-hour fast in 12 horses  
 
Nutrient 
Pellet  
composition (%)* 
Nutrient  
intake (mg/kg)† 
Dry matter 90.5 ± 0.14 NA 
   
Crude protein 
31.13 ± 0.08 1245.2 ± 3.2 
Aspartate and asparagine 1.9 ± 0.37 76 ± 14.8 
Glutamate and glutamine 3.83 ± 0.44 153.2 ± 17.6 
Serine 1.12 ± 0.08 44.8 ± 3.2 
Glycine 0.81 ± 0.05 32.4 ± 2 
Histidine 0.64 ± 0.05 25.6 ± 2 
Arginine 1.71 ± 0.11 68.4 ± 4.4 
Threonine 0.84 ± 0.05 33.6 ± 2 
Alanine 0.88 ± 0.06 35.2 ± 2.4 
Proline 1.1 ± 0.07 44 ± 2.8 
Tyrosine 0.8 ± 0.05 32 ± 2 
Valine 0.98 ± 0.08 39.2 ± 3.2 
Methionine 0.36 ± 0.03 14.4 ± 1.2 
Isoleucine 0.99 ± 0.07 39.6 ± 2.8 
Leucine 1.81 ± 0.11 72.4 ± 4.4 
Phenylalanine 1.31 ± 0.08 52.4 ± 3.2 
Lysine 1.74 ± 0.13 69.6 ± 5.2 
 
  
Acid detergent fiber 8.15 ± 0.4 326 ± 16 
Neutral detergent fiber 12.53 ± 0.47 501.2 ± 18.8 
Water-soluble carbohydrates 12.67 ± 0.49 506.8 ± 19.6 
Ether-soluble carbohydrates 10.72 ± 0.18 428.8 ± 7.2 
Starch 1.81 ± 0.13 72.4 ± 5.2 
Non Fiber Carbohydrates 38.19 ± 0.32 1527.6 ± 12.8 
 
  
Calcium 3.87 ± 0.06 154.8 ± 2.4 
Phosphorus 1.87 ± 0.07 74.8 ± 2.8 
Magnesium 0.41 ± 0.01 16.4 ± 0.4 
Potassium 1.77 ± 0.08 70.8 ± 3.2 
Sodium 0.91 ± 0.004 36.4 ± 0.16 
 
  
Iron (ppm) 715.4 ± 15.84 2.86 ± 0.06 
Zinc (ppm) 482.37 ± 19.95 1.93 ± 0.08 
Copper (ppm) 177.38 ± 19.48 0.71 ± 0.08 
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Table 3.2 continued   
   
Manganese (ppm) 311.32 ± 0.79 1.24 ± 0.01 
Molybdenum (ppm) 5.57 ± 0.06 0.022 ± 0 
* Values for concentrate composition are mean ± standard deviation of 4 samples measured in 
duplicate. † Following a 14-hour feed-withholding period, horses were given 2 equal meals of the 
pelleted feed (targeted total intake of 4g of feed per kg of body weight), separated by 30 minutes.  
NA = Not applicable 
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Table 3. 3 Mean basal plasma amino acid concentrations (µmol/L) in 6 horses 
treated with dexamethasone and 6 controls on 3 different sample days.  
  
DEX  CON  P-Values 
Amino acid Day Mean SE  Mean SE  Treat Day Treat*Day 
Aspartate 
   
  
   
NS NS NS 
 
1 71 7   76 7 
    
 
7 66 8   75 8 
    
 
14 56 5   61 5 
    
Glutamate 
   
  
   
NS 0.1 NS 
 
1 71 8   76 8 
    
 
7 66 8   75 8 
    
 
14 56 5   61 5 
    
Serine 
   
  
   
0.002 0.001 0.002 
 
1 289 15   264 15 
    
 
7 412 19   266 19 
    
 
14 290 16   265 16 
    
Asparagine 
   
  
   
0.0008 0.09 0.008 
 
1 25 5   25 5 
    
 
7 45 5   21 5 
    
 
14 36 5   21 5 
    
Glycine 
   
  
   
0.01 NS 0.09 
 
1 593 45   448 45 
    
 
7 558 34   451 34 
    
 
14 621 42   401 42 
    
Glutamine 
   
  
      
 
1 411 27   396 27 
 
0.005 < .0001 < .0001 
 
7 591 27   396 27 
    
 
14 417 27   392 27 
    
Histidine 
   
  
   
NS 0.0003 NS 
 
1 77 4   77 4 
    
 
7 92 5   88 5 
    
 
14 77 5   77 5 
    
Citruline 
   
  
   
NS 0.001 NS 
 
1 64 5   61 5 
    
 
7 76 8   77 8 
    
 
14 81 9   81 9 
    
Threonine 
   
  
   
0.04 NS NS 
 
1 142 10   119 10 
    
 7 170 10   125 10     
 
14 159 19   125 19 
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Table 3.3 continued       
    
Alanine 
   
  
   
0.001 < .0001 < .0001 
 
1 242 21   200 21 
    
 
7 536 41   195 41 
    
 
14 194 16   177 16 
    
Arginine 
   
  
   
0.06 0.004 0.1 
 
1 81 9   68 9 
    
 
7 122 11   193 21 
    
 
14 91 4   88 4 
    
Proline 
   
  
   
0.003 0.003 0.0003 
 
1 80 7   81 7 
    
 
7 124 7   72 7 
    
 
14 82 7   71 7 
    
Tyrosine 
   
  
   
NS 0.05 0.05 
 
1 65 3   60 3 
    
 
7 79 3   64 3 
    
 
14 69 5   66 5 
    
Valine 
   
  
   
NS NS NS 
 
1 259 16   248 16 
    
 
7 287 16   255 16 
    
 
14 266 16   269 16 
    
Methionine 
   
  
   
NS NS NS 
 
1 32 4   32 4 
    
 
7 37 5   33 5 
    
 
14 31 1   31 1 
    
Isoleucine 
   
  
   
NS 0.02 0.05 
 
1 75 6   77 6 
    
 
7 95 6   80 6 
    
 
14 75 6   79 6 
    
Leucine 
   
  
   
NS NS NS 
 
1 152 13   141 13 
    
 
7 163 13   149 13 
    
 
14 151 13   137 13 
    
Phenylalanine 
   
  
   
0.02 0.02 NS 
 
1 74 5   65 5 
    
 
7 82 5   71 5 
    
 
14 70 5   64 5 
    
Tryptophan 
   
  
   
0.005 0.01 NS 
 
1 81 5   66 5 
    
 7 97 5   72 5     
 
14 87 5   72 5 
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Table 3.3 continued       
    
Ornithine 
   
  
   
NS 0.03 NS 
 
1 44 4   50 4 
    
 
7 57 4   52 4 
    
 
14 43 4   43 4 
    
Lysine 
   
  
   
0.01 0.1 NS 
 
1 107 9   93 9 
    
 
7 120 8   92 8 
    
 
14 101 7   76 7 
    
Abbreviations: CON, control; DEX, dexamethasone; NS, not significant   
Data analyzed with repeated measures analysis using a compound symmetry variance-covariance 
structure for all amino acids. Data are presented as least square means ± standard error of the mean. n = 
6 control and n = 6 DEX horses.  
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Table 3. 4 Mean plasma amino acid response (delta, post feeding concentrations – 
pre feeding concentration, µmol/L) to intake of a high protein pelleted meal (2g/kg 
BW at 0 and 30 minutes) on 3 different sample days in 6 horses treated with 
dexamethasone and 6 controls.  
  
DEX  CON  P-Values 
Amino acid Day Mean SE  Mean SE  Treat Day Treat*Day 
Aspartate 
   
  
   
0.06 NS 0.09 
 
1 19 3   15 3 
    
 
7 7 3   18 3 
    
 
14 11 3   17 3 
    
Glutamate 
   
  
   
NS 0.09 0.09 
 
1 24 5   13 5 
    
 
7 3 5   10 5 
    
 
14 6 5   17 5 
    
Serine 
   
  
   
0.03 0.05 0.05 
 
1 99 15   90 15 
    
 
7 27 15   96 15 
    
 
14 80 15   114 15 
    
Asparagine 
   
  
   
NS NS NS 
 
1 29 6   20 6 
    
 
7 23 6   28 6 
    
 
14 32 6   33 6 
    
Glycine 
   
  
   
0.05 NS NS 
 
1 84 27   89 27 
    
 
7 35 27   78 27 
    
 
14 41 27   124 27 
    
Glutamine 
   
  
      
 
1 142 28   125 28 
 
0.07 0.08 0.05 
 
7 34 28   152 28 
    
 
14 121 28   184 28 
    
Histidine 
   
  
   
0.02 0.02 NS 
 
1 40 5   46 5 
    
 
7 21 5   38 5 
    
 
14 36 5   51 5 
    
Citruline 
   
  
   
NS 0.01 NS 
 
1 5 5   1 5 
    
 
7 -12 5   -11 5 
    
 
14 -5 5   -8 5 
    
Threonine 
   
  
   
NS 0.09 NS 
 
1 60 10   59 10 
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Table 3.4 continued           
 
7 31 10   50 10 
    
 
14 65 10   56 10 
    
Alanine 
   
  
   
NS NS NS 
 
1 127 23   106 23 
    
 
7 86 23   122 23 
    
 
14 131 23   132 23 
    
Arginine 
   
  
   
NS 0.02 NS 
 
1 112 18   93 18 
    
 
7 89 18   107 18 
    
 
14 122 18   142 18 
    
Proline 
   
  
   
NS 0.03 0.05 
 
1 74 9   56 9 
    
 
7 46 9   72 9 
    
 
14 81 9   84 9 
    
Tyrosine 
   
  
   
NS NS NS 
 
1 42 7   35 7 
    
 
7 41 7   42 7 
    
 
14 47 7   46 7 
    
Valine 
   
  
   
NS NS NS 
 
1 71 13   53 13 
    
 
7 45 13   59 13 
    
 
14 83 13   62 13 
    
Methionine 
   
  
   
NS NS NS 
 
1 12 5   12 5 
    
 
7 8 5   9 5 
    
 
14 16 5   17 5 
    
Isoleucine 
   
  
   
NS NS NS 
 
1 44 7   41 7 
    
 
7 33 7   43 7 
    
 
14 50 7   49 7 
    
Leucine 
   
  
   
NS 0.05 NS 
 
1 56 14   43 14 
    
 
7 46 14   52 14 
    
 
14 78 14   72 14 
    
Phenylalanine 
   
  
   
NS 0.1 NS 
 
1 22 5   15 5 
    
 
7 16 5   18 5 
    
 
14 25 5   25 5 
    
Tryptophan 
   
  
   
NS NS NS 
 
1 40 6   34 6 
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Table 3.4 continued           
 
7 36 6   40 6 
    
 
14 45 6   41 6 
    
Ornithine 
   
  
   
0.06 0.1 NS 
 
1 31 6   43 6 
    
 
7 18 6   33 6 
    
 
14 27 6   37 6 
    
Lysine 
   
  
   
NS 0.05 0.1 
 
1 181 22   162 22 
    
 
7 117 22   177 22 
    
 
14 177 22   212 22 
    
Abbreviations: CON, control; DEX, dexamethasone; NS, not significant   
Data analyzed with repeated measures analysis using a compound symmetry variance-covariance 
structure for all amino acids. Data are presented as least square means ± standard error of the mean. n = 
6 control and n = 6 DEX horses.  
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3.6. FIGURES 
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B 
  
Figure 3. 1 Plasma glucose concentrations  
Values are least squared means ± SE. Figure A represents basal glucose concentrations in control 
(white bars) and dexamethasone (black bars) treated horses on each day. a,b Different letters 
indicate differences between days within treatment group (P < 0.05). *Significant difference 
between treatment groups on each day (P < 0.05). Figure B represents glucose responses (delta: 
90 min post feeding concentrations – pre feeding concentrations, mmol/L) in control (white bars) 
and dexamethasone (black bars) treated horses on each day. Data was analyzed with a repeated 
measures analysis with a heterogenous-autoregression variance-covariance structure. N = 6 
control and n = 6 dexamethasone treated horses.   
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Figure 3. 2 Plasma insulin concentrations 
Values are least squared means ± SE. Figure A represents basal insulin concentrations in control 
(white bars) and dexamethasone (black bars) treated horses on each day. Figure B represents 
insulin responses (delta: 90 min post feeding concentrations – pre feeding concentrations, 
µIU/mL) in control (white bars) and dexamethasone (black bars) treated horses on each day. a,b 
Different letters indicate differences between days within treatment group (P < 0.05). 
*Significant difference between treatment groups on each day (P < 0.05). Data was analyzed with 
a repeated measures analysis with a compound symmetry variance-covariance structure. N = 6 
control and n = 6 dexamethasone treated horses.   
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Figure 3. 3 Baseline plasma urea nitrogen concentrations  
Values are least squared means ± SE. Figure A represents basal PUN concentrations on DAY 1 
(white bar), DAY 7 (black bar) and DAY 14 (patterned bar). Values are averaged across 
treatment groups. a,bDifferent letters indicate differences between days (P < 0.05 and 0.05 < P < 
0.1). Figure B represents basal PUN concentrations in CON (white bars) and DEX (black bars) 
over the entire study period. a,b,c Different letters indicate differences between days within 
treatment group (P < 0.05). Data was analyzed with a repeated measures analysis with a 
compound symmetry variance-covariance structure. N = 6 control and n = 6 dexamethasone 
treated horses.  
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Figure 3. 4 Plasma urea nitrogen responses to feeding   
Values are least squared means ± SE of PUN responses (delta: 90 min post feeding 
concentrations – pre feeding concentrations, mmol/L) in control (white bars) and dexamethasone 
(black bars) treated horses on each day. Data was analyzed with a repeated measures analysis 
with compound symmetry variance-covariance structure. N = 6 control and n = 6 dexamethasone 
treated horses. a,b,c Different letters indicate differences between days within treatment group (P < 
0.05). 
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Figure 3. 5 Basal plasma concentrations of amino acids affected by treatment 
Values are least squared means ± SE of baseline amino acid levels that differed significantly 
between control (white bars) and dexamethasone treated horses (black bars). Data was averaged 
across all sample days (P < 0.05 and 0.05 < P < 0.1). Figure 3A represents non-essential amino 
acids: SER, serine; ASN, asparagine; GLY, glycine; ALA, alanine; PRO, proline; TYR, tyrosine; 
GLN, glutamine; ARG, arginine. Figure 3B represents essential amino acids: THR, threonine; 
TRP, tryptophan; PHE, phenylalanine; LYS, lysine. Data analyzed with repeated measures 
analysis using a compound symmetry variance-covariance structure for all amino acids. N = 6 
control and n = 6 dexamethasone treated horses   
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Figure 3. 6 Basal plasma amino acid concentrations affected by a treatment by day 
interaction 
Values are least squared means ± SE of amino acids that differed significantly between 
dexamethasone treated horses (black bars) and controls (white bars) on each day. Figure A: 
Plasma asparagine, Figure B: Plasma glutamine, Figure C: Plasma alanine, Figure D: Plasma 
arginine, Figure E: Plasma proline, Figure F: Plasma isoleucine, Figure G: Plasma serine. a,b,c 
Different letters indicate differences between days within treatment group (P < 0.05 and 0.05 < P 
< 0.1). *Significant difference between treatment groups on each day (P < 0.05). Data analyzed 
with repeated measures analysis using a compound symmetry variance-covariance structure for 
all amino acids. N = 6 control and n = 6 dexamethasone treated horses. 
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Figure 3. 7 Plasma amino acids responses to feeding affected by treatment  
Values are least squared means ± SE of amino acid responses (delta: post feeding concentrations 
– pre feeding concentration, µmol/L) that differed significantly between dexamethasone treated 
horses (black bars) and controls (white bars) across all sample days (P < 0.05 and 0.05 < P < 
0.1). Data analyzed with repeated measures analysis using a compound symmetry variance-
covariance structure for all amino acids. N = 6 control and n = 6 dexamethasone treated horses. 
Abbreviations: ASP, aspartate; SER, serine; GLY, glycine; GLN, glutamine; HIS, histidine; 
ORN, ornithine.  
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Figure 3. 8 Plasma amino acids response to feeding affected by a treatment by day 
interaction 
Values are least squared means ± SE of amino acid responses (delta: post feeding concentrations 
– pre feeding concentration, µmol/L) that differed significantly between dexamethasone treated 
horses (black bars) and controls (white bars) on each day. Figure A: Plasma aspartate, Figure B: 
Plasma glutamate, Figure C: Plasma glutamine, Figure D: Plasma serine, Figure E: Plasma 
proline, Figure F: Plasma lysine. a,b,c Significant difference between days within treatment group 
(P < 0.05 and 0.05 < P < 0.1). *Significant difference between treatment groups on each day (P 
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< 0.05). Data analyzed with repeated measures analysis using a compound symmetry variance-
covariance structure for all amino acids. N = 6 control and n = 6 dexamethasone treated horses.   
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Figure 3. 9 Muscle protein expression in response to feeding  
Values are least squared means ± SE of muscle protein expression that differed significantly 
between pre (white bars) and post (black bars) feeding samples regardless of treatment or sample 
day (P < 0.05). Data for Akt, rpS6, 4E-BP1 and mTOR represent the ratio of phosphorylated to 
total amount of each respective protein. Data for IRS-1 and ULK-P represent the abundance of 
each protein normalized to the total protein as determined by fast green stain. Data were analyzed 
with repeated measures analysis using a compound symmetry variance-covariance structure for 
Akt and IRS-1, heterogenous autoregression structure for 4E-BP1 and a simple structure for rpS6, 
ULK and mTOR. N = 6 control and n = 6 dexamethasone treated horses. 
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Figure 3. 10 Muscle protein expression affected by treatment 
Values are least squared means ± SE of muscle protein expression that differed significantly 
between dexamethasone treated horses (black bars) and controls (white bars) (P < 0.05 and 0.05 
< P < 0.1). Figure A: Overall abundance of FoxO3 (ratio phosphorylated/total FoxO3 protein) 
and IRS-1 (ratio total IRS-1/total protein) which was affected by treatment regardless of time or 
day; Figure B: Basal abundance of IRS-1 (ratio total IRS-1/total protein) and mTOR (ratio 
phosphorylated/total mTOR protein) which was affected by treatment regardless of day. Data 
analyzed with repeated measures analysis using a compound symmetry variance-covariance 
structure for IRS-1 and a simple structure for mTOR. N = 6 control and n = 6 dexamethasone 
treated horses. 
FoxO3 IRS-1
0.0
0.5
1.0
1.5
P
ro
te
in
 e
x
p
re
s
s
io
n
A
rb
it
ra
ry
 u
n
it
s
IRS-1 mTOR
0.00
0.25
0.50
0.75
1.00
1.25
B
a
s
a
l 
p
r
o
te
in
 e
x
p
r
e
s
s
io
n
A
r
b
it
r
a
r
y
 u
n
it
s
DEX 
Control 
 
159 
 
A 
 
C 
 
Figure 3. 11 Muscle protein expression affected by treatment by day interaction 
Values are least squared means ± SE of muscle protein expression that differed significantly 
between dexamethasone treated horses (black bars) and controls (white bars) or within each 
treatment group on each day either at basal level or in response to feeding (delta: post feeding 
expression – pre feeding expression (P < 0.05 and 0.05 < P < 0.1). Figure A: Basal IRS-1 
expression, Figure B: rpS6 response, Figure C: ULK-P response, Figure D: AMPK response. 
Data for rpS6 and AMPK represent the ratio of phosphorylated to total amount of each respective 
protein. Data for IRS-1 and ULK-P represent the abundance of each protein normalized to the 
total protein as determined by fast green stain. Data were analyzed with repeated measures 
analysis using a compound symmetry variance-covariance structure for IRS-1, and a simple 
structure for rpS6, ULK and AMPK.. a,b,c Different letters indicate differences between days 
within treatment group (P < 0.05 and 0.05 < P < 0.1). *Significant difference between treatment 
groups on each day (P < 0.05 and 0.05 < P < 0.1). N = 6 control and n = 6 dexamethasone 
treated horses 
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Figure 3. 12 Representative images of the immunoblots  
The images represent phosphorylated (left two columns) and total form (right two columns) of 
each protein before and after the consumption of a high protein meal. Akt phosphorylated at 
Ser473, mTOR phosphorylated at Ser2448, rpS6 phosphorylated at Ser235/236 and Ser240/244, 4E-BP1 
phosphorylated at Thr37/46, AMPK phosphorylated at Thr172, FoxO3 phosphorylated at Ser253, NF-
κB p65 phosphorylated at Ser536, ULK phosphorylated at Ser757. NA: not applicable; MW, 
molecular weight; kDa, kilodalton.  
  
Protein  Phosphorylated form Total form 
 MW (kDa) Pre feed Post feed Pre feed Post feed 
IRS-1 180 NA  
Akt 60 
 
 
mTOR 289   
rpS6 32   
4E-BP1 15-20   
AMPK 62   
FoxO3 82-97   
Atrogin-1 41 NA  
Myostatin 42 NA  
NF-κB 65  NA 
ULK 140-150 
 
NA 
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CHAPTER 4  
EFFECTS OF SHORT-TERM DEXAMETHASONE ADMINISTRATION ON 
GLUCOSE AND INSULIN DYNAMICS AND MUSCLE PROTEIN SIGNALING 
IN HORSES AFTER AN ORAL SUGAR TEST 
 
Abstract 
Long-term dexamethasone (DEX) administration is known to reduce peripheral insulin 
sensitivity and decrease the activation of insulin-mediated signaling pathways in equine 
skeletal muscle. Whether these changes occur during a shorter period of DEX treatment 
is currently unknown. The objective of this study was to determine the effects of short-
term DEX treatment on glucose and insulin dynamics and muscle insulin signaling in 
response to an oral sugar test (OST). Twelve mature, thoroughbred mares that were used 
of which 6 received oral DEX (0.04 mg/kg BW/day) for 7 days and 6 served as controls 
receiving no DEX. Each horse was sampled 3 times: prior to DEX administration (DAY 
1), following the 7 day DEX treatment period (DAY 7), and 7 days after cessation of 
treatment (DAY 14). On each sampling day, blood and gluteus medius muscle samples 
were collected before and 90 min after the OST. Plasma glucose and insulin 
concentrations were determined, and muscle samples were analyzed using western 
immunoblot techniques to determine the relative abundance and phosphorylation of 
signaling molecules involved in muscle protein metabolism. Data were analyzed using 
mixed procedures of SAS version 9.4 with block, treatment, day and their interactions as 
the fixed effects and horse nested within block as the random subject. Plasma glucose, 
insulin and activation of Akt, rpS6, 4E-BP1, mTOR and ULK were increased after the 
OST, regardless of treatment or day (P < 0.05). Seven days of DEX treatment elevated 
baseline glucose and insulin levels (P < 0.05) and increased (P = 0.02) and tended (P = 
0.1) to increase the insulin response to the OST on DAY 14 and DAY 7, respectively. 
Baseline and 90 min post-OST insulin and glucose concentrations on DAY 14 were not 
different from DAY 1 (P > 0.05). Insulin concentrations 90 min post-OST were higher in 
DEX treated horses on DAY 7 and exceeded the typical threshold level of 60 µIU/mL, 
indicating 7 days of DEX administrations resulted in insulin dysregulation. Regardless of 
day, DEX treatment reduced overall activation of mTOR and FoxO3 but increased total 
abundance of IRS-1 (P < 0.05). In response to an OST, Akt activation and myostatin 
abundance were reduced in DEX treated horses, regardless of sample day. Lastly, DEX 
administration increased total abundance of FoxO3 on DAY 7 (P < 0.05). Collectively, 
these results illustrate that seven days of dexamethasone treatment resulted in transient 
insulin dysregulation and consequently altered insulin-mediated muscle protein 
metabolism signaling in response to an OST. 
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4.1. INTRODUCTION 
Synthetic glucocorticoids (GC) are commonly used to treat a variety of clinical 
conditions including osteoarthritis, respiratory and immune-mediated diseases (e.g. 
allergies) [135, 167, 168]. Although their potent immune-modulating effects make GC, 
such as dexamethasone, a frequently used anti-inflammatory drug in equine veterinary 
medicine, they also induce a variety of less desirable physiological changes. Similar to 
endogenous GC, dexamethasone decreases anabolic processes and upregulates catabolic 
pathways [48, 128, 133, 141]. Dexamethasone administration is known to increase blood 
glucose levels, reduce peripheral insulin sensitivity and consequently alters several 
signaling pathways in insulin-sensitive tissues, including skeletal muscle [29, 30, 32, 33, 
141, 244, 257, 315].  
Skeletal muscle is responsible for the majority of insulin-stimulated glucose 
uptake and insulin signal transduction is a major stimulus for the activation of muscle 
protein synthetic pathways, including the mechanistic target of rapamycin (mTOR) 
pathway [2, 68, 76]. mTOR is a major player in controlling muscle mass and coordinates 
a variety of cellular processes such as cell growth, differentiation, autophagy, survival, 
metabolism [66, 309]. As a key cellular nutrient sensor, mTOR is highly responsive to 
the anabolic stimulus of growth factors, including insulin and insulin-like-growth factor-1 
(IGF-1). The binding of insulin or IGF-1 to their muscle membrane receptors will result 
in the phosphorylation of insulin receptor substrates (IRS) and trigger an intracellular 
signaling cascade eventually leading to the phosphorylation of Akt [76, 77]. Activation of 
this kinase will subsequently result in further downstream phosphorylation of several 
proteins, including mTOR. Activation of mTOR will eventually lead to initiation of 
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protein synthesis through downstream phosphorylation of rpS6 and 4E-BP1, components 
responsible for regulation and proper assembly of protein synthetic machinery [66, 90, 
311]. Considering muscle mass is regulated by the balance between synthetic and 
proteolytic processes, the anabolic stimulus provided by insulin or IGF-1 is also 
responsible for the downregulation of several catabolic signaling molecules, including 
AMPK, FoxO3, atrogin-1, ULK and myostatin [79, 102, 164, 310, 327]. Conversely, a 
GC-induced catabolic state has been shown to result in increased expression and 
activation of these components, creating an imbalance between muscle protein 
breakdown and synthesis, potentially leading to muscle atrophy [48, 307]. Several in 
vitro and in vivo studies have illustrated the acute effects of dexamethasone on muscle 
protein synthesis and breakdown pathways [103, 129, 162, 299, 349]. These effects have 
also made dexamethasone-induced catabolism a popular model to study muscle atrophy 
in humans and rodents. Considering little is known of muscle protein degradation 
pathways in horses, the dexamethasone model could provide an easy method to further 
elucidate the underlying molecular mechanisms involved in muscle proteolysis.  
In horses, it is known that dexamethasone administration affects glucose and 
insulin dynamics as early as 2h post injection, creating a state of insulin resistance by 24h 
[170]. Other studies have illustrated insulin sensitivity decreases during prolonged GC 
treatment, resulting in substantial peripheral insulin resistance [29, 191, 244]. Results 
from these studies illustrated that insulin-mediated muscle signaling was altered in 
dexamethasone treated horses, with decreased activation of molecules involved in 
glucose metabolism and protein synthetic pathways, including glycogen synthase kinase 
3β [33], rpS6 and 4E-BP1 (Chapter 2). Additionally, results from Chapter 2 also showed 
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increased expression of atrogin-1, a muscle specific E-3 ligase and a component of the 
ubiquitin-proteasome pathway (UPP). However, no studies have collected muscle 
samples at any earlier time point during treatment to evaluate the acute effects of 
dexamethasone on muscle protein signaling. Data in rodents has previously suggested 
that certain GC-induced changes could be transient and were seen only in the first few 
days of treatment with a potential role for protective mechanisms to prevent continued 
muscle atrophy during prolonged exposure to excess GC [164].  
Considering that dexamethasone is typically administered for short periods, there 
is a paucity of data evaluating early dexamethasone-induced changes on skeletal muscle 
protein synthetic capacity. Therefore, the objective of this study was to evaluate the 
effects of dexamethasone on glucose and insulin dynamics and insulin-mediated signal 
transduction in skeletal muscle before and after an oral glycemic challenge. 
4.2. MATERIALS AND METHODS 
4.2.1. Animals and housing 
Animals and housing conditions were as described in Chapter 3.  
4.2.2. Experimental procedures 
As described in Chapter 3, 12 mature, thoroughbred mares were randomly 
assigned to receive either 7 days of dexamethasone (DEX) or an equivalent amount of 
saline (CON) and studied for a total of 15 days (See Chapter 3). To study the effects of 
DEX on insulin-mediated mTOR pathway activation, blood and muscle samples were 
collected before and after an oral glycemic challenge in the form of an oral sugar test 
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(OST). This test is commonly used in the field to quickly assess insulin status in horses 
[217]. Sampling procedures were repeated on three occasions during the study: 1) prior to 
DEX treatment (DAY 1), 2) after 7 days of DEX treatment (DAY 7) and 3) following a 
7-day recovery period from treatment (DAY 14). Briefly, on the days prior to sample 
collection, horses received their allotted evening hay and concentrate portions (Table 1 
Chapter 3) 18h before initiation of sampling procedures [14]. Any remaining hay was 
removed approximately 14h before sample collection to ensure horses were in a post-
absorptive state. Ad libitum access to water was maintained at all times. On the morning 
of sampling days, a 10 mL baseline blood sample (10 mL, pre-OST) was collected via 
venipuncture, after which the horses were lightly sedated with 3 mL of xylazine 
hydrochloride. Following collection of a basal muscle biopsy as described in Chapter 3, 
horses were allowed to recover in their stalls. When horses were visually alert, they each 
received 150 mg/kg BW (0.15ml/kg BW) of dextrose derived digestible sugars 
administered directly into the mouth with an oral dosing syringe (Karo light corn syrup, 
ACH Food Companies, Cordova, TN). A second blood sample was collected exactly 90 
min post OST and biopsy procedures were repeated as described previously (referred to 
as post-OST). Muscle samples collected on the same day were obtained from 
contralateral sides. After the second biopsy, horses recovered in their stalls until they 
were visually alert, at which point they were fed their daily hay portions. After the last 
biopsy collection in each sample period (i.e. Feed day or OST day), horses received 2g of 
non-steroidal anti-inflammatory phenylbutazone paste (ButaPaste, Butler Animal Health 
Supply, Dublin, OH) for 2 days. Following DAY 1 sample collections, horses started on 
their respective treatments and received either a daily dose of dexamethasone (DexaJet 
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SPc; 0.04 mg/kg/BW), or an equal volume of 0.9% saline, for 7 days which was top-
dressed on their evening concentrate. All sample procedures were repeated on DAY 7 
and 14. 
Blood and muscle samples were processed as described in Chapter 3. 
4.2.3. Data analysis 
All data were analyzed using mixed or glimmix procedures of SAS version 9.3 
(SAS Institute Inc.) with significance set at P < 0.05. Statistical trends were considered 
when 0.05 < P < 0.10. Normality of the data was assessed by visual inspection of the 
distribution of studentized residuals and a Shapiro-Wilk test (P < 0.05). If necessary, 
outliers identified as > 2 standard deviations from the mean were removed from the 
dataset after which all data was normal. The response to the administration of the OST 
was analyzed as the delta (post concentrations – pre concentrations) of the 90 min post 
values and the baseline (0 min) values of each dependent variable. Baseline and response 
data were analyzed using repeated measures analysis with an appropriate variance-
covariance matrix chosen based on lowest values for respective fit statistics. Treatment 
(DEX vs CON), sample day (DAY 1, DAY 7, DAY 14) and their interaction were 
considered fixed effects and horse nested within block as the random subject. In addition 
to the comparison of baseline and response to feeding, insulin data was also analyzed for 
overall effects of time (0 min vs 90 min) and western blot data for overall effect of time 
and treatment (DEX vs CON) with block, treatment, day, time and their interaction as the 
fixed effects and horse nested within block as the random subject. When fixed effects 
were significant, least square means were compared using a pdiff test. All data are 
presented as least square means ± SE. 
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4.3. RESULTS 
No differences were observed in average age (DEX 15 ± 1 and CON 16 ± 1 years 
old; P > 0.05) or bodyweight (DEX 558 ± 15 and CON 567 ± 16 kg; P > 0.05) between 
the treatment groups. Bodyweight also did not change significantly throughout the study 
in either treatment group (P > 0.05). 
4.3.1. Plasma glucose 
Baseline glucose concentrations were significantly affected by a treatment by day 
interaction (P = 0.006). Dexamethasone treated horses had 1.2-fold higher basal glucose 
levels on DAY 7 versus control horses (P = 0.002, Figure 4.1 A). No differences were 
detected between the treatment groups on any other sample days (P > 0.05). Basal 
glucose levels did not differ between sample days in the control group but within the 
dexamethasone treated horses, glucose concentrations increased 1.2-fold from DAY 1 to 
DAY 7 (P = 0.0002, Figure 4.1 A). However, by DAY 14, baseline glucose levels were 
returned to levels similar to DAY 1 (P > 0.05, Fig 4.1 A).  
Administration of an OST increased glucose levels in all horses (overall effect of 
time, P < 0.0001), however there was no difference in post-OST glucose responses 
between or within treatment groups throughout the study period (P > 0.05, Figure 4.1 B). 
4.3.2. Plasma insulin 
There was a significant treatment by day interaction for baseline insulin 
concentrations (P < 0.0001). Dexamethasone treated horses had 4-fold higher basal 
insulin levels versus control horses on DAY 7 (P = 0.0005) with concentrations of 22.2 ± 
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2.3 and 5.2 ± 2.3 µIU/mL for the dexamethasone and control groups, respectively (Figure 
4.2 A). There were no differences between the treatment groups on any of the other day 
(P > 0.05). Horses with basal concentrations > 20 µIU/mL in a post-absorptive state are 
typically considered to be at risk for insulin dysregulation. Basal insulin concentrations 
did not differ throughout the study in the control group (P > 0.05). Within the 
dexamethasone group basal insulin concentrations increased 4-fold from DAY 1 to DAY 
7 and similarly decreased 4-fold by DAY 14 (P < 0.05, Figure 4.2 A).  
The OST increased insulin levels above basal levels in all horses (overall effect of 
time, P < 0.0001). Insulin responses to the OST were significantly affected by a day by 
treatment interaction (P = 0.02). There was a significant difference in insulin responses 
between treatment groups on DAY 14 (P = 0.02) and a trend for a difference on DAY 7 
(P = 0.1). There was no difference between groups on DAY 1, but horses treated with 
dexamethasone had a tendency for post-OST insulin responses to be 4-fold greater than 
control horses on DAY 7 (P = 0.1) (Figure 4.2 B). Insulin concentrations 90 min after 
administration on DAY 7 were 67.6 ± 11.3 and 25.3 ± 11.3 µIU/mL for dexamethasone 
treated and control horses, respectively. An insulin response > 60 µIU/mL 60-90 min 
after administration of oral sugar is typically considered a sign of insulin dysregulation. 
Interestingly, post-OST insulin responses on DAY 14 were 0.5-fold higher in the control 
horses compared to dexamethasone horses (P = 0.02, Figure 4.2 B). Within the control 
group, insulin response to the OST on DAY 14 was higher versus DAY 1 (P = 0.03) but 
was not different from the response on DAY 7 (Figure 4.2 B). Within the dexamethasone 
treated horses the insulin response to the OST increased approximately 4-fold from DAY 
1 to DAY 7 (P = 0.004) and similarly decreased 4-fold by DAY 14 (P = 0.003). There 
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was no difference between insulin responses on DAY 1 and DAY 14 in the 
dexamethasone group (P > 0.05). 
4.3.3. Western blots 
Regardless of day or treatment, administration of an OST increased activation of 
Akt (P < 0.0001), rpS6 (P < 0.0001), 4E-BP1 (P = 0.09), mTOR (P < 0.0001), ULK-P 
(P = 0.004) in all horses (Table 4.2).  
For the following section, data regarding treatment effects on activation, 
phosphorylated form and total form of each protein can be found in Table 4.2, 4.3 and 
4.4, respectively.  
There was an overall effect of treatment on the activation (ratio of phosphorylated 
to total protein abundance) of mTOR (P = 0.002), FoxO3 (P= 0.09) and on total 
abundance (ratio of protein abundance/ total protein stain) of IRS-1 (P = 0.04). 
Regardless of day or time of biopsy, activation of mTOR (P = 0.002) and FoxO3 (P = 
0.09) was overall lower in dexamethasone horses compared to control horses (Table 4.2, 
Figure 4.4 A). Conversely, overall total abundance of IRS-1 protein was higher in 
dexamethasone treated horses compared to control horses (P = 0.04, Table 4.4, Figure 
4.4 A). There was no treatment effect on basal levels of any protein measured throughout 
the study (P > 0.05).  
In response to the OST (as determined by the delta of the values at 90 and 0 min), 
the activation (phosphorylated to total protein ratio) of Akt (P = 0.006), abundance of 
phosphorylated Akt (P = 0.04) and total abundance of myostatin (P = 0.02) were 
affected by treatment. The activation (P = 0.006) and abundance of the phosphorylated 
form (P = 0.04) of Akt in response to the OST was lower in dexamethasone treated 
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horses compared to the control group (Tables 4.2 and 4.3, Figure 4.4 B). In response to 
the OST, myostatin levels decreased but were reduced to a lesser extent in horses treated 
with dexamethasone compared control horses (P = 0.02, Table 4.4, Figure 4.4 B).  
A trend for a treatment by day interaction was observed for the total abundance of 
FoxO3 (P = 0.07) and AMPK (P = 0.1) at baseline and for activation of Akt (ratio of 
phosphorylated to total protein abundance) in response to the OST (P = 0.07). There was 
a trend for basal levels of total FoxO3 to be higher in dexamethasone treated horses 
compared to control horses on DAY 7 (P = 0.1, Table 4.4, Figure 4.5 A). There was no 
difference in basal levels of total FoxO3 within the control horses but levels were higher 
on DAY 7 compared to DAY 1 (P = 0.0007) and DAY 14 (P = 0.003) in 
dexamethasone-treated horses (Table 4.4). Within the dexamethasone group, total FoxO3 
abundance was not different between DAY 1 and 14 (P > 0.05, Table 4.4, Figure 4.5 A). 
Total abundance of AMPK tended to be higher in the dexamethasone-treated group on 
DAY 1 (P = 0.09) but was not different between groups on any other days (Table 4.4). 
Within the dexamethasone-treated group, total AMPK levels significantly increased from 
DAY 1 to DAY 7 (P = 0.007, Table 4.4) but were significantly lower at DAY 14 
compared to DAY 7 (P = 0.01). Within the control horses, total AMPK levels decreased 
and were lower on DAY 14 compared to DAY 1 (P = 0.08) and DAY 7 (P = 0.04). Akt 
activation in response to the OST was lower in dexamethasone treated horses compared 
to the control horses on DAY 14 (P = 0.001, Table 4.2, Figure 4.5 B). However, there 
was no difference between the groups on any of the other days. Within the control group, 
Akt activation in response to the OST was higher on DAY 14 versus DAY 1 (P = 0.02) 
and 7 (P = 0.03), but there was no difference between DAY 1 and 7 (P > 0.05, Table 
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4.2). Within the dexamethasone group, there was no difference in Akt activation after the 
OST throughout the study (P > 0.05, Table 4.2, Figure 4.5 B).   
Regardless of treatment, sample day affected activation (phosphorylated to total 
protein ratio) of mTOR (P = 0.03), abundance of phosphorylated FoxO3 (P = 0.06) and 
NF-κB (P = 0.03) and total abundance of AMPK (P = 0.09) in response to the OST. The 
administration of an OST elicited a tendency for total AMPK levels to increase to a 
greater extent on DAY 1 compared to DAY 7 (P = 0.03, Table 4.4). The activation of 
mTOR (phosphorylated to total protein ratio) in response to the OST was significantly 
greater on DAY 7 compared to DAY 1 (P = 0.03) and responses on DAY 7 tended to be 
higher than those on DAY 14 (P = 0.07) (Table 4.2). The response of phosphorylated 
FoxO3 post-OST was lower on DAY 7 versus DAY 1 (P = 0.02) and tended to be lower 
on DAY 14 compared to DAY 1 (P = 0.09) (Table 4.3). In response to the OST, levels of 
phosphorylated NF-κB were higher on DAY 1 compared to DAY 14 (P = 0.009) but 
were not different from DAY 7 (P > 0.05) (Table 4.3).  
Sample day also affected baseline activation status (phosphorylated to total 
protein ratio) of rpS6 (P = 0.09), 4E-BP1 (P = 0.05), mTOR (P = 0.1) and FoxO3 (P = 
0.05), baseline levels of phosphorylated forms of NF-κB (P = 0.006), ULK (P = 0.09) 
and FoxO3 (P = 0.01) and baseline total abundance of 4E-BP1 (P = 0.07), AMPK (P = 
0.005), atrogin-1 (P = 0.02), FoxO3 (P = 0.002), IRS-1 (P = 0.01), myostatin (P = 0.03), 
regardless of treatment. Baseline activated rpS6 (phosphorylated to total protein ratio) 
was lower on DAY 7 compared to DAY 1 (P = 0.04) (Table 4.2). Basal levels of 
activated 4E-BP1 (phosphorylated to total protein ratio) were significantly higher on 
DAY 14 compared to DAY 7 (P = 0.01) (Table 4.2). Additionally, baseline abundance of 
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total 4E-BP1 was higher and tended to be higher on DAY 7 vs DAY 1 (P = 0.02) and 
DAY 14 (P = 0.08), respectively (Table 4.4). Basal activated mTOR was higher on DAY 
1 compared to DAY 7 (P = 0.04) and 14 (P = 0.04) (Table 4.2). There was a 
significantly greater abundance of baseline activated FoxO3 on DAY 1 compared to 
DAY 7 (P = 0.01) (Table 4.2). Baseline abundance of total FoxO3 was higher on DAY 7 
compared to DAY 1 (P = 0.0009) and DAY 14 (P = 0.009) (Table 4.4). Baseline 
abundance of total AMPK was significantly higher on DAY 7 compared to DAY 14 (P = 
0.002) and levels on DAY 7 tended to be higher than DAY 1 (P = 0.06) (Table 4.4). 
Basal atrogin levels were significantly higher on DAY 7, compared to DAY 14 (P = 
0.008) but did not differ from DAY 1 (P > 0.05) (Table 4.4). Baseline abundance of IRS-
1 was significantly lower on DAY 14 compared to DAY 1 (P = 0.04) and DAY 7 (P = 
0.004) (Table 4.4). Baseline levels of myostatin were significantly higher on DAY 7 
compared to those on DAY 14 (P = 0.008) and tended to be higher on DAY 7 compared 
to DAY 1 (P = 0.09) but did not differ between DAY 1 and DAY 14 (Table 4.4). Basal 
levels of phosphorylated NF-κB were significantly lower on DAY 1 compared to DAY 7 
(P = 0.002) and DAY 14 (P = 0.04) but were not different between DAY 7 and 14 (P > 
0.05) (Table 4.3). Lastly, there was a tendency for baseline levels of phosphorylated ULK 
to be higher on DAY 7 versus DAY 1 (P = 0.04) (Table 4.3).  
Interestingly, there was an effect of block on overall phosphorylated levels of 
FoxO3 (P = 0.0009) and ULK (P = 0.004), levels of total IRS-1 (P < 0.0001), basal total 
Akt levels (P = 0.03), and the atrogin response to the OST (P = 0.01). Regardless of time 
or treatment, horses in block 1 had significantly higher overall levels of phosphorylated 
FoxO3 and ULK but lower levels of total Akt and IRS-1 compared to horses in block 2. 
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In response to the OST, there was a greater decrease in atrogin levels for horses in block 
2 compared to block 1.  
4.4. DISCUSSION 
Both short and long-term dexamethasone treatment has been shown to result in 
substantial insulin dysregulation (ID) and alters muscle protein signaling in response to 
an anabolic stimulus provided by a isoglycemic-hyperinsulinemic clamp (IHC) or a high 
protein meal (Chapters 2 and 3). Although the IHC is a gold standard to assess peripheral 
insulin sensitivity, the artificial nature of the procedure often makes it difficult to relate 
muscle responses to such a hyper-physiological stimulus to normal conditions. 
Additionally, it is known that the gut and its associated organs play an important role in 
the pathophysiology of ID, which would not be taken into account with an IHC. The 
objective of the current study, therefore, was to investigate the response of muscle insulin 
signaling pathways after an oral glycemic challenge before and after dexamethasone 
treatment. Dexamethasone treated horses had overall lower levels of phosphorylated 
mTOR and FoxO3, higher levels of IRS-1 and less activation of Akt in response to the 
OST. Additionally, myostatin levels in the dexamethasone group decreased to a lesser 
extent after the OST in the dexamethasone group compared to the control group. Baseline 
abundance of total FoxO3 and total AMPK also tended to be higher in dexamethasone 
horses on DAY 7. Seven days of dexamethasone treatment increased basal glucose and 
insulin levels and tended to increase insulin responses to the OST. Basal concentrations 
of glucose and insulin returned to pre-treatment levels within 7 days of recovery from 
treatment, however, the insulin response to the OST was lower on DAY 14 in horses 
previously treated with dexamethasone. 
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Considering the horses in the current study were the same as those in Chapter 3 
and studied in the same time period, the glycemic and insulinemic responses were similar 
to those described in Chapter 3 and in line with previous reports in horses after GC 
treatment [29]. By reducing tissue sensitivity to insulin-stimulated glucose uptake and 
promoting gluconeogenic pathways [37, 257], dexamethasone administration predictably 
resulted in increased basal plasma glucose levels. Consequently, GC treatment is 
typically associated with compensatory hyperinsulinemia [258], as was observed in the 
current study. Mean basal plasma insulin concentrations on DAY 7 (22.2 ± 2.3 µIU/mL) 
were similar to those reported previously in horses after 7 days of dexamethasone 
treatment and were >20 µIU/mL, the commonly used threshold level of in the diagnosis 
of ID [23, 29, 32]. Although the literature is somewhat controversial on the main 
mechanism underlying GC-associated hyperinsulinemia, evidence shows that GC 
increase both pancreatic insulin secretion and lower hepatic insulin clearance [29, 37, 
257, 260, 261]. Both basal glucose and insulin concentrations returned to pre-treatment 
levels after 7 days of recovery as previously reported [268], indicating the effects of GC 
on insulin and glucose homeostasis are transient. 
Although perhaps not as robust as the IHC or the frequently sample intravenous 
glucose tolerance test, the OST is a practical and commonly used dynamic field test to 
evaluate insulin sensitivity and has shown to closely correlate to an intravenous glucose 
tolerance test [217]. No other data currently exists on the insulin response following an 
OST in horses treated with dexamethasone, however, the mean 90 min values (67.6 ± 
11.3 µIU/mL) are in range with concentrations reported in horses with natural ID 
following an OST [357]. Insulin concentrations >60 µIU/mL at 90 min post-OST are a 
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commonly used diagnostic threshold level for horses with suspected ID [23].  
Furthermore, previous studies investigating the effects of prolonged dexamethasone 
treatment in horses showed that insulin sensitivity was significantly decreased by day 7 
[29, 32, 268]. Collectively, these data give strong indication that the horses in the current 
study were ID after 7 days of GC treatment, despite the fact that that we did not use more 
robust measurements of insulin sensitivity.  
Although the absolute insulin increment in response to the OST was 4-fold greater 
in the dexamethasone horses compared to controls, there was only a trend for a treatment 
difference between groups on DAY 7. However, large individual differences to the 
insulin response, as reflected by the measures of variation, seem to have prevented this 
difference from reaching statistical significance. Insulin responses to a glucose challenge 
are known to depend on initial degree of insulin sensitivity [27], and although all our 
horses were well below threshold levels for suspected ID prior to the start of the study, 
individual differences were evident and likely contributed to the observed inter-horse 
variation.  
The insulin response to an oral glucose challenge can be influenced by a variety 
of factors, including rate of digestion and absorption, gut incretin responses, gut glucose 
metabolism and release into the portal system, pancreatic glucose sensitivity and insulin 
release pattern and hepatic insulin metabolism [37, 245, 358, 359]. The contribution of 
the gut and the enteroinsular axis in particular has been implicated in the 
hyperinsulinemic response after an oral glycemic challenge in horses with natural ID 
[245]. Whether dexamethasone influences the gut function in horses is unknown; 
however, a study in dexamethasone treated dogs reported reduced glucose release into the 
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portal vein after an oral glucose test in comparison to untreated dogs [37]. Additionally, 
studies humans and rodents have illustrated that GC treatment augments gut permeability 
[267, 360]. More specifically, patients receiving oral corticosteroids had significantly 
greater urinary sucrose excretion after a sucrose permeability test, indicating enhanced 
gastroduodenal permeability [266]. Altered absorptive capacity for oral dextrose may 
therefore also have contributed to the results in the current study and warrants further 
investigation in horses. In further support of these findings, studies in other species have 
reported that GC alters the expression of gut enzymes and postprandial incretin release, 
possibly contributing to aberrations in postprandial insulin secretion associated with 
dexamethasone treatment [145, 361]. Additionally, there are several reports of GC-
enhanced pancreatic responsiveness to glucose [304, 340], which could also play a role in 
the hyperinsulinemic response to the OST observed in the current study. Collectively, 
these data illustrate the complexity of the insulin response to an oral glucose challenge, 
which could have been altered by dexamethasone at several steps. Therefore, several 
factors may have contributed to the observed increase in the insulin responses to the OST 
after 7 days of dexamethasone treatment in healthy horses, making it difficult to pinpoint 
exact causative mechanisms.  
Interestingly, the insulin response to the OST on DAY 14 was lower in the 
dexamethasone group compared to the control group, which would indicate greater 
insulin sensitivity after 7 days of recovery from treatment. Such an increased response to 
insulin has been previously been described 72h after a single injection of dexamethasone 
in horses [30]. Conversely, other authors have reported that insulin sensitivity, as 
determined by a proxy measure for insulin sensitivity (RISQI, the reciprocal of the square 
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root of insulin), did not return to pre-treatment levels until 15 days after the last 
dexamethasone dose [268]. However, in the latter study, dexamethasone treatment lasted 
3 weeks and with the knowledge that GC mediate their effects through both genomic and 
non-genomic mechanisms [133], variable durations of treatment could have different 
physiological impacts. It should also be noted that the insulin response to the OST 
increased within the control group on DAY 14. Considering that the insulin response to 
the OST on DAY 14 was not different from those on DAY 1 within the dexamethasone 
group itself, the changes within the control group are likely the predominant reason for 
the treatment difference observed on DAY 14. It is unclear why the insulin response to 
the OST increased in the control group and although both challenges are not directly 
comparable, no difference was observed in the insulin responses to the high protein meal 
for this group (Chapter 3). Considering all horses were stalled, fasted, of similar breed 
and all studied within a 2-month window during fall, it is unlikely that any major external 
factors have influenced these results. One possible explanation is the poor repeatability of 
the OST, which has previously been reported [362]. 
Growth factors, including insulin and insulin-like growth factor-1 (IGF-1) are 
major anabolic switches, triggering intracellular signaling pathways involved in glucose, 
lipid and protein metabolism in various tissues [2]. In the muscle specifically, insulin 
binding to its membrane receptor will phosphorylate insulin receptor substrates (IRS) 
which will relay the anabolic signal by initiating a series of signaling cascades leading to 
glucose uptake and activation of protein synthetic pathways [10]. The major pathway 
involved in regulating muscle protein metabolism is the mammalian target of rapamycin 
(mTOR), which is particularly sensitive to the stimulus of growth hormones. Insulin 
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infusion has been previously shown to increase the mTOR signaling pathway in several 
species, including horses [5, 6, 363]. Whether an oral glucose bolus would result in a 
similar effect on insulin-stimulated muscle protein synthesis signaling in horses was 
unknown. The majority of available data in other species is related to the capacity of 
carbohydrates to stimulated post-exercise protein synthesis. Reports generally indicate 
that carbohydrate ingestion alone is not as efficient in stimulating protein synthetic 
pathways as the ingestion of amino acids or a combination of amino acids and 
carbohydrates [364, 365]. In the current study, the administration of an OST increased 
phosphorylation of Akt, rpS6, 4E-BP1, mTOR and ULK in all horses, regardless of 
treatment. This clearly indicates that the oral sugar load provided by the OST elicited an 
anabolic response that was strong enough to initiate mTOR pathway signaling. Although 
the exact composition of the commercial syrup was not available, it provided 
approximately 150 mg of dextrose derived digestible sugar per kg BW, therefore the 
average horse (~562 kg BW) would have ingested ~85g of sugars. This amount is fairly 
low compared to studies in humans (using ~100g) [364, 365] and the average amount of 
sugars provided in high energy equine feeds (~ 40-50g simple sugars /100g feed). 
However, most previous data in humans measured protein turnover rates with isotopic 
methods rather than by studying mTOR pathway activation. Although protein synthesis 
cannot occur without the presence of amino acids, the amount of easily digestible sugars 
provided by the OST was able to activate several upstream and downstream components 
of the mTOR pathway in the current study. It is possible that endogenous muscle amino 
acids were mobilized to initiate protein synthetic machinery, although application of 
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isotopic methods would be necessary to verify whether changes in protein turnover 
occurred. 
We have previously shown that 21 days of dexamethasone treatment diminished 
insulin-stimulated activation of downstream mTOR signaling components rpS6 and 4E-
BP1, while also increasing the expression of atrogin-1, an important marker for muscle 
degradation (Chapter 2). The current study showed similar results with reduced activation 
of the mTOR pathway as reflected by lower overall Akt activation in response to the OST 
and lower overall levels of phosphorylated mTOR in dexamethasone-treated horses. 
Conversely, total abundance of IRS-1 protein was increased after GC treatment. As 
predicted, some of the current finding were similar to those described in Chapter 3 as the 
same horses were studied during the same period of time. For example, similar to Chapter 
3, dexamethasone administration resulted in a general decrease in levels of 
phosphorylated to total mTOR protein and increased levels of total IRS-1 abundance. GC 
can affect mTOR signaling through various mechanisms involving both non-genomic and 
genomic GC-receptor (GR)-mediated interference with function and expression of 
intracellular signaling components [48, 133, 136]. As noted in Chapter 3, it was unclear 
why total abundance of IRS-1 was increased in dexamethasone treated horses in the 
current study. This finding is in contrast with the majority of the literature, which reports 
that GC typically decrease the protein expression of IRS by stimulating pathways that 
lead to its degradation [149]. In addition, GC also interfere with IRS-1 signal 
transduction by inhibiting proper phosphorylation through interference with the function 
of several of its kinases [153]. However, one study reported a decreased expression of 
IRS-1 in the muscle, but increased expression in the liver of dexamethasone treated rats 
 
180 
 
and concluded that levels of IRS-1 are regulated in a tissue-specific manner, and are 
modulated by both hyperinsulinemia and excess steroids [36]. It could therefore be 
speculated that the hyperinsulinemic state induced by dexamethasone dominated over the 
steroid effect and stimulated IRS-1 translation or that IRS-1 expression in equine muscle 
is differently regulated than in other species. Other studies reported increased expression 
and phosphorylation of IRS-2 in adipocytes in the face of dexamethasone-induced IR, 
suggesting this might be in compensation of reduced expression of IRS-1 [320]. These 
authors also indicated that overexpression of IRS-1 protein did not ameliorate GC-
induced IR, indicating that its total abundance does not necessarily reflect its signaling 
potential. Unfortunately, we were unable to measure IRS-1 phosphorylation and therefore 
cannot make any conclusions whether IRS-1 activation was affected in dexamethasone 
treated horses. However, decreased activation of Akt in response to the OST in the 
dexamethasone group, suggests that insulin signal transduction was interrupted or 
diminished by GC treatment. 
Insulin stimulated Akt phosphorylation is mediated through phosphatidylinositol-
3-kinase (PI3K), which becomes activated after interaction with phosphorylated IRS-1. 
Besides interference with initial IRS-1 signaling as discussed earlier, GC can also reduce 
Akt phosphorylation by preventing PI3K activation through upregulation of its regulatory 
subunit p85α [152]. Additionally, it’s been shown that the activated GR can acutely 
inhibit the interaction between PI3K and IRS-1 by binding to the p85α subunit, 
preventing PI3K activation [153]. Lastly, dexamethasone can also directly decrease the 
phosphorylation of Akt by reducing expression of heat shock protein 70, a protein 
responsible for protecting Akt phosphorylation, and upregulation of the myostatin 
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pathway [48]. Interestingly, myostatin expression was decreased to a lesser extent in 
dexamethasone treated horses in response to the OST, supporting the previous hypothesis 
that GC might have upregulated this pathway leading to decreased Akt phosphorylation. 
Despite the fact that the overall effect of treatment indicated Akt activation was reduced 
in the dexamethasone group, closer investigation of the treatment by day interaction 
illustrated that this effect was only observed on DAY 14. Additionally, the data showed 
that, for unknown reasons, Akt activation in response to the OST was increased in the 
control group on DAY 14, which was likely the determining factor for a treatment effect 
detected between groups on this day. 
In addition to the interference with the initial signal transduction by modulation of 
IRS-1 and consequently Akt, GC can also directly inhibit mTOR via Akt-independent 
pathways. It is known that mTOR repressors REDD1 and KLF-15 are direct targets of the 
GR in skeletal muscle, and are therefore upregulated by steroid stimulation [147]. While 
REDD1 has a more direct inhibitory effect on mTOR activation, KLF-15 interrupts 
upstream anabolic simulation from amino acids and upregulates atrogenes involved in 
proteolytic pathways [83, 147]. These molecular mechanisms could explain the observed 
decrease in overall mTOR activation in dexamethasone-treated horses in the current 
study. Despite the overall decrease in mTOR activation, GC treatment did not affect 
insulin-mediated activation of its downstream components 4E-BP1 and rpS6, which are 
responsible for proper assembly of protein translational machinery [90]. Similarly, we 
saw no effect of GC treatment on 4E-BP1 activation following consumption of a high 
protein meal; however, feeding increased and decreased rpS6 activation in the 
dexamethasone group on DAY 7 and DAY 14, respectively (Chapter 3). These results are 
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in contrast with previous findings that showed a decrease in insulin-stimulated rpS6 and 
4E-BP1 phosphorylation after 21 days of dexamethasone treatment (Chapter 2). These 
discrepancies can be partly explained by the different nature of the challenges applied in 
these studies. In particular it is known that amino acids stimulate mTOR through insulin-
independent pathways [344]. Additionally, in the first study, horses received 
dexamethasone for 21 days instead of the 7-day period in the current study. It could 
therefore be speculated that more pronounced effects of GC became evident after 
prolonged treatment, or that insulin stimulation by IHC resulted in different effects 
compared to the OST. The results of this study indicate that despite the observed GC-
mediated alterations in upstream signaling components, the activation of 4E-BP1 and 
rpS6 was maintained in response to the OST. In vitro studies have reported an increase in 
S6K1 (the kinase responsible for rpS6 phosphorylation) and 4E-BP1 phosphorylation in 
dexamethasone-treated cells after addition of insulin or IGF-1, suggesting that the 
hyperinsulinemia observed in this study could have overcome GC-mediated catabolic 
effects [47, 320]. 
Opposing the actions of insulin and IGF-1, myostatin negatively regulates muscle 
growth by decreasing Akt/mTOR pathway signaling and regulating the expression of 
differentiation-inducing genes [322]. Because their regulatory function involves mutual 
pathways, myostatin modulates the stimulatory actions of insulin and IGF-1 and vice 
versa [366]. Consequently, the presence of elevated insulin following the OST could have 
decreased myostatin protein expression in the current study. Upregulation of myostatin 
gene and protein expression plays a key role in GC-induced muscle atrophy [164] and 
although we did not observe an overall increase in basal levels of myostatin, its 
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diminished decreased after insulin stimulation suggests this pathway might have been 
upregulated in dexamethasone-treated horses. This could also partly explain the observed 
decrease in FoxO3 phosphorylation in dexamethasone-treated horses, as increased 
myostatin pathway activation would have lifted the Akt-inhibitory effect on the FoxO 
protein [126]. 
FoxO transcription factors play a major role in muscle atrophy by upregulating 
the expression of muscle specific E3 ligases atrogin-1 and MuRF-1, components of the 
ubiquitin proteasome pathway (UPP) [111]. These ligases are responsible for tagging 
regulatory and structural muscle protein for degradation [367]. Under anabolic conditions 
FoxO transcription factors are phosphorylated by Akt, thereby sequestering them in the 
cytosol [79]. GC-mediated downregulation of Akt would lift its inhibitory action on 
FoxO3 resulting in decreased phosphorylation, as detected in the current study. 
Additionally, we observed an increase in total abundance of FoxO3 in dexamethasone 
treated horses on DAY 7. This could be explained by evidence that the steroid stimulated 
GR is known to upregulate expression of FoxO1 and FoxO3 [162]. However, despite 
increased FoxO3 abundance and activation, we did not see a change in levels of its 
downstream target gene, atrogin-1. This was in contrast to observations after 21 days of 
dexamethasone treatment, where an increase in atrogin-1 was detected (Chapter 2). This 
suggests that modest changes in FoxO3 abundance and activation status do not 
necessarily lead to the upregulation of atrogenes or that other mechanisms prevented 
atrogin-1 transcription or its subsequent translation. Future measurement of mRNA levels 
would give further insight into the regulation of different steps involved in upregulation 
of synthetic and proteolytic pathways. In addition to GC, AMP-activated protein kinase 
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(AMPK) is a known upregulator of the FoxO protein [112] and total AMPK abundance 
increased significantly from DAY 1 to DAY 7 within the dexamethasone group. 
Similar to mTOR, AMPK plays a large role in modulating anabolic and catabolic 
processes by sensing the intracellular energy status. A high AMP/ATP ratio will 
stimulate the AMPK-mediated decrease of energy consuming pathways, including 
protein synthesis, while enhancing upregulation of proteolytic pathways [108, 112, 348]. 
Although GC treatment has been previously shown to increase AMPK activity [327], we 
did not detect a change in AMPK phosphorylation in the current study. As mentioned 
previously, there was a trend for total abundance of AMPK to increase in dexamethasone 
treated horses from DAY 1 to DAY 7, although this change did not result in a treatment 
difference between groups. In addition to its role in the upregulation of FoxO protein, 
AMPK also stimulates the activation of cellular autophagy machinery to deliver cytosolic 
components to lysosomes for degradation [106].  
Both AMPK and mTOR are known to positively and negatively modulate 
autophagy regulatory proteins ULK 1 and 2 (Unc-51-like kinase), respectively, by 
phosphorylation at different sites [107]. In the current study, ULK Ser757 was measured, a 
site that is known to be specifically phosphorylated by mTOR. Downregulation of this 
site would be expected in the face of GC-induced insulin resistance, however, no 
differences in ULK 1 were observed between treatment groups.  
Similar to previous results in Chapters 2 and 3, dexamethasone treatment did not 
affect levels of phosphorylated NF- κB p65, a key player in the upregulation of pro-
inflammatory and cell-survival genes. It has been shown that this transcription factor is 
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also involved in the upregulation of muscle atrophy by interfering with muscle 
differentiation, promoting expression of muscle wasting inflammatory molecules and 
upregulating components in the UPP [98, 119, 121, 323]. Similar to previous reports, the 
potent anti-inflammatory effect of GC together with a hyperinsulinemic state would 
explain the lack of NF- κB activation in dexamethasone treated-horses [324, 325]. 
Interestingly, NF- κB phosphorylation status was not different between groups at any 
time throughout the study, indicating that GC did not downregulate NF- κB under the 
current study conditions. 
Similar to results in Chapter 3, the expression of several protein was affected by 
sample day, regardless of treatment, suggesting the possible contribution of external 
factors. Basal levels of NF- κB were higher on DAY 7 and 14 compared to DAY 1, 
suggesting the upregulation of inflammatory processes for similar reasons as described in 
Chapter 3. Inflammation could have contributed to the observed differences in basal 
activation status of rpS6, 4E-BP1, mTOR and abundance of phosphorylated ULK1 
between sample days. Additionally, it has been previously illustrated that inflammatory 
responses associated with repeated biopsies alter mTOR activation in horses when no 
NSAID’s were administered [355]. Therefore, a certain degree of inflammation could 
also explain changes in the activation of mTOR and FoxO3 in response to the OST as the 
study proceeded. Sample day also affected basal levels of phosphorylated FoxO3 as well 
as total abundance of FoxO3, AMPK, atrogin-1 and myostatin, which all tended to be 
higher on DAY 7 compared to DAY 1 and DAY 14 in all horses. Considering these 
proteins are all markers of proteolytic pathways, these findings suggest there was an 
upregulation of catabolic pathways in all horses, regardless of treatment. Although these 
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results could be due to an effect of repeated biopsies, inflammation or other potential 
external factors, it is still unclear why most of these effects disappeared by DAY 14.  
An effect of block was also detected for several proteins, as described in Chapter 
3. Horses in block 1, which were slightly older than those in block 2, had higher levels of 
phosphorylated FoxO3 and ULK1, but had smaller total abundance of Akt and IRS-1, 
compared to those studied in block 2. Additionally, horses in block 2 had a greater 
decrease in atrogin-1 levels in response to the OST than horses studied in block 1. These 
findings are indicative of a subtle shift in the balance between protein synthesis and 
degradation associated with aging, which is well-known in humans [368]. Developmental 
differences in the regulation of mTOR signaling has previously been illustrated in horses, 
consistent with some results in the current study [14]. 
In conclusion, 7 days of dexamethasone treatment induced substantial but 
transient IR in mature, healthy mares. Administration of an OST resulted in a 
hyperinsulinemic response comparable to that observed in horses with natural ID. Despite 
an overall decrease in mTOR activation and a tendency for decreased Akt activation in 
response to the OST, rpS6 and 4E-BP1 activation was not affected by 7 days of 
dexamethasone treatment. These results suggest that despite subtle posttranslational 
changes that might have been triggered by excess GC, protein synthetic capacity seems to 
be maintained. However, measurement of protein turnover rates would be needed to 
confirm these conclusions. As mentioned previously, the regulatory mechanisms 
maintaining the balance between muscle protein synthesis and degradation is complex 
and subtle shifts are quickly counterbalanced in attempt to maintain homeostasis. 
Therefore, it is possible that other protective factors could have contributed to maintain 
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protein synthetic capacity and consequently muscle mass. Conversely, despite lack of 
change in basal or post-OST atrogin-1 expression, increased basal levels of total AMPK, 
diminished decrease in myostatin levels following insulin stimulation and overall 
enhanced FoxO3 activation indicates that 7 days of dexamethasone did upregulate certain 
key players involved in muscle protein degradation. 
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4.5. TABLES 
 
Table 4. 1 Mean plasma glucose and insulin concentrations before and 90 min after 
an oral sugar test (0.15ml/kg BW of Karo Syrup) on each day in dexamethasone and 
controls horses 
Abbreviations: DEX, dexamethasone group; CON, control horses 
Data are presented as least square means ± standard error of the mean. Data analyzed with a repeated 
measures analysis with a compound symmetry variance-covariance structure. N = 6 DEX and N = 6 CON 
horses. a,b Different letters indicate differences between treatment group within each day (P < 0.05). 
*Significant difference between days within each treatment group (P < 0.05). 
 DEX  CON 
Measure DAY 1 DAY 7 DAY 14  DAY 1 DAY 7 DAY 7 
Baseline insulin 
(μIU/mL) 
6.2 ± 1.5a 22.2 ± 2.3a* 6.0 ± 1.1a  
7.4 ± 
1.5a 
5.2 ± 2.3b 4.7 ± 1.1
a 
90 min insulin 
(μIU/mL) 
19.1 ± 
3.3a 
67.6 ± 
11.3a* 
18.6 ± 
4.3a 
 
24.0 ± 
3.3a 
25.3 ± 
11.3b 
29.7 ± 4.3a 
Baseline glucose 
(mmol/L) 
5.1 ± 0.1a 6.1 ± 0.2a* 5.1 ± 0.1a  
5.1 ± 
0.1a 
5.0 ± 0.2b 5.1 ± 0.1
a 
90 min glucose 
(mmol/L)  
7.6 ± 0.2a 8.6 ± 0.3
a* 7.2 ± 0.2a  
7.6 ± 
0.2a 
7.3 ± 0.3b 7.4 ± 0.2a 
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4.6. FIGURES 
 
A 
 
B 
 
Figure 4. 1 Plasma glucose concentrations  
Values are least squared means ± SE. Figure A represents basal glucose concentrations in control 
(white bars) and dexamethasone (black bars) treated horses on each day. a,b Different letters 
indicate differences between days within treatment group (P < 0.05). *Significant difference 
between treatment groups on each day (P < 0.05). Figure B represents glucose responses (delta: 
90 min post OST concentrations – pre OST concentrations, mmol/L) in control (white bars) and 
dexamethasone (black bars) treated horses on each day. Data was analyzed with a repeated 
measures analysis with a compound symmetry variance-covariance structure. N = 6 control and n 
= 6 dexamethasone treated horses.  
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Figure 4. 2 Plasma insulin concentrations 
Values are least squared means ± SE. Figure A represents basal insulin concentrations in control 
(white bars) and dexamethasone (black bars) treated horses on each day. Figure B represents 
insulin responses (delta: 90 min post OST concentrations – pre OST concentrations, µIU/mL) in 
control (white bars) and dexamethasone (black bars) treated horses on each day. a,bDifferent 
letters indicate differences between days within treatment group (P < 0.05). *Significant 
difference between treatment groups on each day (P < 0.05). Data was analyzed with a repeated 
measures analysis with a heterogeneous-autoregression variance-covariance structure. N = 6 
control and n = 6 dexamethasone treated horses. 
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Figure 4. 3 Muscle protein expression in response to the OST 
Values are least squared means ± SE of muscle protein expression that differed significantly 
between pre (white bars) and post (black bars) OST samples regardless of treatment or sample 
day (P < 0.05 and 0.05 < P < 0.1). Data for Akt, rpS6, 4E-BP1 and mTOR represent the ratio of 
phosphorylated to total amount of each respective protein. Data for ULK-P represent the 
abundance of phosphorylated ULK-1 normalized to the total protein as determined by fast green 
stain. Data were analyzed with repeated measures analysis using a compound symmetry variance-
covariance structure for Akt, heterogenous autoregression structure for 4E-BP1 and a simple 
structure for rpS6, ULK and mTOR. N = 6 control and n = 6 dexamethasone treated horses. 
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Figure 4. 4 Muscle protein expressions affected by treatment 
Values are least squared means ± SE of muscle protein expression that differed significantly 
between dexamethasone treated horses (black bars) and controls (white bars) (P < 0.05). Figure 
A: overall abundance of mTOR (ratio phosphorylated/total mTOR protein), FoxO3 (ratio 
phosphorylated/total FoxO3 protein) and IRS-1 (ratio total IRS-1/total protein) which was 
affected by treatment regardless of day or time or biopsy. Figure B: expression of Akt (ratio 
phosphorylated/total Akt protein) and total abundance of myostatin (ratio total myostatin/total 
protein stain) in response to the OST (delta: post OST expression – pre OST expression) affected 
by treatment, regardless of day. Data were analyzed with repeated measures analysis using a 
compound symmetry variance-covariance structure. N = 6 control and n = 6 dexamethasone 
treated horses.  
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Figure 4. 5 Muscle protein expression affected by treatment by day interaction 
Values are least squared means ± SE of muscle protein expression that differed significantly 
between dexamethasone treated horses (black bars) and controls (white bars) or within each 
treatment group on each sample day either at basal level or in response to the OST (delta: post 
OST expression – pre OST expression) (P < 0.05 and 0.05 < P < 0.1). Figure A: Basal levels of 
total FoxO3, Figure B: Akt response. Data for FoxO3 represents the total FoxO3 protein 
abundance and Akt data represent the ratio of phosphorylated to total amount of protein. Data 
were analyzed with repeated measures analysis using a compound symmetry variance-covariance 
structure for Akt, and an antedependence structure for FoxO3. a,b,c Different letters indicate 
differences between days within treatment group (P < 0.05 and 0.05 < P < 0.1). *Significant 
difference between treatment groups on each day (P < 0.05 and 0.05 < P < 0.1). N = 6 control 
and n = 6 dexamethasone treated horses 
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Protein  Phosphorylated form Total form 
 MW (kDa) Pre OST Post OST Pre OST Post OST 
IRS-1 180 NA  
Akt 60 
 
 
mTOR 289   
rpS6 32   
4E-BP1 15-20   
AMPK 62   
FoxO3 82-97 
 
 
Atrogin 41 NA  
Myostatin 42 NA  
NF-κB 65 
 
NA 
ULK 140-150 
 
NA 
 
Figure 4. 6 Representative images of the immunoblots 
The images represent phosphorylated (left two columns) and total form (right two columns) of 
each protein before and after administration of an OST.  
Akt phosphorylated at Ser473, mTOR phosphorylated at Ser2448, rpS6 phosphorylated at Ser235/236 
and Ser240/244, 4E-BP1 phosphorylated at Thr37/46, AMPK phosphorylated at Thr172, FoxO3 
phosphorylated at Ser253, NF-κB p65 phosphorylated at Ser536, ULK phosphorylated at Ser757.  
NA: not applicable; MW, molecular weight, kDa, kilodaltons. 
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CHAPTER 5  
A HIGH PROTEIN MEAL AFFECTS PLASMA INSULIN CONCENTRATIONS 
AND AMINO ACID METABOLISM IN HORSES WITH EQUINE METABOLIC 
SYNDROME 
 
Abstract 
Equine metabolic syndrome (EMS) is a common clinical condition characterized 
by a variety of metabolic abnormalities. It is well known that this endocrine disease is 
associated with an abnormal insulin response to a glycemic challenge but there is a 
paucity of data that addresses the influence of dietary protein load on insulin dynamics in 
horses with EMS. Accordingly, our objective was to evaluate postprandial glycemic and 
insulinemic responses to a high protein meal in healthy and EMS horses. Twelve mature 
horses of mixed breed and gender were used, of which 6 were classified as EMS and 6 
were non-EMS, age-matched controls. Following an overnight fast, horses were fed 
2g/kg BW of a high protein pellet (31% CP) at time 0 and 30 minutes. Blood samples 
were collected throughout the 4 h period and analyzed for plasma glucose, insulin, amino 
acid and urea concentrations. Glucose concentrations were elevated over baseline levels 
in all horses after feeding (P = 0.0002), but were not different between groups (P = 0.2). 
Horses with EMS had a 9-fold greater insulinemic response to the consumption of a high 
protein meal compared with controls (P = 0.049). Most plasma amino acid concentrations 
were elevated over baseline level in all horses but postprandial levels of histidine, 
citrulline, tyrosine, valine, methionine, isoleucine, leucine and ornithine were higher in 
EMS horses (P < 0.05). Conversely, baseline plasma glutamate, asparagine and urea 
nitrogen concentrations tended to be lower in horses with EMS (0.05 < P < 0.1). With 
the knowledge that certain amino acids act as insulin secretagogues, these findings 
provide evidence that dietary protein content must be taken into consideration to avoid 
exacerbation of the condition. This study demonstrates that the intake of a high protein 
meal causes a hyperinsulinemic response and affects amino acid metabolism in horses 
with EMS. 
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5.1. INTRODUCTION 
Equine metabolic syndrome (EMS), named after a similar condition in obese 
humans, is now an officially accepted term to describe a cluster of symptoms associated 
with endocrinopathic laminitis [369]. The three core components of EMS are increased 
adiposity (general or regional), insulin dysregulation (ID) and a predisposition toward 
laminitis [272]. Because weight loss and improved insulin sensitivity reduce the risk for 
laminitis [216, 370], research has focused on management and preventative strategies to 
reduce obesity and ID, in particular on using nutrition as a modulating tool. It has been 
well established that obese, ID horses and those with EMS have elevated basal insulin 
levels and an exacerbated insulin response to an oral or intravenous glycemic challenge 
[27, 40, 217, 245, 357, 371-373]. Additionally, consumption of diets high in non-
structural carbohydrates (NSC) can induce or worsen ID and increase the risk for the 
development of laminitis [215, 250, 251]. These findings have resulted in the exclusion 
of high glycemic feedstuffs, such as processed grains and rich pasture, from the diets of 
horses with EMS. Although NSC are a primary concern in the diets of horses with ID, 
little attention has been given to the effects of other dietary components, such as protein, 
on insulin and glucose dynamics. 
Evidence in human literature clearly shows that protein metabolism is altered in 
subjects with ID and that insulin resistance affects not only glucose but also protein and 
lipid metabolism [224, 226, 229]. Elevated levels of plasma amino acids, as often 
observed in obese and diabetic humans, have been strongly correlated with fasting insulin 
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levels and insulin sensitivity [45, 225]. More recent metabolomics-based studies have 
confirmed this correlation between ID and perturbation of normal amino acid 
metabolism, showing that elevations of specific amino acids are associated with the risk 
of developing future diabetes [227]. Specifically, branched chain amino acids (BCAA) 
and their metabolites seem to be strongly associated with ID, making them a potential 
early biomarker to identify diabetes [228]. Whether an altered amino acid profile is a 
cause or the consequence of abnormal insulin metabolism is not entirely clear. The 
underlying physiological mechanisms may involve accelerated protein turnover and/or 
decreased insulin stimulated amino acid uptake and use for protein synthesis, leading to 
increased circulating amino acids [44]. Excessive amino acid availability has been shown 
to contribute to ID and induce skeletal muscle insulin resistance through a negative 
feedback loop involving the over-activation of the mechanistic target of rapamycin 
pathway (mTOR), a central player in nutrient metabolism. It was reported that 
overactivation of mTOR by amino acids leads to decreased cellular insulin sensitivity and 
therefore reduced insulin stimulated glucose uptake [95].  
Conversely, the strong insulinotropic effect of certain amino acids has long been 
known in healthy humans and animals, including horses [177, 196-200]. Interestingly, the 
stimulatory effect of amino acids is often stronger in humans suffering from conditions 
with underlying ID, such as diabetes and obesity [209]. It is also well-known that the 
combined intake of carbohydrate and protein has a synergistic stimulatory effect of on 
plasma insulin concentrations [195, 203, 204, 374]. In horses, simultaneous 
administration of glucose and leucine resulted in a greater insulin response in comparison 
to glucose alone [195, 205]. This synergistic effect is maintained in humans with type 2 
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diabetes mellitus (T2DM), indicating that amino acids provide a glucose-independent 
stimuli to the pancreatic beta cells [207]. Moreover, consumption of a protein-
carbohydrate mixture seems to have glucose-lowering effects in subjects with T2DM, 
making certain protein sources a potential beneficial dietary component in the 
management of the disease [194, 213]. Although this glucose lowering effect was not 
observed in healthy horses given a combination of glucose with leucine or whey protein 
[195], the effects in horses with EMS in not yet known. 
Despite the clear evidence that amino acids can modulate insulin and glucose 
dynamics, there is a paucity of data examining the impact of dietary protein on the 
pathogenesis of ID in equine metabolic syndrome. Considering equine diets often provide 
protein levels exceeding daily requirements, it is essential to improve our understanding 
of amino acid metabolism in horses affected by EMS to avoid worsening or predisposing 
horses to this condition. The objective of this study therefore was to evaluate the effects 
of a meal high in protein on plasma glucose, insulin and amino acid metabolism in horses 
with EMS. 
5.2. MATERIALS AND METHODS 
5.2.1. Animals and housing 
A total of 12 mature horses, of mixed breed and gender, were used from the 
University of Kentucky’s Department of Veterinary Science, Woodford farm (Table 5.1).  
Six of these horses were diagnosed with EMS and another six were age matched non-
EMS controls (CON). Within the EMS group there was one Tennessee walking horse, a 
Standardbred cross, a Warmblood mix, a Morgan and two mixed breed horses of which 
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there were two geldings and four mares. The control group had three thoroughbred 
horses, a quarter horse and two mixed breed horses of which there was one gelding and 
five mares. 
EMS status in the horses was determined according to criteria described by the 
ACVIM consensus statement [23] which included general and regional adiposity, insulin 
dysregulation and a history or predisposition to laminitis. Obesity and assessment of 
regional adiposity was determined by body condition score (BCS) and “cresty neck 
score” (CNS) according to systems designed by Henneke and Carter et al [375, 376]. 
Horses with increased adiposity, a BCS  > 6.5 and a CNS greater than 2.5 were included 
in the EMS group. The selected horses also had a known history of/or predisposition to 
laminitis. Insulin dysregulation was assessed from basal blood samples and an oral sugar 
test (OST) conducted before their morning meal, as described previously [217]. Briefly, 
two blood samples were collected via jugular venipuncture before and 90 min after 
receiving an oral administration of 150mg/kg BW (0.15mL/kg BW) of dextrose derived 
digestible sugars (Karo light corn syrup, ACH Food Companies). Horses with baseline 
hyperinsulinemia (>20µIU/mL) and an increased insulin response to the oral sugar 
challenge (>60µIU/mL) were classified as being insulin dysregulated (Table 5.1). To 
exclude horses with pituitary pars intermedia dysfunction, a thyrotropin releasing 
hormone (TRH) stimulation test was done, as previously described [377]. Briefly, a 
baseline blood sample was collected, followed by an intravenous injection of 1mg/mL of 
TRH dissolved in 0.9% saline (Sigma-Aldrich) and a second blood sample 10 min later. 
Blood was collected in ethylenediaminetetraacetic acid tubes, transported on ice and 
plasma removed immediately after centrifugation. Plasma samples were shipped on dry 
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ice to Cornell University Animal Health Diagnostic Center’s Endocrinology Laboratory 
for analysis of adrenocorticotropic hormone (ACTH) concentrations (Automated 
chemiluminescent enzyme immunoassay system, Immulite). Based on the equine 
endocrinology group’s recommendations, horses with ACTH concentrations >110 pg/mL 
10 min post TRH injection were excluded from the study. All phenotypic measures taken 
are presented in Table 5.1.  All horses were housed at the University of Kentucky’s 
Woodford farm facilities and maintained on minimal pasture with ad libitum access to a 
mixed grass hay, water and salt blocks. The Institutional Care and Usage Committee of 
the University of Kentucky approved all methods. 
5.2.2. Experimental procedures 
All horses remained in their normal pastures during the time of study and all hay 
was removed in the afternoon on the day prior to sample collection. Due to poor pasture 
condition, intake of any remaining grass was assumed to be negligible. An 18h feed 
withholding period is believed to provide sufficient time to empty the small intestine, the 
primary site of glucose and amino acid absorption, without eliciting a starvation state and 
has been previously used in horses to study insulin signaling pathways [57]. On the 
morning of sampling procedures (0700h), horses were moved into individual pens with 
continuous access to water. After local desensitization of the overlying skin with 0.5 mL 
of 2% lidocaine hydrochloride, a 14-G, 9 cm catheter (Milacath, Mila international, Inc.) 
was aseptically inserted into one jugular vein of each horse. Catheters were fitted with an 
extension set, sutured against the neck and patency maintained by flushing with 10 mL of 
heparinized 0.9% sodium chloride solution. All horses were allowed to recover from 
catheterization procedures for approximately one hour after which they were fed 2g/kg 
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BW, on an as-fed basis, of a commercially available high protein balancer pellet (M30, 
main protein sources are soybean and alfalfa meal, McCauley Bros, Versailles, KY; 
Table 5.2) at 0 min and 30 min for a total intake of 4g/kg BW. This feeding regime has 
previously shown to induce differences in plasma glucose, insulin and amino acids 
concentrations in horses [14, 57].  Feed intake was monitored and any unconsumed feed 
was removed and weighed at the end of the sample period. After the collection of a 
baseline venous blood sample, the first meal was fed (t = 0 min). Subsequent blood 
samples (10 mL) were taken at 15 min intervals for 60 min and every 30 min thereafter 
until t = 240 min. All samples were collected in evacuated tubes with sodium heparin and 
centrifuged as soon as possible. Plasma was removed and stored at -20 °C until further 
analysis. A sample of the high protein balancer pellet was sent to DairyOne (Ithaca, NY, 
USA) for proximate nutrient analysis (Table 5.2). Amino acid composition of the feed 
was analyzed using high performance liquid chromatography (HPLC), as described 
below. 
5.2.3. Plasma glucose and insulin analysis 
Plasma glucose concentrations were determined enzymatically using an 
automated analyzer (YSI 2700 Select Analyzer, YSI Inc. Life Sciences). Plasma insulin 
levels were assayed using a commercially available radioimmunoassay kit (Porcine 
insulin RIA, Millipore Sigma) which has previously been used for analysis of equine 
insulin and validated in our lab by running parallelisms. The inhibition curves produced 
by adding decremental volumes of diluted plasma were parallel to the insulin standards. 
All samples for each assay were run in duplicate and within the same day. Insulin intra-
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assay coefficient of variation for low and high quality controls was 11.8% and 11.6%, 
respectively. 
5.2.4. Amino acids 
Plasma free amino acid concentrations and feed amino acid content were 
determined by reserve-phase HPLC of phenyisothiocyanate derivatives, as previously 
described [57]. Methionine content of the feed was determined by performic acid 
oxidation prior to acid hydrolysis procedures, as previously described [338].   
5.2.5. Plasma urea  
Plasma urea nitrogen concentrations were assayed using a spectrophotometric 
enzymatic assay as previously described (Millipore Sigma) [339], with an intra-assay 
coefficient of variation of 4.6 %. All samples were run as a single batch to avoid any 
effects of inter-assay variation. 
5.2.6. Data analysis 
All data were analyzed using mixed and glimmix procedures of SAS version 9.3 
(SAS Institute Inc.) with significance set at P < 0.05. Statistical trends were considered 
when 0.05 < P < 0.10. One horse in the EMS group did not consume the feed in a timely 
manner, therefore only its baseline values were included in the statistical analysis. 
Treatment group (EMS status) and time point were considered fixed effects and horse 
nested within group as the random subject. When fixed effects were significant, least 
square means were compared using a pdiff test. Area under the response curve, time to 
peak and peak plasma concentrations of all dependent variables were analyzed with a 
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one-way ANOVA, with group as the fixed effect and horse nested within group as the 
random subject. Glucose, insulin, amino acid and urea concentrations were analyzed 
using repeated measures, with group, time and their interaction as the fixed effects and 
horse nested within group as the random subject. For all repeated measures, the variance-
covariance matrix was chosen based on lowest values for respective fit statistics. Because 
plasma insulin concentrations had a non-normal distribution and heterogeneous 
variances, these values were transformed to their natural logarithm before statistical 
analysis. After analysis, the least squared means were back-transformed to give the 
geometric mean. To give an indication of degree of variation for this parameter, plasma 
insulin concentrations will be presented with their 95% CI, since a pooled standard error 
cannot be reported for back-transformed means. Otherwise, all data are presented as least 
square means and standard error of the mean. 
5.3. RESULTS 
5.3.1. Plasma glucose  
There was no significant effect of group or group by time interaction on plasma 
glucose concentrations (P > 0.05) (Figure 5.1). There was a an overall effect of time (P = 
0.0002) which showed that plasma glucose concentrations were elevated over baseline 
level at 150 min and remained elevated for all time points thereafter. Baseline and peak 
glucose concentrations, time to peak, and glucose area under the curve (Table 5.3) were 
not different between groups (P > 0.05). It is important to note there was a large inter-
horse variation and that glucose concentrations in several horses fell below baseline over 
time resulting in a negative area under the curve, thereby lowering the overall average 
values.  
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5.3.2. Plasma insulin  
There was a significant effect of group (P = 0.001), time (P < 0.0001) and group 
by time interaction (P = 0.03) on plasma insulin concentrations. Feeding increased insulin 
concentrations over baseline levels at 30 and 45 min for EMS and control horses 
respectively, and for all time points thereafter in both groups (P < 0.05) (Figure 5.2). 
Insulin concentrations over time were higher in EMS horses versus control horses at time 
= 15 min and for all time points thereafter (P < 0.05) (Figure 5.2). Geometric means of 
insulin concentrations and associated 95% CI are presented in Table 5.4. Separate 
analysis of non-transformed baseline insulin concentrations showed that EMS horses had 
higher basal insulin levels vs control horses (P = 0.02) (Table 5.3). Peak insulin 
concentrations were higher in EMS horses vs control horses (P = 0.03) but time to reach 
peak insulin levels did not differ between groups (P > 0.05) (Table 5.3). Insulin area 
under the curve was 9-fold larger in horses with EMS versus control horses (Table 5.3).  
5.3.3. Plasma urea 
There was a significant effect of time (P = 0.03) on plasma urea nitrogen (PUN) 
concentrations in both groups. Postprandial PUN concentrations were higher at 240 min 
versus 120 min in both groups (P = 0.02) but not different from baseline concentrations 
(P > 0.05) (Figure 5.3). There was a trend (P = 0.1) for baseline plasma urea nitrogen 
(PUN) concentrations to be lower in horses with EMS (5.2 ± 0.4 mmol/L) in comparison 
to the control horses (6.1 ± 0.4 mmol/L).  
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5.3.4. Plasma amino acids 
There was a significant time effect for all plasma amino acids measured with the 
exception of citrulline, glycine and glutamine (P < 0.05) (Table 5.5). There was a 
significant group effect for plasma glutamate, histidine, citrulline, valine, methionine, 
isoleucine, leucine and ornithine and a significant group by time effect for histidine (P < 
0.05) (Table 5.5). For plasma amino acids affected by time, there was a general increase 
over baseline levels at approximately 30-45 min after feeding the first meal, and for all 
time points thereafter. Horses with EMS had lower overall plasma glutamate 
concentrations but higher levels of citrulline, valine, methionine, isoleucine, leucine and 
ornithine in comparison with control horses. Postprandial plasma histidine concentrations 
were higher in EMS horses at 90 min and all time points thereafter compared to control 
horses. Peak plasma concentrations were similar between groups with the exception of 
isoleucine and ornithine, which were higher in horses with EMS. Peak plasma isoleucine 
concentrations were 128 ± 9 and 159 ± 10 µmol/L for control and EMS horses, 
respectively (P = 0.04). Peak plasma ornithine concentrations were 90 ± 8 and 122 ± 9 
µmol/L for control and EMS horses, respectively (P = 0.02). Peak plasma tyrosine (P = 
0.09), valine (P = 0.06), methionine (P = 0.06) and leucine ((P = 0.09) also tended to be 
higher in EMS horses vs controls. Average time to reach peak amino acid concentrations 
was 168 ± 16 and 166 ± 14 min post-feeding the first meal for EMS and control horses, 
respectively, but was not different between groups for any of the amino acids measured 
(P > 0.05).   
Baseline aspartate levels were lower in EMS (6 ± 1 µmol/L) versus control horses 
(11 ± 1 µmol/L) (P = 0.04). Glutamate (P = 0.09) and asparagine (P = 0.06) 
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concentrations tended to be lower in EMS horses and were 53 ± 5, 37 ± 5, 43 ± 5 and 31 
± 5 µmol/L for CON asparagine, EMS asparagine, CON glutamate and EMS glutamate, 
respectively. 
5.4. DISCUSSION 
The consumption of two meals high in crude protein, separated by 30 minutes, 
resulted in a hyperinsulinemic response in horses diagnosed with EMS. Additionally, this 
study is also the first to provide evidence of differences in pre- and postprandial amino 
acid profiles between EMS and non-EMS controls. Together with a tendency for lower 
PUN concentrations, these results suggest that horses with EMS may also have altered 
amino acid metabolism, which could play a role in the pathophysiology of the disease. In 
accordance with data in other species, the findings supported the hypothesis that high 
levels of dietary protein contribute to an exacerbated postprandial insulin surge in obese, 
ID horses. 
Postprandial glucose responses were not different between groups, which is in 
accordance with previous data in obese, ID horses [26, 27]. In contrast to other species, 
most horses maintain pancreatic capacity to secrete adequate amounts of insulin to 
maintain glycemic control, even in conditions of insulin resistance [378, 379]. 
Insulin concentrations were elevated over baseline levels by 30 minutes after 
feeding the first meal and remained elevated for the rest of the sample period in the EMS 
group. Neither glucose nor insulin concentrations returned to baseline levels by 240 min. 
Other studies reported a timeframe of 240-420 minutes before glucose and insulin 
returned to baseline levels in healthy horses, depending on the composition of the 
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feedstuffs [176, 186]. Moreover, data in ID horses showed that insulin concentrations 
were still highly elevated at 4h after feeding an energy rich diet [245]. Therefore, the 4h 
blood sampling period, together with a 30 minute interval between meals, was likely too 
short for these blood values to return to normal. This delayed decline in plasma insulin 
levels was expected in EMS horses and has been previously attributed to both 
hypersecretion of insulin and decreased hepatic insulin clearance in obese, ID humans 
and horses [214, 379-382]. Mean time to reach peak insulin levels was not different 
between groups however, the chosen feeding strategy may have affected the calculated 
mean time to reach peak levels. The first insulin peak was reached by approximately 90 
minutes post feeding in control horses but not until 150 minutes in EMS horses. With all 
horses having consumed their meals in approximately equal amounts of time, this 
delayed insulin peak indicated that postprandial release of insulin might be altered in 
horses with EMS. A delay in initial postprandial insulin secretion and insulin peak has 
been previously shown in humans with T2DM and has been attributed to decreased 
pancreatic responsiveness to glucose and abnormal postprandial free fatty acid and 
glucagon levels [208]. Although the relationship between free fatty acids and pancreatic 
β-cell function in horses is not entirely clear, there is evidence of elevated plasma non-
esterified fatty acids and dyslipidemia in obese, ID horses which has been correlated to 
altered insulin responses [40, 233]. Additionally, it is known that the enteroinsulinar axis 
plays a major role in postprandial insulin response, and alterations in incretin secretion 
lead to inadequate insulin release in diabetic patients [383]. More recently, a change in 
enteroinsulinar dynamics has also been proposed to play a role in ID horses [245, 378]. 
Interestingly, although mainly sensitive to glucose, incretins are also stimulated by other 
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nutrients, including amino acids [384, 385]. The observed hyperinsulinemic response to a 
high protein meal in the current study suggests that further investigation of the effects of 
dietary protein levels on the enteroinsulinar axis in obese, ID horses is warranted. 
An exacerbated and/or prolonged insulin response following a glucose tolerance 
or insulin sensitivity test in horses with ID has been described in numerous studies, and 
the current study illustrated a similar response is seen following a high protein meal. 
Horses diagnosed with EMS had a 9-fold greater insulin response to nutrient influx from 
the diet. Postprandial hormonal responses are function of absorptive capacity of the 
gastro-intestinal tract and consequentially the appearance of nutrients into circulation. It 
is known that metabolic dysfunction can alter intestinal function and absorption of 
nutrients. For example, in horses it is known that small intestinal sodium/glucose co-
transporter expression adapts to dietary challenges [386], making modulation of nutrient 
transporter expression by disease a possible cause for dysfunction. Although there were 
no major differences in the rise of plasma glucose and amino acids between both groups, 
the dynamic inter-organ flux and tight homeostatic regulation of these metabolites could 
potentially disguise minor differences in absorption. A study in horses reported 
differences between glucose responses in normal and hyperinsulinemic horses following 
oral D-glucose administration suggesting potential changes in intestinal glucose transport 
[245]. Whether this is the case for other nutrients, including amino acids in horses with 
metabolic disease should be further investigated. 
As described previously, insulin secretion is stimulated via different pathways and 
although we cannot exclude the contribution of digestive hormones and a mixture of 
ingredients in the feed, the pellet contained only 13% non-structural carbohydrates (NSC) 
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(ethanol soluble carbohydrates, 11% and starch, 2%) which provided approximately 280g 
of NSC per 500 kg horse. Conversely, the total protein intake for both meals was 
intended to provide the total daily protein requirement for each horse according to NRC 
recommendations for idle horses. This feeding strategy has been previously shown to 
result in a substantial postprandial anabolic response and measurable changes in insulin-
mediated muscle signaling pathways [14]. Furthermore, these authors reported that 
mature horses had a greater insulinemic response to the high protein meal in comparison 
to yearling and two-year old horses [14]. This suggests that the anabolic effect of dietary 
amino acids could change with age and physiological status. This is in accord with 
studies in diabetic humans, showing evidence of increased pancreatic sensitivity to the 
insulinotropic effects of amino acids under conditions of reduced glucose sensitivity 
[207]. Additionally, the synergistic effect of amino acid and glucose administration on 
insulin responses has been well described in various species including horses and is 
maintained in humans with T2DM [195, 203, 204, 207]. Whether pancreatic sensitivity to 
amino acids or glucose is altered in horses with EMS is currently unknown, but our data 
clearly illustrates that relatively small amounts of dietary NSC combined with high 
protein induces a significant increase in circulating insulin. We therefore believe that the 
ingested amino acids contributed significantly to the hyperinsulinemic response seen in 
this study. However, further research is warranted to single out the effects of ingested 
amino acids on insulin responses in horses. 
In addition to their postprandial insulinotropic effects, altered amino acid 
metabolism has been associated with the development of human diabetes and correlated 
to insulin sensitivity [45, 228]. Moreover, it has been suggested that specific amino acid 
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profiles could be used as early biomarkers to identify diabetes [387]. To the best of our 
knowledge, the current study was the first to evaluate pre- and postprandial amino acid 
profiles in obese, ID horses. Basal aspartate levels were lower and glutamate and 
asparagine tended to be lower in horses with EMS. Similar observations for these amino 
acids have been reported in mature horses when compared to two-year old and yearling 
horses. Interestingly, these authors also reported the mature horses to be less insulin 
sensitive compared to their younger counterparts [14]. Lower basal glutamate levels have 
also been reported in obese woman [334]. Asparagine, glutamate and aspartate play key 
roles in many important metabolic functions such as the urea and Krebs cycle, 
gluconeogenesis and maintenance of the acid-base balance. In particular, glutamate and 
aspartate are essential nitrogen (N) scavengers and are key components of the urea cycle, 
which is tightly regulated by substrate availability [55]. Lower plasma levels of these 
amino acids in EMS horses could indicate a shift in nitrogen metabolism and mechanisms 
of disposal. A tendency for lowered basal plasma urea nitrogen (PUN) levels in EMS 
horses further supports this hypothesis. Low substrate availability might have contributed 
to decreased urea cycle activity in these horses, which is consistent with data in other 
species with metabolic syndrome. Diet-induced obesity in rats resulted in decreased urea 
excretion due to decreased amino acid uptake by the liver and decreased hepatic activity 
of key urea cycle enzymes [388]. Similarly, genetically obese pigs had lower serum urea 
concentrations in comparison to their lean counterparts [389]. Another study 
demonstrated that high-energy diets inhibited urea cycle function and inter-organ amino 
acid metabolism, further contributing to a surplus amino acid availability and decreased 
urea formation [390]. 
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With the exception of citrulline, glycine and glutamine, plasma amino acid levels 
were elevated above baseline levels approximately 30-45 minutes after receiving the first 
meal in all horses, indicating that dietary protein was absorbed. Average time to reach 
peak amino acid concentrations was not different between the groups, indicating similar 
rates of absorption. Postprandial plasma amino acid concentrations in the control horses 
were similar to those observed in healthy horses using a similar feeding strategy [14, 57]. 
Feed intake also significantly increased circulating PUN concentrations by the end of 
blood sampling regardless of metabolic status, indicating upregulation of nitrogen 
catabolism. Previous data in horses also showed increased PUN concentrations when fed 
high protein diets [62]. It has been suggested that postprandial PUN levels at 4 h best 
predict daily urinary nitrogen excretion [391]. This suggests that ingestion of the high 
protein meal in this study likely exceeded the capacity to use the large influx of amino 
acids therefore shunting them into catabolic pathways. 
Horses with EMS also had overall lower postprandial levels of plasma glutamate, 
but higher concentrations of histidine, citrulline, valine, methionine, isoleucine, leucine 
and ornithine. In healthy mature horses, postprandial glutamate and aspartate were 
reported to be lower compared to yearling and two-year old horses, using a similar 
feeding strategy [14]. Unfortunately, the majority of published amino acid profiles in 
obese and insulin resistant subjects are from fasted states and little data is available on the 
effect of high protein intake on immediate postprandial amino acid levels in horses or 
other species. There is however, a vast body of evidence illustrating the relationship 
between elevated fasted levels of the BCAA valine, isoleucine and leucine and obesity, 
insulin resistance and T2DM in humans [226, 228]. Whether these elevations in BCAA 
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are cause or effect of ID is still somewhat controversial but it is suggested to be caused 
by their reduced catabolism [392]. It has been shown that activity of branched-chain α-
ketoacid dehydrogenase complex (BCKD) is decreased in conditions of impaired insulin 
action and a free fatty acid – rich environment [230, 231]. This cellular environment 
leads to increased β-oxidation of fatty acids and accumulation of NADH which has 
shown to inhibit the BCKD complex [232]. Abnormal lipid profiles have been clearly 
illustrated in the EMS horse [233], therefore it is reasonable to believe that reduced 
activity of BCKD could be contributing to the observed elevations in BCAA in this 
study. It should be noted that these elevations were not seen in the fasted state but only 
became apparent following ingestion of the high protein meal. Considering normal 
postprandial inter-organ amino acid flux, a rise in plasma BCAA was expected as the gut 
and subsequently the liver readily release these amino acids into circulation following 
ingestion of a high protein meal. However, the distinct difference between the two horse 
groups could suggest that aberrations in the metabolism of specific amino acids might 
only be reflected under anabolic stimulation. This is consistent with findings in dietary-
induced obese rats showing that alterations in protein synthetic activity were only 
observed in response to nutrient ingestion and not in a basal state [393]. Although the 
relationship between BCAA’s and insulin function seems to be a consistent finding, 
elevated levels of other essential amino acids, such as methionine and histidine have also 
been implicated in diseases associated with ID and are in accordance with our 
observations in the current study [227, 394, 395]. 
In comparison to the essential amino acids, less information is available on 
changes in the metabolism of non-essential amino acids in an ID state. Horses with EMS 
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had elevated postprandial plasma citrulline and ornithine levels, which has also been 
reported in severely obese and non-obese, diabetic humans [42, 396]. As the intestinal 
cells are a major site of synthesis of these amino acids through a partial urea cycle, 
elevations in plasma citrulline and ornithine originating from portal drained viscera were 
expected. However, compromised gut function has received a lot of attention in relation 
to the pathophysiology of obesity and ID in several species [396, 397] and it has been 
suggested that horses with EMS have altered gut microbial profiles [398]. Evidence of 
the fluidity by which inter-organ amino acid fluxes rapidly shift in the face of stress or 
disease supports the hypothesis that gut amino acid metabolism could be altered in horses 
with EMS. Lastly, glutamate levels were overall lower in horses with EMS, which could 
suggest decreased synthesis or increased tissue extraction and utilization in these horses. 
Subtle shifts in glutamine and glutamate fluxes have been reported in high or low protein 
fed animals [399]. Alternatively, the aforementioned alterations in cellular redox status 
seen in obese individuals could also lead to increased use of glutamate as precursor for 
the synthesis of the antioxidant glutathione. 
A limitation of the study was the variation of horse breeds within the treatment 
groups, which might have contributed to the large individual variations in metabolic 
responses. Recent studies have illustrated the importance of breed differences in glucose 
and insulin responses, in particular related to the interpretation of insulin sensitivity tests 
[15]. Additionally, the total protein content provided by the two meals was intended to 
meet the total daily requirements for each horse, which might have caused a 
supraphysiological hormonal response. Typically, horses would consume this amount of 
protein over several meals throughout the day. This feeding strategy was chosen based on 
 
219 
 
previous studies where it was shown that this level of intake resulted in significant 
stimulation of muscle protein synthetic pathways. However, further studies should 
investigate the effects of providing feeds with different levels of protein as well as long-
term effects of elevated protein intake on amino acid and insulin metabolism, in 
particular in those horses susceptible to metabolic disease. 
In summary, this study demonstrated that horses with EMS had a 
hyperinsulinemic response to the consumption of two meals high in crude protein. 
Furthermore, distinct differences in the pre- and postprandial amino acid profiles between 
both groups are in accordance with previously reported data in obese and/or ID subjects. 
Although we cannot define a causative relationship between protein intake and ID, our 
findings suggest that EMS is associated with alterations in amino acid metabolism, which 
could further contribute to the pathophysiology of the disease. 
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5.5. TABLES 
 
Table 5. 1 Insulin concentrations before and 90 min post oral sugar test (OST), 
ACTH 10 min post TRH test, BCS, CNS, body weight and age 
Abbreviations: EMS, Equine Metabolic Syndrome; CON, control; ACTH, adrenocorticotropin hormone; 
BCS, body condition score; CNS, cresty neck score.   
Data are presented as least square means ± standard error of the mean. n = 6 CON and n = 6 EMS horses.  
  
Phenotypic measure EMS CON P-values 
Insulin OST 0min 
(μIU/ml) 
46.4 ± 4.3 14.6 ± 4.3 0.0004 
Insulin OST 90min 
(μIU/ml) 
92.6 ± 8.7 26.9 ± 8.7 0.0003 
ACTH (pg/ml) 29.3 ± 4.9 20.3 ± 4.9 0.2 
BCS 7.4 ± 0.4 6.2 ± 0.4 0.04 
CNS  2.9 ± 0.3 1.3 ± 0.4 0.02 
Body weight (kg) 579 ± 30 517 ± 30 0.2 
Age (years old) 17 ± 1.5 15 ± 1.5 0.5 
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Table 5. 2 As-fed nutrient composition of the high protein pelleted feed and nutrient 
intake (mg/kg of body weight) from the diet fed after a 18-hour fast in 12 horses. 
Nutrient 
Pellet  
composition (%)a 
Nutrient  
intake (mg/kg)b 
Dry matter 90.5 ± 0.14 NA 
   
Crude protein 31.13 ± 0.08 1245.2 ± 3.2 
Aspartate and asparagine 1.9 ± 0.37 76 ± 14.8 
Glutamate and glutamine 3.83 ± 0.44 153.2 ± 17.6 
Serine 1.12 ± 0.08 44.8 ± 3.2 
Glycine 0.81 ± 0.05 32.4 ± 2 
Histidine 0.64 ± 0.05 25.6 ± 2 
Arginine 1.71 ± 0.11 68.4 ± 4.4 
Threonine 0.84 ± 0.05 33.6 ± 2 
Alanine 0.88 ± 0.06 35.2 ± 2.4 
Proline 1.1 ± 0.07 44 ± 2.8 
Tyrosine 0.8 ± 0.05 32 ± 2 
Valine 0.98 ± 0.08 39.2 ± 3.2 
Methionine 0.36 ± 0.03 14.4 ± 1.2 
Isoleucine 0.99 ± 0.07 39.6 ± 2.8 
Leucine 1.81 ± 0.11 72.4 ± 4.4 
Phenylalanine 1.31 ± 0.08 52.4 ± 3.2 
Lysine 1.74 ± 0.13 69.6 ± 5.2 
 
  
Acid detergent fiber 8.15 ± 0.4 326 ± 16 
Neutral detergent fiber 12.53 ± 0.47 501.2 ± 18.8 
Water-soluble carbohydrates 12.67 ± 0.49 506.8 ± 19.6 
Ether-soluble carbohydrates 10.72 ± 0.18 428.8 ± 7.2 
Starch 1.81 ± 0.13 72.4 ± 5.2 
Non Fiber Carbohydrates 38.19 ± 0.32 1527.6 ± 12.8 
 
  
Calcium 3.87 ± 0.06 154.8 ± 2.4 
Phosphorus 1.87 ± 0.07 74.8 ± 2.8 
Magnesium 0.41 ± 0.01 16.4 ± 0.4 
Potassium 1.77 ± 0.08 70.8 ± 3.2 
Sodium 0.91 ± 0.004 36.4 ± 0.16 
 
  
Iron 715.4 ± 15.84† 2.86 ± 0.06 
Zinc 482.37 ± 19.95† 1.93 ± 0.08 
Copper 177.38 ± 19.48† 0.71 ± 0.08 
Manganese 311.32 ± 0.79† 1.24 ± 0.01 
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aValues represent the amount of the nutrient present as a portion of the total diet on an as-fed basis.  
bFollowing an 18-hour feed-withholding period, horses were given 2 equal meals of the pelleted feed 
(targeted total intake of 4g of feed per kg of body weight), separated by 30 minutes.  
NA = Not applicable 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5.2 continued   
   
Molybdenum 5.57 ± 0.06† 0.022 ± 0 
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Table 5. 3 Mean peak plasma glucose and insulin concentrations, mean time to peak 
and mean area under the curve for EMS and control horses 
Abbreviations: EMS, Equine Metabolic Syndrome; CON, control; AUC, Area under the curve. Data are 
presented as least square means ± standard error of the mean. n = 6 CON and n = 5 EMS horses, except for 
baseline values where data of all 6 EMS horses was used. 
  
Measure EMS CON P-values 
Baseline insulin (μIU/mL) 22.3 ± 2.3 13.2 ± 2.3 0.02 
Peak insulin (μIU/mL) 168.7 ± 40.0 34.8 ± 32.7 0.03 
Time to peak insulin  (min) 180 ± 22.6 135 ± 20.6 0.2 
Insulin AUC 27592 ± 8053 2825± 7351 0.05 
Baseline glucose (mmol/L) 4.5 ± 0.4 4.4 ± 0.4 0.8 
Peak glucose (mmol/L)  5.7 ± 0.4 5.2 ± 0.3 0.4 
Time to peak glucose (min) 180 ± 24.8 155 ± 22.7 0.5 
Glucose AUC 148.8 ± 65.1 15.3 ± 59.4 0.2 
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Table 5. 4 Geometric means of insulin concentrations (μIU/mL) over time and 95% 
confidence intervals for each time point after feeding a high- protein pelleted diet 
(2g/kg BW at 0 and 30 minutes) in EMS and control horses. 
Abbreviations: EMS, Equine Metabolic Syndrome; CON, control 
Data are presented as geometric least square means and the 95% confidence interval for plasma insulin 
concentration at each time point for both groups. Values were determined by repeated measures analysis of 
the natural logarithm transformed data, using a Toeplitz variance-covariance matrix. n = 6 CON and n = 5 
EMS horses, except for baseline values where data of all 6 EMS horses was used. ab Within time point 
values are significantly different between groups (P < 0.05)  
  
Time 
EMS  CON  
Mean 95% CI  
lower 
95% CI  
upper 
 Mean 95% CI  
lower 
95% CI  
upper 
 
         
Baseline 21.4 15.8 29.0  12.1 6.8 21.5  
15 23.0a 11.1 45.5  11.1b 6.9 17.8  
30 34.8 a 20.8 55.8  14.6 b 8.6 24.7  
45 49.7 a 27.5 85.9  18.7 b 12.4 28.1  
60 58.0 a 29.9 108.4  22.5 b 12.5 40.7  
90 89.2 a 47.7 160.5  27.8 b 18.1 42.6  
120 116.9 a 40.7 324.7  24.9 b 16.3 37.9  
150 134.8 a 48.8 359.2  26.2 b 16.8 41.0  
180 123.6 a 35.9 273.9  23.0 b 13.1 40.3  
210 127.9 a 30.2 327.8  23.1 b 11.8 45.0  
240 123.3 a 34.8 425.3  24.4 b 15.6 38.1  
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Table 5. 5 Mean postprandial plasma amino acid concentrations (µmol/L) over time 
in 5 horses with EMS and 6 healthy controls after feeding a high- protein pelleted 
diet (2g/kg BW at 0 and 30 minutes). 
  EMS  CON  P-values 
Amino acid Time Mean SE  Mean SE  Group Time Group*time 
Aspartate        NS 0.02 NS 
 Baseline 7 1  11 1     
 15 9 1.6  13 1.5     
 30 10 1.7  10 1.5     
 45 9 1.1  10 1.0     
 60 12 1.2  10 1.1     
 90 13 1.7  10 1.5     
 120 14 1.7  14 1.6     
 150 14 2.3  16 2.1     
 180 20 4.7  15 4.3     
 210 14 2.0  15 1.8     
 240 14 2.2  15 2.0     
Glutamate        0.04 NS NS 
 Baseline 32 5  44 5     
 15 36 4.7  45 4.3     
 30 35 4.3  46 3.9     
 45 36 5.2  44 4.7     
 60 39 3.4  48 3.1     
 90 43 5.2  40 4.7     
 120 44 5.3  49 4.9     
 150 44 4.8  51 4.4     
 180 49 6.8  51 6.2     
 210 41 5.8  54 5.3     
 240 44 7.4  52 6.7     
Serine        NS < 0.0001 NS 
 Baseline 223 14  235 13.0     
 15 242 15.2  233 14.6     
 30 235 14.2  242 13.3     
 45 288 26.9  264 25.0     
 60 291 19.9  278 18.3     
 90 324 22.1  272 20.3     
 120 352 23.5  303 21.5     
 150 360 26.5  299 24.2     
 180 349 23.9  301 21.8     
 210 346 20.4  303 18.6     
 240 340 18.8  310 17.2     
Asparagine        NS < 0.0001 NS 
 Baseline 37 5  55 5     
 15 38 6.1  53 5.9     
 30 42 5.2  55 5.0     
 45 55 7.4  64 6.9     
 60 64 5.9  68 5.4     
 90 83 7.3  83 6.8     
 120 113 13.2  104 12.1     
 150 125 14.8  106 13.5     
 180 129 15.6  102 14.2     
 210 123 14.0  106 12.8     
 240 115 12.1  108 11.1     
Glycine        0.07 NS NS 
 Baseline 413 49  436 49     
 15 446 24.0  385 21.9     
 30 426 22.1  396 20.7     
 45 460 42.1  425 40.2     
 60 463 30.2  422 27.7     
 90 473 33.0  394 30.3     
 120 489 29.3  414 26.8     
 150 498 29.3  401 26.8     
 180 514 25.3  404 23.1     
 210 497 43.8  380 40.0     
 240 502 29.9  416 27.3     
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Table 5.5 continued 
 
Glutamine 
        
NS 
 
< 0.0001 
 
NS 
 Baseline 390 29  406 29     
 15 409 31.1  402 29.3     
 30 394 31.1  429 29.3     
 45 448 31.1  450 29.3     
 60 469 31.1  488 29.3     
 90 507 31.1  470 29.3     
 120 576 31.1  528 29.3     
 150 593 31.1  514 29.3     
 180 566 31.1  516 29.3     
 210 573 31.1  527 29.3     
 240 564 31.1  542 29.3     
Histidine        0.03 < 0.0001 0.02 
 Baseline 66 5  65 5     
 15 66 5.5  61 5.1     
 30 69 5.5  67 5.1     
 45 83 5.5  71 5.1     
 60 90 5.5  80 5.1     
 90 101 5.5  80 5.1     
 120 112 5.5  91 5.1     
 150 114 5.5  90 5.1     
 180 108 5.5  91 5.1     
 210 105 5.5  87 5.1     
 240 102 5.5  82 5.1     
Citrulline        0.01 NS NS 
 Baseline 84 8  75 8     
 15 86 8.7  74 8.3     
 30 92 9.7  74 9.0     
 45 88 8.5  76 7.8     
 60 89 7.4  73 6.8     
 90 86 6.4  64 5.8     
 120 89 6.5  65 5.9     
 150 92 6.6  60 6.0     
 180 86 5.9  60 5.4     
 210 89 6.5  59 5.9     
 240 91 6.6  58 6.0     
Threonine        NS < 0.0001 NS 
 Baseline 89 11  101 11     
 15 92 11.7  94 11.3     
 30 93 12.0  97 11.3     
 45 120 12.2  107 11.3     
 60 123 12.3  112 11.3     
 90 149 12.3  123 11.3     
 120 172 12.3  138 11.3     
 150 182 12.4  140 11.3     
 180 180 12.4  149 11.3     
 210 173 12.4  146 11.3     
 240 175 12.4  150 11.3     
Alanine        NS < 0.0001 NS 
 Baseline 156 18  162 18     
 15 167 19.0  161 18.2     
 30 175 19.4  173 18.2     
 45 223 19.7  186 18.2     
 60 240 19.8  205 18.2     
 90 263 19.9  218 18.2     
 120 282 19.9  246 18.2     
 150 294 20.0  251 18.2     
 180 289 20.0  257 18.2     
 210 285 20.0  269 18.2     
 240 271 20.0  280 18.2     
Arginine        NS < 0.0001 NS 
 Baseline 87 7  100 7     
 15 100 7.2  96 6.9     
 30 110 6.6  103 6.1     
 45 152 14.3  127 13.3     
 60 165 11.4  140 10.5     
 90 198 13.1  165 12.0     
 120 238 24.7  191 22.6     
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Table 5.5 continued           
 150 237 25.8  187 23.6     
 180 230 21.9  187 20.0     
 210 221 23.3  189 21.3     
 240 211 22.9  204 20.9     
Proline        NS < 0.0001 NS 
 Baseline 55 5  66 5     
 15 59 5.2  63 5.0     
 30 65 4.5  67 4.2     
 45 85 8.2  83 7.6     
 60 97 8.5  92 7.9     
 90 114 8.6  110 7.9     
 120 134 15.1  127 13.8     
 150 138 17.3  127 15.8     
 180 135 13.9  127 12.7     
 210 125 15.2  131 13.9     
 240 118 12.1  137 11.1     
Tyrosine        0.04 < 0.0001 NS 
 Baseline 53 7  58 7     
 15 58 7.4  55 7.1     
 30 62 7.6  58 7.1     
 45 77 7.7  63 7.1     
 60 86 7.7  72 7.1     
 90 101 7.8  79 7.1     
 120 122 7.8  90 7.1     
 150 126 7.8  90 7.1     
 180 124 7.8  92 7.1     
 210 125 7.8  97 7.1     
 240 119 7.8  105 7.1     
Valine        0.02 < 0.0001 NS 
 Baseline 235 16  238 16     
 15 246 11.8  231 11.2     
 30 248 16.2  245 14.9     
 45 291 21.0  255 19.3     
 60 303 23.0  278 21.0     
 90 331 13.6  278 12.5     
 120 369 24.1  298 22.0     
 150 380 27.8  294 25.4     
 180 366 21.7  302 19.8     
 210 364 18.3  311 16.7     
 240 357 15.7  322 14.3     
Methionine        0.02 0.01 NS 
 Baseline 29 2  26 2     
 15 32 2.2  24 2.1     
 30 30 2.2  26 2.1     
 45 37 4.3  29 4.0     
 60 41 4.6  29 4.2     
 90 44 3.5  31 3.2     
 120 51 6.2  31 5.6     
 150 47 6.6  35 6.0     
 180 49 3.9  33 3.5     
 210 49 3.3  36 3.0     
 240 43 2.8  36 2.5     
Isoleucine        0.007 < 0.0001 NS 
 Baseline 70 7  74 7     
 15 76 7.3  68 7.0     
 30 79 7.5  74 7.0     
 45 101 7.6  79 7.0     
 60 109 7.6  90 7.0     
 90 124 7.6  99 7.0     
 120 143 7.6  108 7.0     
 150 148 7.6  107 7.0     
 180 144 7.6  112 7.0     
 210 141 7.6  118 7.0     
 240 136 7.6  121 7.0     
Leucine        0.04 0.0005 NS 
 Baseline 127 8  138 8     
 15 139 6.4  126 6.0     
 30 140 8.8  135 8.1     
 45 183 13.2  148 12.1     
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Table 5.5 continued           
 60 181 12.5  160 11.5     
 90 208 11.0  170 10.0     
 120 240 21.2  184 19.4     
 150 248 22.9  186 20.9     
 180 244 20.5  187 18.7     
 210 233 16.9  196 15.4     
 240 221 15.2  202 13.9     
Phenylalanine        NS 0.0001 NS 
 Baseline 50 3  58 3     
 15 56 3.7  57 3.5     
 30 57 3.1  59 2.9     
 45 72 8.3  63 7.6     
 60 71 5.0  69 4.6     
 90 81 7.9  71 7.3     
 120 94 7.6  78 6.9     
 150 97 7.5  78 6.8     
 180 97 6.7  80 6.1     
 210 92 5.9  83 5.4     
 240 89 6.7  87 6.1     
Tryptophan        NS 0.02 NS 
 Baseline 67 8  78 8     
 15 73 8.0  77 7.7     
 30 76 8.0  81 7.7     
 45 89 8.1  86 7.7     
 60 95 8.2  96 7.7     
 90 105 8.2  98 7.7     
 120 122 8.3  110 7.7     
 150 124 8.3  109 7.7     
 180 120 8.4  113 7.7     
 210 119 8.5  118 7.7     
 240 117 8.5  123 7.7     
Ornithine        0.004 < 0.0001 NS 
 Baseline 57 6  53 6     
 15 64 5.9  53 5.7     
 30 65 5.9  53 5.7     
 45 83 6.0  59 5.7     
 60 85 6.1  64 5.7     
 90 97 6.1  68 5.7     
 120 113 6.2  78 5.7     
 150 115 6.3  80 5.7     
 180 114 6.3  82 5.7     
 210 115 6.3  83 5.7     
 240 114 6.3  87 5.7     
Lysine        NS < 0.0001 NS 
 Baseline 86 13  104 13     
 15 107 19.1  101 18.8     
 30 127 18.7  110 18.0     
 45 191 20.8  143 19.9     
 60 214 30.5  161 28.8     
 90 277 35.4  201 33.3     
 120 349 61.7  241 57.6     
 150 358 60.7  248 56.4     
 180 342 46.3  248 42.8     
 210 326 44.7  248 41.2     
 240 311 40.1  269 36.9     
Abbreviations: EMS, Equine Metabolic Syndrome; CON, control; AUC, Area under the curve.   
Data are presented as least square means ± standard error of the mean. n = 6 control and n = 5 EMS horses, except for 
baseline values where data of all 6 EMS horses was used.  Data analyzed with repeated measures analysis using a 
compound symmetry variance-covariance structure for glutamine and histidine, toeplitz structure for tryptophan and 
ornithine, autoregression structure for isoleucine, tyrosine, alanine and threonine and a heterogeneous-autoregression  
variance-covariance structure for all other amino acids 
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5.6. FIGURES 
 
 
 
Figure 5. 1 Plasma glucose concentrations over time 
Plasma glucose concentrations (least square means ± pooled SE) for EMS (solid line) and control 
(hatched line) horses after feeding 2 equal meals of a high protein pelleted feed (targeted total 
intake of 4g of feed per kg of body weight), separated by 30 minutes as indicated by arrows.  N = 
6 CON and 5 EMS, except for baseline values for which data of all 6 EMS horses was used. Data 
analyzed with repeated measures analysis using a compound symmetry variance-covariance 
structure. *Within the time effect, values are different from the value at 0 minutes across groups 
(P < 0.05). 
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Figure 5. 2 Natural log of plasma insulin concentrations over time 
Plasma insulin concentrations for EMS (solid line) and control (hatched line) horses after feeding 
2 equal meals of a high protein pelleted feed (targeted total intake of 4g of feed per kg of body 
weight), separated by 30 minutes as indicated by arrows. Values represent natural logarithm 
transformed data (least square means ± pooled SE). N = 6 CON and 5 EMS, except for baseline 
values for which data of all 6 EMS horses was used. Data analyzed with repeated measures 
analysis using a Toeplitz variance-covariance structure. *Significant increment from basal value 
either for a specific sampling time within a treatment group when given singly or both groups 
when spanning a range of sampling times (P < 0.05). ab Within a time point, values are different 
between groups (P < 0.05). 
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Figure 5. 3 Plasma urea nitrogen concentrations over time 
Plasma urea nitrogen (PUN) concentrations (least square means ± pooled SE) for EMS (triangles) 
and control (squares) horses after feeding 2 equal meals of a high protein pelleted feed (targeted 
total intake of 4g of feed per kg of body weight. N = 6 CON and 5 EMS, except for baseline 
values for which data of all 6 EMS horses was used. Data analyzed with repeated measures 
analysis using a autoregression variance-covariance structure. ab Across groups, values are 
different between time points (P < 0.05). 
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CHAPTER 6  
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
It has been well established that insulin plays a pivotal anabolic role in whole-
body protein metabolism. It is to be expected that insulin dysregulation will disturb 
pathways regulating protein homeostasis. Furthermore, skeletal muscle is more than just 
a storage site for body protein, and is known to play an active role in the inter-organ 
nutrient fluxes thereby maintaining overall health. Consequently, shifts in muscle nutrient 
metabolism will trigger feedback mechanisms affecting sensitivity to the anabolic 
stimulus of insulin in order to ensure cell survival. This intricate relationship between 
insulin and protein metabolism explains why alterations in one system will impact the 
other. Additionally, insulin action can also be modulated by the activation of counter-
regulatory mechanisms, including excess availability of nutrients or their metabolites and 
insulin-antagonistic hormones such as glucocorticoids. Despite the fact that the anabolic 
and anti-catabolic role of insulin in protein metabolism is accepted as dogma, little 
research has been conducted regarding these pathways in horses.   
The aims of this research were to examine the muscle signaling pathways 
associated with protein synthesis and degradation, how insulin dysregulation would affect 
muscle protein metabolism and how this might be reflected in blood amino acid profiles. 
In the first three research Chapters, we used a glucocorticoid-induced model of insulin 
dysregulation, which has been used extensively in other species to study molecular 
mechanisms associated with muscle atrophy.  
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In Chapter 2, we found that 21 days of dexamethasone treatment induced 
substantial peripheral IR, increased basal concentrations of glutamine and alanine and 
resulted in overall higher amino acid concentrations in an insulin-stimulated state. 
Additionally, insulin-stimulated activation of downstream mTOR signaling components, 
rpS6 and 4E-BP1, was decreased. These findings indicate that prolonged GC treatment 
induced a catabolic state in which insulin-stimulated amino acid uptake and activation of 
protein synthetic machinery in skeletal muscle of mature horses was diminished. The 
conclusion that protein accretion was reduced was further supported by increased 
expression of atrogin-1, a muscle specific ligase that targets muscle differentiation 
regulatory proteins. Together the results in the 2nd Chapter gave strong indication that the 
molecular effects of GC resulted in disturbed insulin signal transduction and tipped the 
balance between protein synthesis and degradation in favor of catabolism.  
The beneficial effects of GC on health parameters, such as lung function in horses 
with RAO, are noticeable a couple hours after initial administration. Similarly, adverse 
effects of GC on insulin and glucose dynamics have been observed as early as 2h post-
treatment. With this knowledge, the objective of the following two studies was to 
evaluate whether molecular changes in protein metabolism pathways would be detectable 
after short-term dexamethasone treatment. In contrast to the 2nd Chapter, where a 
hyperinsulinemic-isoglycemic clamp was used to assess muscle insulin signaling, the 
following Chapters provided an anabolic stimulus that would more closely reflect 
postprandial metabolic responses, namely a high protein feed and an oral sugar bolus.  
In the 3rd Chapter, we illustrated that 7 days of dexamethasone treatment 
increased basal concentrations of insulin, glucose and several amino acids, including 
 
234 
 
glutamine and alanine, which was in accordance with the first study and suggests that 
horses were in a catabolic state with reduced tissue insulin sensitivity. Additionally, the 
insulin response to a high protein meal was 3-fold greater in dexamethasone-treated 
horses. This confirmed that GC induced a state of tissue IR and potentially affected 
insulin clearance and/or pancreatic response to amino acid influx, resulting in basal and 
postprandial hyperinsulinemia. Unexpectedly, the plasma increment of lysine and 
histidine and several non-essential amino acids following the high protein meal in 
dexamethasone-treated horses were lower than that in the control horses. We speculate 
that this could result from GC-induced alterations in normal tissue metabolism and flux 
of these amino acids, in particular that of the gut. Therefore, further studies are warranted 
to evaluate the effects of GC on gastro-intestinal function in horses.  
In contrast to the 2nd Chapter, the activation of mTOR, Akt and 4E-BP1 was 
maintained and rpS6 activation increased following the high protein meal in 
dexamethasone-treated horses. It has previously been shown that the amino acid 
stimulation of the kinase responsible for rpS6 activation (S6K1) is not affected by GC 
treatment. These results suggest that the insulin-independent mechanisms by which 
amino acids are able to stimulate protein synthesis, are functional in horse muscle tissue 
and may not have been strongly affected by short-term GC treatment. The discrepancy 
between the 2nd and 3rd Chapters indicate that prolonged dexamethasone treatment 
resulted in a more severe catabolic state compared to short-term treatment. A follow-up 
study looking at postprandial responses to a high protein meal after 21 days of 
dexamethasone treatment would provide further insight into these mechanisms. With the 
exception of the enhanced activation of AMPK, an indicator of low cellular energy, and a 
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trend for increased FoxO3 activation, we did not find an increase in any other proteolytic 
markers. Although we did not measure GLUT-4 function, GC-induced IR might have 
contributed to lower cellular energy availability and increased activation of AMPK.  
Although the provided meal contained a high amount of protein and low amount 
of non-structural carbohydrates, the hormonal and metabolic response to feed intake is 
complex, which limits defining causative relationships. We therefore cannot conclude 
that the observed effects on plasma insulin and protein signaling pathways were solely 
due to high protein intake. However, the results of the 3rd Chapter strongly suggest that 
short-term dexamethasone treatment did not significantly alter postprandial muscle 
protein synthetic capacity in the presence of amino acids. However, upregulation of 
certain proteolytic markers suggests the potential for an environment that favors muscle 
protein degradation. The effects of short-term GC treatment on glucose and insulin was 
transient and concentrations returned to basal levels by 7 days of recovery from 
treatment. 
As expected, insulin and glucose dynamics in the 4th Chapter were very similar to 
those in the 3rd Chapter. The results from the OST after 7 days of dexamethasone 
treatment indicated that the horses were insulin dysregulated, as illustrated by basal and 
post-OST hyperinsulinemia. Similar to the 3rd Chapter, an overall treatment effect 
illustrated reduced mTOR phosphorylation in dexamethasone-treated horses, however the 
post-OST activation of mTOR, 4E-BP1 and rpS6 was not different between treatment 
groups. Conversely, the overall Akt response was decreased in dexamethasone treated 
horses, which suggested a potential decrease in insulin signal transduction, although it 
must be noted that for unknown reasons Akt response increased in the control group 
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which may have driven this treatment effect. Therefore, it can be concluded that despite 
subtle changes detected in basal and post-OST mTOR pathway activation, short-term 
dexamethasone treatment did not significantly reduce insulin-stimulated protein synthetic 
capacity after ingestion of an oral sugar bolus. Similar to the 3rd Chapter, we observed 
increased total levels of AMPK, and increased activation of FoxO3. Additionally we 
measured an increase in basal total abundance of FoxO3 in dexamethasone-treated 
horses. Although this suggests increased FoxO3 activity, an important marker of protein 
degradation, we did not observe an increase in its gene target, atrogin-1, which was in 
contrast with results of Chapter 2. Additionally, dexamethasone-treated horses had a 
greater myostatin abundance post-OST, another important player in GC-mediated muscle 
atrophy. Collectively, these results indicate that proteolytic pathways were upregulated 
after 7 days of GC treatment.  
The discrepancy between results of Chapter 3 and 4 are not entirely clear, in 
particular for the postabsorptive measurements as they were obtained from the same 
horses over the same period of time. A potential increase in inflammation due to repeated 
biopsies may have contributed to these results as discussed in Chapter 3 and 4. Some of 
the post-anabolic differences might be explained by the nature of the two anabolic stimuli 
provided. Previous literature has clearly illustrated that the presence of amino acids is 
essential for full activation of the mTOR pathway and several studies have reported that 
muscle atrophy is prevented by the administration of amino acids. This might explain 
why upregulation of protein degradation was less evident in the second study compared 
to the third. However, the overall results of Chapters 3 and 4 indicate that short-term 
dexamethasone treatment did impact protein metabolism as evident from altered blood 
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amino acid profiles and upregulation of markers in protein degradation but that muscle 
protein synthetic capacity was maintained.  
Together these three Chapters were the first to investigate the effects of GC on 
mTOR signaling pathways in horses and suggest that long-term dexamethasone treatment 
might potentially result in muscle atrophy. It should be noted that the use of GC as a 
model for insulin dysregulation introduces interpretive limitations, as it is impossible to 
conclude that the observed effect are solely due to GC-induced IR. As previously 
described, GC mediate their catabolic effects through insulin-dependent and -independent 
genomic and non-genomic mechanisms, and impact other regulatory hormones such as 
glucagon and IGF-1, which were not measured in these Chapters. However, despite its 
limitations, the dexamethasone model still provides a potentially easy and useful tool to 
study the mechanisms underlying muscle atrophy in horses. 
As extensively discussed, the end-stage manifestations of insulin dysregulation 
can occur through a variety of pathophysiological processes. With the limitations of the 
GC-model in mind, the final objective of this research was to evaluate the postprandial 
blood insulin and amino acid response in horses with natural insulin dysregulation 
(Chapter 5). Interestingly, the exacerbated postprandial insulin response in horses with 
EMS was very similar to that observed in the GC-treated horses in the 3rd Chapter. 
However, it was notable that, although the insulin concentrations of both GC-treated and 
EMS horses reached peak levels of ~120-130 μIU/mL, the response lagged behind in 
horses with EMS. This suggests that dysfunction in other physiological systems are likely 
contributing to the observed postprandial insulin responses in horses with EMS, including 
gut, pancreas and liver function. Regardless, it is noteworthy that horses with naturally 
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occurring insulin dysregulation showed a 9-fold greater insulin response to a high protein 
meal compared to control horses.  
In accordance with results from the 3rd Chapter, the basal plasma concentrations 
of several amino acid were increased, although with the exception of isoleucine, these 
amino acids were not the same between the two Chapters. In EMS horses (Chapter 5), 
elevated basal levels were mostly essential amino acid whereas those elevated in GC-
treated horses were mainly non-essential amino acids. As expected, this indicates that 
alteration in amino acid and/or protein metabolism can be mediated through a variety of 
mechanisms. It is known that horses with EMS suffer from a multitude of metabolic 
abnormalities, including dyslipidemia and immune-mediated processes, which may all 
impact protein and amino acid metabolism. Further support of these conclusions was the 
difference in postprandial amino acid responses between GC-treated and EMS horses. 
More specifically, horses treated with GC had an overall smaller increment in plasma 
amino acid concentrations following the high protein meal whereas horses with EMS had 
higher concentrations of several amino acids compared to the control horses. However, it 
should be noted that the response to feeding in the 3rd Chapter was measured as the 
difference between 90 and 0 min blood samples, whereas the concentrations in the 5th 
Chapter were simply measured over time. Interestingly, the concentration of BCAA was 
elevated in EMS horses, a symptom that has been strongly associated with insulin 
dysregulation in human studies. The fact that blood BCAA levels have been proposed as 
early biomarkers for future development of diabetes in humans, warrants further 
investigation of their role in equine metabolic syndrome. Although we were not able to 
measure muscle protein signaling pathways in these horses, we did detect lower levels of 
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plasma urea nitrogen and specific amino acids involved in nitrogen transport. Together 
the findings of Chapter 5 suggest that naturally occurring insulin dysregulation in horses 
alters basal and postprandial amino acid metabolism and that further studies are needed to 
investigate protein metabolism at the tissue level. Furthermore, the excessive insulin 
response to a high protein meal strongly indicates that more research is necessary to 
investigate the impact of protein content in the feedstuffs of these horses. 
Overall this research confirmed our hypothesis that whole-body protein 
metabolism is impacted by conditions associated with insulin dysregulation in horses. We 
showed that both short and prolonged treatment with synthetic glucocorticoids shifted 
blood amino acid profiles and activated muscle proteolytic pathways. Furthermore, these 
studies illustrated that the response of muscle protein signaling depends on the nature of 
the anabolic stimuli. This emphasizes the need for further research regarding the 
influence of protein quantity and quality on the maintaining muscle mass in horses 
affected by insulin dysregulation. Additionally, the evidence of altered blood amino acid 
profiles in these horses indicates that more research is necessary to evaluate the 
contribution of abnormal protein metabolism in the development of equine metabolic 
diseases. Increasing our understanding of the molecular mechanisms underlying equine 
insulin dysregulation will allow earlier diagnosis and further improve treatment and 
preventative strategies. 
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APPENDIX  
 
A.1 Antibody validations for western immunoblot analysis  
Of the antibodies used in the research Chapters total and ser473 Akt, total and Ser235/236 
and Ser240/244 rpS6, total and Thr37/46 of 4E-BP1, total and Thr172 AMPK, total and Ser536 
NF-κB p65, atrogin-1, MuRF-1 and myostatin were previously validated in our lab for 
determination of these protein in equine muscle tissue [14, 132]. The following are 
images of the validations for total and Ser2448 mTOR, Ser253 FoxO3 and total IRS.  
 
 
 
A.1.a An example of total mTOR antibody validation 
To determine cross species reactivity of the primary and secondary antibodies used to 
measure abundance of 289 kDa mTOR, one aliquot of pooled muscle sample and four 
randomly picked (2 pre-DEX and 2 post-DEX samples) equine gluteal muscle samples 
from two horses used in Chapters IV and V were loaded into polyacrylamide gels (6%). 
Each sample was loaded in duplicate onto 1 gel with an empty well between the two sets 
of 5 equine samples. Two molecular markers (Spectra and Magic Mark) were also loaded 
onto each gel, one serving to follow separation during electrophoresis (Spectra) while the 
order was used verify the molecular weight of the protein bands after 
chemiluminescence. After separation by electrophoresis, the proteins were transferred 
onto a PVDF membrane and stained with Fast Green stain to verify if the protein transfer 
was successful. More information about the electrophoresis, transfer and staining 
220 kDa 
220 kDa 
1 2 3 4 5 6 7 8 9 10   11  12 
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procedures can be found in Chapter 3. After the stain was removed with destain, the 
membrane was cut between wells 7 and 9, with each half of the membrane having an 
identical set of samples loaded. The membranes were placed in separate containers, 
washed and blocked with a 5% fat-free milk solution for 1 hour at room temperature with 
gentle rocking. Meanwhile, the primary antibody and the primary antibody and antigen 
(blocking peptide) mixtures were prepared as follows: a rabbit polyclonal antibody 
specific to total mTOR (Cell Signaling Technology) was mixed as a 1:1000 dilution in a 
5% bovine serum albumin solution; a blocking peptide mixture was made in a 1:1 mTOR 
antibody to antigen (mTOR blocking peptide, Cell Signaling Technology) ratio mixed in 
a 5% bovine serum albumin solution. Both mixtures were allowed to incubate at room 
temperature for 30 minutes which was according to the manufacturers suggestions to 
allow for antibody-antigen interaction. The mixtures were then poured onto the 
membranes and allowed to incubate and 4 °C under gentle rocking for approximately 20 
hours overnight. The following day, the antibody solutions were removed and the 
membranes washed and probed with a goat anti-rabbit IgG antibody conjugated to 
horseradish peroxidase (Cell Signaling Technology, 1:2000 dilution in 5% bovine serum 
albumin solution) which was incubated for 1 hour at room temperature under gentle 
rocking. Membranes were then developed using a chemiluminescent kit (Amersham ECL 
Plus western blotting detection reagent, GE Healthcare Bio-Sciences, Pittsburgh, PA) and 
visualized using a digital imager (Azure c600, Azure biosystems, Dublin, CA). The wells 
of the above figure contained: (1) mature post-DEX equine gluteal muscle, horse 1 (2) 
mature pre-DEX equine gluteal muscle, horse 1 (3) mature post-DEX equine gluteal 
muscle, horse 8 (4) mature pre-DEX equine gluteal muscle, horse 8 (5) pooled equine 
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gluteal muscle (6) molecular weight marker, wells 7-12 were an exact replica of wells 1-
6. Wells 1-6 were incubated with the primary antibody to total mTOR whereas well 7-12 
were treated with the blocking peptide solution. As visual from these images, application 
of the 1:1 antigen solution prevented the mTOR antibody from binding to equine gluteal 
muscle samples, thereby validating the use of this primary antibody in the horse.  
 
 
 
 
 
A.1.b An example of Ser2448 mTOR antibody validation 
To determine cross species reactivity of the primary and secondary antibodies used to 
measure abundance of 289 kDa phosphoraylated mTOR, one aliquot of pooled muscle 
sample and four randomly picked (2 pre-DEX and 2 post-DEX samples) equine gluteal 
muscle samples from a horse used in Chapters IV and V were loaded into polyacrylamide 
gels (6%). Each sample was loaded in duplicate onto 1 gel with an empty well between 
the two sets of 5 equine samples. Two molecular markers (Spectra and Magic Mark) 
were also loaded onto each gel, one serving to follow separation during electrophoresis 
(Spectra) while the order was used verify the molecular weight of the protein bands after 
chemiluminescence. After separation by electrophoresis, the proteins were transferred 
onto a PVDF membrane and stained with Fast Green stain to verify if the protein transfer 
was successful. More information about the electrophoresis, transfer and staining 
procedures can be found in Chapter 3. After the stain was removed with destain, the 
220 kDa 220 kDa 
7 8 9 10   11  12 1 2 3 4 5 6 
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membrane was cut between wells 7 and 9, with each half of the membrane having an 
identical set of samples loaded. The membranes were placed in separate containers, 
washed and blocked with a 5% fat-free milk solution for 1 hour at room temperature with 
gentle rocking. Meanwhile, the primary antibody and the primary antibody and antigen 
(blocking peptide) mixtures were prepared as follows: a rabbit polyclonal antibody 
specific to total mTOR (Cell Signaling Technology) was mixed as a 1:1000 dilution in a 
5% bovine serum albumin solution; a blocking peptide mixture was made in a 1:1 mTOR 
antibody to antigen (phospho-mTOR Ser2448 blocking peptide, Cell Signaling 
Technology) ratio mixed in a 5% bovine serum albumin solution. Both mixtures were 
allowed to incubate at room temperature for 30 minutes which was according to the 
manufacturers suggestions to allow for antibody-antigen interaction. The mixtures were 
then poured onto the membranes and allowed to incubate and 4 °C under gentle rocking 
for approximately 20 hours overnight. The following day, the antibody solutions were 
removed and the membranes washed and probed with a goat anti-rabbit IgG antibody 
conjugated to horseradish peroxidase (Cell Signaling Technology, 1:2000 dilution in 5% 
bovine serum albumin solution) which was incubated for 1 hour at room temperature 
under gentle rocking. Membranes were then developed using a chemiluminescent kit 
(Amersham ECL Plus western blotting detection reagent, GE Healthcare Bio-Sciences, 
Pittsburgh, PA) and visualized using a digital imager (Azure c600, Azure biosystems, 
Dublin, CA). The wells of the above figure contained: (1) 90 min, mature post-DEX 
equine gluteal muscle; horse 2 (2) 0 min, mature post-DEX equine gluteal muscle; horse 
2 (3) 90 min, mature pre-DEX equine gluteal muscle; horse 2 (4) 0 min, mature pre-DEX 
equine gluteal muscle, horse 2; (5) pooled equine gluteal muscle (6) molecular weight 
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marker; wells 7-12 were an exact replica of wells 1-6. Wells 1-6 were incubated with the 
primary antibody to phospho-mTOR whereas well 7-12 were treated with the blocking 
peptide solution. As visual from these images, application of the 1:1 antigen solution 
prevented the phospho-mTOR antibody from binding to equine gluteal muscle samples, 
thereby validating the use of this primary antibody in the horse.  
 
 
 
 
A.1.c An example of total IRS-1 antibody validation 
To determine cross species reactivity of the primary and secondary antibodies used to 
measure abundance of 180 kDa total IRS-1, one aliquot of pooled muscle sample and 
four randomly picked (2 pre-DEX and 2 post-DEX samples) equine gluteal muscle 
samples from two horses used in Chapters IV and V were loaded into polyacrylamide 
gels (6%). Each sample was loaded in duplicate onto 1 gel with an empty well between 
the two sets of 5 equine samples. Two molecular markers (Spectra and Magic Mark) 
were also loaded onto each gel, one serving to follow separation during electrophoresis 
(Spectra) while the order was used verify the molecular weight of the protein bands after 
chemiluminescence. After separation by electrophoresis, the proteins were transferred 
onto a PVDF membrane and stained with Fast Green stain to verify if the protein transfer 
was successful. More information about the electrophoresis, transfer and staining 
procedures can be found in Chapter 3. After the stain was removed with destain, the 
1 2 3 4 5 6 7 8 9 10     11     
12 
220 kDa 
120 kDa 
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membrane was cut between wells 7 and 9, with each half of the membrane having an 
identical set of samples loaded. The membranes were placed in separate containers, 
washed and blocked with a 5% fat-free milk solution for 1 hour at room temperature with 
gentle rocking. Meanwhile, the primary antibody and the primary antibody and antigen 
(blocking peptide) mixtures were prepared as follows: a rabbit polyclonal antibody 
specific to total IRS-1 (Cell Signaling Technology) was mixed as a 1:1000 dilution in a 
5% bovine serum albumin solution; a blocking peptide mixture was made in a 1:1 IRS-1 
antibody to antigen (IRS-1 blocking peptide, Cell Signaling Technology) ratio mixed in a 
5% bovine serum albumin solution. Both mixtures were allowed to incubate at room 
temperature for 30 minutes which was according to the manufacturers suggestions to 
allow for antibody-antigen interaction. The mixtures were then poured onto the 
membranes and allowed to incubate and 4 °C under gentle rocking for approximately 20 
hours overnight. The following day, the antibody solutions were removed and the 
membranes washed and probed with a goat anti-rabbit IgG antibody conjugated to 
horseradish peroxidase (Cell Signaling Technology, 1:2000 dilution in 5% bovine serum 
albumin solution) which was incubated for 1 hour at room temperature under gentle 
rocking. Membranes were then developed using a chemiluminescent kit (Amersham ECL 
Plus western blotting detection reagent, GE Healthcare Bio-Sciences, Pittsburgh, PA) and 
visualized using a digital imager (Azure c600, Azure biosystems, Dublin, CA). The wells 
of the above figure contained: (1) mature post-DEX equine gluteal muscle, horse 2 (2) 
mature pre-DEX equine gluteal muscle, horse 2 (3) mature post-DEX equine gluteal 
muscle, horse 8 (4) mature pre-DEX equine gluteal muscle, horse 8 (5) pooled equine 
gluteal muscle (6) molecular weight marker, wells 7-12 were an exact replica of wells 1-
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6. Wells 1-6 were incubated with the primary antibody to total IRS-1 whereas well 7-12 
were treated with the blocking peptide solution. As visual from these images, application 
of the 1:1 antigen solution prevented the IRS-1 antibody from binding to equine gluteal 
muscle samples, thereby validating the use of this primary antibody in the horse.  
 
 
 
 
 
 
A.1.d An example of Ser253 FoxO3 antibody validation 
To determine cross species reactivity of the primary and secondary antibodies used to 
measure abundance of 97 kDa FoxO3 Ser253, one aliquot of pooled muscle sample and 12 
samples of equine gluteal muscle samples from one of the horses used in Chapters IV and 
V were loaded into polyacrylamide gels (8%). Each sample set of 12 was loaded in 
duplicate onto 2 gels. Two molecular markers (Spectra and Magic Mark) were also 
loaded onto each gel, one serving to follow separation during electrophoresis (Spectra) 
while the order was used verify the molecular weight of the protein bands after 
chemiluminescence. After separation by electrophoresis, the proteins were transferred 
onto a PVDF membrane and stained with Fast Green stain to verify if the protein transfer 
was successful. More information about the electrophoresis, transfer and staining 
97 kDa 
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procedures can be found in Chapter 3. After the stain was removed with destain, the 
membranes were washed and blocked with a 5% fat-free milk solution for 1 hour at room 
temperature with gentle rocking. Meanwhile, the primary antibody and the primary 
antibody and antigen (blocking peptide) mixtures were prepared as follows: a rabbit 
polyclonal antibody specific to total FoxO3 (Cell Signaling Technology) was mixed as a 
1:2000 dilution in a 5% bovine serum albumin solution; a blocking peptide mixture was 
made in a 1:1 (volume) FoxO3 Ser253 antibody to antigen (FoxO3 blocking peptide, Cell 
Signaling Technology) ratio mixed in a 5% bovine serum albumin solution. Both 
mixtures were allowed to incubate at room temperature for 30 minutes, which was 
according to the manufacturers suggestions to allow for antibody-antigen interaction. The 
mixtures were then poured onto the membranes and allowed to incubate and 4 °C under 
gentle rocking for approximately 20 hours overnight. The following day, the antibody 
solutions were removed and the membranes washed and probed with a goat anti-rabbit 
IgG antibody conjugated to horseradish peroxidase (Cell Signaling Technology, 1:2000 
dilution in 5% bovine serum albumin solution) which was incubated for 1 hour at room 
temperature under gentle rocking. Membranes were then developed using a 
chemiluminescent kit (Amersham ECL Plus western blotting detection reagent, GE 
Healthcare Bio-Sciences, Pittsburgh, PA) and visualized using a digital imager (Azure 
c600, Azure biosystems, Dublin, CA). The wells of the above figure contained: (1) D15 
90 min, mature equine gluteal muscle, (2) D15 0 min, mature equine gluteal muscle, (3) 
D14 90 min, mature equine gluteal muscle (4) D14 0 min, mature equine gluteal muscle 
(5) D8 90 min, mature equine gluteal muscle (6) D8 0 min, mature equine gluteal muscle, 
(7) D7 90 min, mature equine gluteal muscle, (8) D7 0 min, mature equine gluteal 
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muscle, (9) D0 90 min, mature equine gluteal muscle, (10) D0 0 min, mature equine 
gluteal muscle, (11) D-1 90 min, mature equine gluteal muscle, (12) D-1 0 min, mature 
equine gluteal muscle, (13) pooled equine muscle sample, (14) molecular weight marker, 
wells 1-14 on the second gel were an exact replica of gel 1. Gel 1 was incubated with the 
primary antibody to total FoxO3 whereas well gel 2 was treated with the blocking peptide 
solution. As visual from these images, application of the 1:1 antigen solution prevented 
the FoxO3 Ser253 antibody from binding to equine gluteal muscle samples, thereby 
validating the use of this primary antibody in the horse.  
 
A.2 Example of normalization to Total protein  
The use of “housekeeping genes”, such as α-tubulin, as loading controls in 
western blotting procedures has long been common practice as these genes are assumed 
to be highly expressed at relatively constant levels across cells, tissue and disease/injury 
types. However, the validity of this assumption has been increasingly criticized and 
normalization to total protein (TP) has emerged as a reliable loading control [400]. This 
procedure makes use of TP stains, which have shown to be linear over several orders of 
magnitude, correlate well with total protein levels obtained by Bradford assays, 
accurately correct for errors in loading and are reversible [401]. Therefore, we decided to 
use the TP as a loading control instead of α-tubulin to normalize all protein measured in 
Chapters 3 and 4. Following is a brief description of the procedures used with TP 
staining.  
After electrophoresis, the proteins were transferred to a PVDF membrane after 
which they were stained with Fast Green FCF (1% fast green, 50% methanol, 1% glacial 
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acetic acid), an anionic dye which binds to all protein present on the membrane. This 
stain is frequently used to evaluate transfer efficiency and quick quantification of the total 
amount of protein present in each lane [402]. The PVDF membranes were incubated with 
Fast Green for approximately 2 min after which they were washed with destain buffer 
(50% methanol, 1% glacial acetic acid) until the background was white and only the 
protein bound stain was visible. At this point, an image of the total protein stain was 
obtained using a digital imager (Versadoc Imaging system, Biorad). The membranes 
were then washed until all remaining Fast Green stain was removed and immunoblotting 
procedures continued as described in Chapter 3. The image of the TP stain was later used 
for quantification of the total amount of protein in each lane using the AzureSpot 
software (Azure Biosystems). Briefly, each individual lane, representing different muscle 
samples loaded in each of the wells in the polyacrylamide gel, will be identified by the 
software. After subtraction of background, the software will then calculate the total 
protein signal in each lane. The lane values were then normalized to the TP signal for the 
positive control that was loaded onto each gel (pooled sample of equine muscle tissue). 
These normalized TP values were then used to subsequently normalize the band densities 
obtained for each protein measured as described in Chapter 3. Below is a representative 
image of the total protein stain. Lanes 1-12 are equine muscle samples obtained from 1 
horse on different days throughout the study, lane 13 represents the pooled sample of 
equine muscle as the positive control and lane 14 is a molecular weight marker.   
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A.3 Pilot study 
Time course of the effects of dexamethasone on insulin-mediated skeletal muscle 
signaling pathways in mature, thoroughbred mares 
Rationale 
The purpose of this pilot study was to evaluate the time course effects of dexamethasone 
administration on muscle protein signaling pathways. From the results in Chapter 2 it was 
evident that 21-days of dexamethasone treatment resulted in substantial insulin resistance 
and affected insulin-stimulated signaling in equine skeletal muscle. In a follow-up study, 
we wanted to evaluate whether short-term dexamethasone administration would result in 
similar effects. To determine the length of time of dexamethasone treatment necessary to 
see changes in abundance and activation of muscle signaling pathways we conducted a 
pilot study lasting 21 days with muscle biopsy collections on 4 occasions.  
Animals and housing 
Four healthy, mature thoroughbred mares (age 19 ± 0.8 years old; 544.4 ± 42.5 kg BW, 
mean ± SD) from University of Kentucky Main Chance farm, were selected for the study. 
For the duration of the study, all horses were housed in 3 x 15 m, partially covered, dry-
lot pens with crushed limestone footing having ad libitum access to water and a salt 
block. With exception of sample days, all horses were turned out in group into grass lot 
pens for approximately 8h each day, with muzzles. Horses remained in their individual 
pens overnight and on sampling days, to allow for individual feeding and handling during 
experimental procedures. All horses were acclimated to the housing and turnout paddocks 
and monitored for water intake while wearing the muzzles for 1 week prior to any sample 
collection. Horses had ad libitum access to water and a salt block in their individual 
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overnight pens and were fed alfalfa hay and a commercial ration balancer twice daily (at 
0700 and 1600) at 1.85 and 0.15 % of their BW, respectively, to meet requirement for 
mature, idle horses. 
Experimental procedures 
All horses were studied for 21 days and underwent sampling procedures on d -1, d 0 (pre-
DEX) and on d 7, d 8, d 14, d 15, d 20 and d 21 of daily dexamethasone administration. 
On days -1, 7, 14 and 20 an oral sugar test (OST) was performed in all horses to evaluate 
insulin status during the study as described in Chapter 4. Briefly, before their morning 
meal a venous blood sample was obtained, after which each horse received 150 mg/kg 
BW (0.15ml/kg BW) of dextrose-derived digestible sugars, administered directly into the 
mouth with an oral dosing syringe (Karo light corn syrup, ACH Food Companies, 
Cordova, TN). A second blood sample was collected exactly 90 min post OST.  
On days 0, 8, 15 and 21, blood and muscle samples were collected from each 
horse before and 90 min after the consumption of 4g/kg BW of a high protein pelleted 
feed (as described in Chapter 3), top dressed with the same amount of Karo syrup that 
each horse had received the previous day. On days prior to sample collections, horses 
received their allotted evening hay and concentrations portions ~18h before initiation of 
sampling procedures. Any remaining hay was removed approximately 14h before sample 
collection to ensure horses were in a post-absorptive state. Ab libitum access to water 
was maintained at all times. On the morning of sample collection, horses were fitted with 
a jugular vein catheter and a 10 mL baseline blood sample was collected, after which 
horses were lightly sedated with xylazine hydrochloride. A percutaneous biopsy of the 
gluteus medius muscle was performed as described in Chapters 2 and 3. After the basal 
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muscle sample collection (pre feeding), horses were allowed to recover from sedation in 
their stalls until they were visually alert (~30-45 min) after which they received 2g/kg 
BW of the high protein pellet at t = 0 and 30 min, for a total of 4g/kg BW of feed. 
Additional 10 mL blood samples were collected at t = 15, 30, 45, 60 and 90 min post-
feeding. After the 90 min blood sample, a second biopsy was collected as described 
previously. All horses were given 2g of non-steroidal anti-inflammatory phenylbutazone 
paste (ButaPaste, Butler Animal Health Supply, Dublin, OH) for 2 days after each biopsy 
day. After the pre-DEX (d 0) sample day, all horses received a daily dose of 
dexamethasone (DexaJet SPc; 0.04 mg/kg/BW) top-dressed on their afternoon feed for 21 
days.  
Blood and muscle samples were processed and analyzed as described in Chapter 
3. Plasma glucose and insulin concentrations were determined and western immunoblot 
analysis was used to determine abundance and postprandial activation of Akt and rpS6 in 
all muscle samples.  
Results 
Plasma glucose and insulin concentrations 
Dexamethasone treatment did not affect baseline of post-OST glucose concentrations 
throughout the study (P > 0.05, Table A.3.1). Baseline insulin concentrations were 
increased 3.3 fold from DAY 1 to DAY 7 and the insulin response to the OST was 2.4 
fold greater on DAY 7 compared to DAY 1 (P < 0.05, Table A.3.1). A basal insulin 
concentration >20uIU/ml and > 60uIU/ml (at 60-90 min) in response to an OST is 
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typically considered indication for ID. However, both basal and 90 post OST responses 
on DAY 7, 14 and 21 were not different from each other (P > 0.05, Table A.3.1). 
Table A.3.1 Mean plasma glucose and insulin concentrations before and 90 min after an 
oral sugar test (0.15ml/kg BW of Karo Syrup) on each day in all horses 
 
 
 
 
 
 
 
 
Data are presented as least square means ± standard error of the mean. Data analyzed with a repeated measures analysis 
with a compound symmetry variance-covariance structure. N = 4 
a,b Different letters indicate differences between days for each measure (P < 0.05). *Significant difference between 0 
and 90 min within each day (P < 0.05). 
 
Glucose response, measured as the area under the glucose response curve, in response to 
the high protein meal tended to be greater on DAY 14 and DAY 21 compared to DAY 1 
and Day 7 (P = 0.08, Figure. A.3.1).  
Baseline insulin concentrations on feeding days were significantly higher on days of 
dexamethasone treatment compared to DAY 1 (P = 0.02, Figure A.3.2). Insulin 90 min 
post feeding (Figure A.3.3) did not differ on any of the days measured (P > 0.05). The 
insulin response to feeding, as measured by the delta (90 min – 0 min values, Figure 
A.3.4) was not different between any of the days (P > 0.05).     
 
   
 Treatment day 
Measure DAY 1 DAY 7 DAY 14 DAY 21 
Baseline insulin (μIU/mL) 12.9 ± 10.9a* 43.6 ± 10.9b* 49.0 ± 10.9b 56.9 ± 10.9b 
90 min post OST insulin (μIU/mL) 34.3 ± 10.9a 84.5 ± 10.9b 91.4 ± 10.9b 95.7 ± 10.9b 
Baseline glucose (mmol/L) 5.9 ± 0.4 4.6 ± 0.4 5.0 ± 0.4 5.4 ± 0.4 
90 min post OST glucose (mmol/L)  5.3 ± 0.4 6.1 ± 0.4 5.5 ± 0.4 6.5 ± 0.4 
 
255 
 
 
 
 
 
 
 
Figure A.3.1 Glucose area under the curve  
Values are least squared means ± SE of area under the glucose response curve for all 
horses after consumption of a high protein meal (4g/kg BW) topdressed with Karo syrup 
(0.15 ml/kg BW) on DAY 1 (white bar), DAY 7 (light grey bar), DAY 14 (dark grey bar) 
and DAY 21 (black bar). a,b,c Different letters indicate differences between days (P < 
0.05). N = 4 dexamethasone treated horses. 
 
 
 
 
 
 
Figure A.3.2 Basal plasma insulin concentrations 
Values are least squared means ± SE of basal, post-absorptive plasma insulin 
concentrations (µIU/mL) in all horses on different days. *Significant difference between 
values during dexamethasone treatment compared to DAY 1 (P < 0.05). N = 4 
dexamethasone treated horses. 
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Figure A.3.3 Postprandial plasma insulin concentrations 
Values are least squared means ± SE of plasma insulin concentrations (µIU/mL) after 
consumption of a high protein meal (4g/kg BW) topdressed with Karo syrup (0.15 ml/kg 
BW) in all horses on different days (P > 0.05). N = 4 dexamethasone treated horses. 
 
 
 
 
 
 
 
 
 
 
Figure A.3.4 Plasma insulin response to feeding 
Values are least squared means ± SE of plasma insulin responses (delta: 90 min post 
feeding concentrations – pre feeding concentrations, µIU/mL) in all horses on different 
days (P > 0.05). N = 4 dexamethasone treated horses.  
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Western immunoblots 
As expected, Akt and rpS6 phosphorylation increased in response to feeding the high 
protein meal topdressed with Karo syrup on each day (P < 0.001). Regardless of time, the 
ratio of phosphorylated to total Akt was lower on DAY 1 compared to all other days (P = 
0.04, Figure A.3.5). There was no difference in the ratio of phosphorylated rpS6 between 
any of the days (P > 0.05, Figure A.3.6).  
 
 
 
 
 
 
Figure A.3.5 Muscle Akt expression in response to feeding 
Values are least squared means ± SE of the relative gluteus medius muscle Akt 
expression (ratio of phosphorylated to total Akt) in pre (white bars) and post feeding 
(black bars) samples in all horses on different sample days. a,b Different letters indicate 
differences between days within time point (i.e. pre and post samples) (P < 0.05). 
*Significant difference between pre and post feeding samples (P < 0.05). N = 4 
dexamethasone treated horses.  
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Figure A.3.6 Muscle rpS6 expression in response to feeding 
Values are least squared means ± SE of the relative gluteus medius muscle rpS6 
expression (ratio of phosphorylated to total Akt) in pre (white bars) and post feeding 
(black bars) samples in all horses on different sample days. *Significant difference 
between pre and post feeding samples (P < 0.05). N = 4 dexamethasone treated horses. 
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Graduate Association, University of Kentucky, KY 
 
2015: First place, Graduate Student Oral Presentation, Equine Science Society 
Symposium, St. Pete Beach, Florida 
 
Funding obtained: 
‣ Industry grant ($20,000) 2013-2014 Cavalor®, Equine feeds, supplements and 
care products; Glycemic and insulinemic responses of healthy, thoroughbred 
mares in response to the consumption of commercial horse feeds containing 
various levels of non-structural carbohydrates 
‣ 2017: University of Kentucky Graduate School Student Travel Funding 
Award ($400) 
  
Affiliations and additional activities: 
 
Professional memberships: 
‣ Equine Science Society (ESS), 2015 - present 
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‣ American Society of Animal Science (ASAS), 2018 
 
University of Kentucky: 
‣ Animal and Food Science Graduate Student Association  
2017:  Social Chair 
2015-2016: Vice President  
‣ Equine Graduate Student Association 
2017-to date: Co-president 
 
Publications: 
Abstracts submitted 
‣ C. M. M. Loos, T. Barnes, S. Dorsch, K.L Urschel Effects of short-term 
dexamethasone treatment on glucose and insulin dynamics and muscle protein 
signaling pathways in horses, Journal of Equine Veterinary Science 52 (2017): 
49-50; Equine Science Society Symposium, 2017, Minnesota 
‣ S.C. Dorsch, T. Barnes, A.M. Hannan, C.E. Harrell, C. M. M. Loos, K.L. Urschel 
Effects of alfalfa hay cubes versus timothy hay cubes on measures of whole-body 
protein metabolism in mature horses, Journal of Equine Veterinary Science 52 
(2017): 77-78; Equine Science Society Symposium, 2017, Minnesota 
‣ C. M. M. Loos, T. Barnes, K.M. Brennan, K.L. Urschel Effects of prolonged 
dexamethasone treatment on signaling pathways associated with muscle protein 
degradation in mature horses. Journal of Equine Veterinary Science 35.5 (2015): 
419; Equine Science Society Symposium, 2015, Florida 
 
Online publications - Cavalor® University 
‣ C.M.M. Loos, Oct 2015, Matching the right feed to your horse’s need 
http://cavaloruniversity.com/matching-the-right-feed-to-your-horses-need/ 
‣ C.M.M. Loos, Nov 2015, Feeding the metabolically challenged horse 
http://cavaloruniversity.com/feeding-the-metabolically-challenged-horse/ 
‣ C.M.M. Loos, Dec 2015, The impact of proper nutrition on health of the equine 
stomach 
http://cavaloruniversity.com/stop-ulcers-before-they-start/ 
‣ C.M.M. Loos, Nov 2016, Colic, preventing your worst nightmare 
http://cavaloruniversity.com/colic-preventing-your-worst-nightmare/ 
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‣ C.M.M. Loos, Dec 2016, Beyond the Olympics – feeding your horse in the off-
season 
http://cavaloruniversity.com/beyond-the-olympics-nutritional-management-in-
the-off-season/ 
 
Manuscripts in preparation 
‣ C. M. M. Loos, T. Barnes, K.M. Brennan, K.L. Urschel Prolonged 
dexamethasone treatment affects protein metabolism in equine skeletal muscle 
‣ C.M.M. Loos, T. Barnes, J. Pagan, K.L. Urschel Timing of feeding prior to 
exercise affects activation of synthetic pathways in the muscle of mature horses 
‣ C.M.M.Loos, T.Barnes, S. Dorsch, K.L. Urschel Effects of short-term 
dexamethasone administration on glucose and insulin dynamics and muscle 
protein signaling in horses after the consumption of a high protein meal 
‣ C.M.M.Loos, T.Barnes, S. Dorsch, K.L. Urschel Effects of short-term 
dexamethasone administration on glucose and insulin dynamics and muscle 
protein signaling in horses after an oral sugar test 
‣ C.M.M.Loos, T.Barnes, S. Dorsch, A.A. Adams, K.L. Urschel A high protein 
meal affects plasma insulin concentrations and amino acid metabolism in horses 
with equine metabolic syndrome 
 
 
